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ABSTRACT OF DISSERTATION 
 
 
 
 
ALTERNATIVELY ACTIVATED MACROPHAGES IN PSEUDOMONAS 
AERUGINOSA PNEUMONIA: 
MODULATION OF THE NF-ΚB SIGNALING PATHWAY  
AND THE IMMUNOMODULATORY ROLE OF ARGINASE-1 
 
Background: Azithromycin polarizes macrophages into an alternative phenotype 
and promotes a regulated immunity. Arginase is an important effector of these 
macrophages believed to play an essential role in decreasing injury and 
promoting repair. 
 
Hypothesis: Decreases in inflammation in response to Pseudomonas aeruginosa 
(PA) pneumonia achieved by polarizing macrophages to an alternative 
phenotype is dependent upon the production of arginase. 
 
Methods: Requirement of arginase was examined by pharmacological inhibition 
using S-(2-boronoethyl)- L-cysteine (BEC) or L-norvaline and by infecting 
arginase-1 conditional knock-out mice (Arg1flox/flox;Lyz2-cre (Arg1∆M)) with PA 
intratracheally. Arg1∆M and control Arg1flox/flox mice were then dosed with 
azithromycin daily via oral gavage beginning four days prior to infection. Analysis 
of weight loss in addition to characterization of inflammatory cells and cytokine 
production via flow cytometry was performed. Macrophages were then stimulated 
with LPS and polarized with IL4/13, IFNγ, or azithromycin plus IFNγ. Western 
blot for signaling mediators, p65 translocation assay, and immunofluorescence 
were performed. 
 
Results: Myeloid arginase-1 deletion resulted in greater morbidity along with 
more severe inflammatory response compared to the Arg1flox/flox mice. Arg1Δm 
mice had greater numbers of neutrophils, macrophages, and lymphocytes in their 
airways and lymph nodes compared to the Arg1flox/flox mice. Conversely, global 
arginase inhibition resulted in greater weight loss along with greater neutrophil 
and macrophage infiltration compared to Arg1Δm mice. BEC and L-norvaline 
treated mice had higher numbers of lymphocytes in their lymph nodes with 
variable effects on airway lymphocyte counts. Azithromycin treatment 
comparably reduced the acute inflammatory responses in both Arg1∆M and 
Arg1flox/flox mice. To evaluate this mechanism, we show in vitro that azithromycin 
decreases NF-κB activation by preventing p65 nuclear translocation and by 
decreasing STAT1 activation in a concentration-dependent manner. These 
effects were reversed with IKKβ inhibition. 
 
Conclusions: Myeloid arginase is essential for control of inflammatory responses in 
PA pneumonia with potentially different effects of other cellular sources 
demonstrated with global arginase inhibition. Azithromycin reduces excessive 
inflammation even in the absence of arginase, potentially through a cross-
inhibitory mechanism involving STAT1 and NF-κB pathways through IKKβ. 
 
 
KEYWORDS: Azithromycin, Alternative Macrophages, Arginase-1, STAT1 and 
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Chapter 1: Introduction 
 
I. Cystic fibrosis and infection 
 
Cystic fibrosis is a hereditary progressive disease of the secretory glands 
acquired by inheriting the mutated genes of a chloride ion transport channel 
called the cystic fibrosis transmembrane conductance regulator (CFTR) [1]. The 
autosomal recessive mutation of the CFTR gene on chromosome 7 affects about 
1 in 3300 white newborns with lower incidence in other races [2]. People with 
defective CFTR suffer from abnormal thickening of their mucoid secretions. 
Thickened mucus constitutes a major problem in the lungs although other organs 
can be affected including the kidneys, intestines, pancreas, and liver [2-6]. In the 
lungs, a vicious cycle of thickened mucus, repetitive infections, and extensive 
inflammation result in mucoid plugging of the airways, lung injury, and 
progressive pulmonary function decline [1-5, 7].  
 
According to the Cystic Fibrosis Foundation, more than 70,000 people in the 
world suffer from cystic fibrosis [2, 6]. In the United States, more than 30,000 
people live with cystic fibrosis with an expected increase of 1000 new patients 
annually. Today, patients suffering from this life-shortening disease have a 
median survival of 37 years with an anticipated increase in survival beyond 50 
years of age [1, 7]. This is considered a major advancement since 1962 when 
patients used to die by 10 years of age due to extensive mucus accumulation in 
their lungs and inability to breathe [2-6]. At least 50% of the cystic fibrosis 
patients in the United States are above 18 years of age according to the 2017 
Cystic Fibrosis Foundation Patient Registry [2, 6]. 
 
Newborns with cystic fibrosis develop structural abnormalities, mucus 
accumulation and obstruction of the airways, along with hypertrophy of the 
mucosal glands [8-11]. Radiological evidence of lung destruction is strongly 
correlated with chronic lung infections. The increased risk for chronic bacterial 
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colonization along with the exaggerated inflammation result in progressive airway 
wall thickening and lumen dilatation along with permanent scarring in the lungs 
[12-16]. Additionally, early signs of inflammation occur shortly after birth 
preceding structural changes and are predictive of the future disease progression 
[14]. The mucosal glands in cystic fibrosis are hypertrophied and ducts of these 
glands are obstructed due to mucus cell hyperplasia. Early structural changes in 
cystic fibrosis also include increased smooth muscle content and smooth muscle 
cell hyperplasia in the airway walls in early disease stages [12]. These structural 
abnormalities are also responsible for changes in the velocity and resistance of 
the airflow in cystic fibrosis lungs compared to healthy lungs [13]. Additionally, 
elevated pro-inflammatory mediators in the patients’ lungs constitute a positive 
indicator for the early development of bronchiectasis, a condition where the lung 
structure is lost due to irreversible damage with thickened and dilated airways 
[15].  Bronchiectasis occurs in end-stage cystic fibrosis and results in respiratory 
failure and death.  
 
Additionally, the lungs of cystic fibrosis patients are plugged with dense mucus. 
The mucus becomes abnormally heavy and thick due to loss of water content 
resulting from the abnormal ion transport across the mutated CFTR channels. 
Besides the ion and water abnormalities, some reports suggest increased mucus 
secretion in cystic fibrosis due to increased expression of mucin genes (e.g. 
Muc1, Muc6, Muc5AC, and Muc5B) [13]. Mucins are large glycoproteins that 
normally constitute about 1-2% of mucus along with water which constitutes 
about 98%.  When mucin concentration in mucus increases, it results in mucus 
hyperconcentration and dehydration [13]. Collectively, the increased mucin 
concentration and the disrupted chloride channels increase the mucus viscosity 
in cystic fibrosis to 104-105 times higher than that of water. Increased mucus 
accumulation in cystic fibrosis complicates the disease via mechanically 
obstructing the airways, trapping bacteria and pathogens in the lungs, therefore 
driving inflammation.  
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Infection and inflammation are the other two main pathological aspects of cystic 
fibrosis to be extensively discussed in this dissertation. Chronic infections are the 
leading cause of mortality in these patients with the most predominant pathogen 
being Pseudomonas aeruginosa (PA) [17-19]. In fact, about 60% of patients with 
cystic fibrosis are infected with PA, which chronically colonizes the lungs of 80% 
of the patients older than 18 years of age [17-19].  According to Davies et al., for 
a given bacterial load, a person with cystic fibrosis will have up to 10 times more 
inflammation than a person with a lower respiratory tract infection but without the 
disease [15]. Many scientists initially approached the inflammatory aspect of 
cystic fibrosis as a consequence of the chronic and repetitive infections. 
However, it has become clear that inflammation is an independent factor of cystic 
fibrosis pathophysiology. Yet, it is not very well understood why the immune 
system responds in an exaggerated manner to the infections. 
 
Several factors increase the infection risk in cystic fibrosis lungs including 
environmental, structural, and immune abnormalities. The resultant dense and 
viscous mucus along with the dampened mucociliary clearance are believed to 
create a favorable environment for the growth and replication of bacteria and 
microorganisms in the lower respiratory tract [20]. It is hypothesized that the 
excessively high salt concentrations in the airways due to the malfunctional 
CFTR channels are responsible for pulmonary infections. The high salt 
concentrations inactivate host antimicrobial defensin proteins [21, 22]. 
Additionally, the malfunctional channels disrupt the homeostatic balance of the 
water volume in the airways. The inability to efficiently transport the sodium and 
chloride across the airway epithelium disrupts the isotonic state and results in 
volume and water depletion. This eventually results in increased viscosity and 
malfunctional mucociliary clearance; thus, invading microbes are trapped in the 
lower respiratory tract [23, 24].  
 
Patients with cystic fibrosis are also more susceptible to bacterial infections due 
to altered macrophage function [20]. The specific macrophage alterations in 
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cystic fibrosis are extensively discussed in later sections. However, reduced 
macrophage autophagosome function and the reduced ability to engulf and 
phagocytize pathogens contribute to increased susceptibility for pulmonary 
infections. The loss of CFTR channels on the surface of these immune cells is in 
part responsible for the loss of macrophage functions [25-35].  
 
Moreover, the structural abnormalities discussed above also contribute to the 
increased risk of infection [20]. Structural changes blunt the effectiveness of 
physical defense mechanisms in clearing invading pathogens. Additionally, these 
changes make the sites of infection in the lower respiratory tract inaccessible for 
macrophages and other immune cells [11, 25-28, 30-36]. Specific changes in the 
trachea, airway size, and wall thickness can also contribute to the increased 
infection risk. Long et al. and Meyerholz et al. found dilated and thickened 
airways and bronchioles in children with cystic fibrosis before any infectious and 
pulmonary symptoms occur [11, 36]. These changes promote colonization of the 
initially sterile lower respiratory airways and thus comprise challenges to the 
normal host-defense mechanisms. This “otherwise harsh lung environment” with 
limited oxygen and nutrient supply for microbiota favors the development of 
evolving survival tools for bacteria. This drives the bacteria to mutate in order to 
adapt and colonize the lower airways for prolonged durations [37-42].  
 
Acidification of the lung microenvironment also increases the risk of pulmonary 
infections in patients with cystic fibrosis [20]. Mucus in cystic fibrosis lungs is of 
gel-rubber consistency which results in ciliary dyskinesia and increased acidity. 
Acidification of the lung environment impairs the host-defense mechanisms 
which are sensitive to pH and creates an aerobic condition favorable for 
microbes and harmful for the patients’ lung function [11, 20-24, 29-36]. 
Collectively, these factors contribute to an excessive inflammatory response in 
an anatomical region of the lung which is normally free of any immune reactions. 
Thus, the inflammatory response itself constitutes an additional factor for 
prolonged bacterial colonization of the lower respiratory tract in cystic fibrosis.  
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Similarly, infections with PA are predominant in cystic fibrosis due to microbial, 
environmental, and immune factors [43-48]. PA is a rod-like bacterium which 
benefits from the tremendous pulmonary changes. This microorganism 
undergoes genotypic and phenotypic changes which make it able to survive in 
the cystic fibrosis lungs for prolonged periods. PA is able to combat the oxidative 
and nutrient stresses and it develops efficient and specialized antibiotic 
resistance mechanisms. Additionally, PA is able to change its lifecycle by 
reducing its metabolic rate, decreasing its motility and dampening its growth and 
replication cycles. Moreover, PA chronically colonizing the lungs are 
characterized by reduced quorum sensing and increased alginate production 
[20]. PA commonly found the lungs of patients with cystic fibrosis have highly 
evolved virulence factors along with increased ability to line the airways with 
biofilm formation. Thus, these facultative anaerobic Gram-negative bacteria can 
alter the cystic fibrosis lung environment to favor its survival and replication [45-
47]. 
 
Chronic infections with PA are also related to the unique ability of this micro-
organism to down- and up-regulate the expression of different genes related to 
virulence and infectivity [48-54].  PA colonizing cystic fibrosis airways can 
compete with other pathogens by regulating the nutrient levels and by releasing 
antimicrobial substances capable of killing other bacteria. For instance, PA 
competes with the second most common pathogen in cystic fibrosis, 
Staphylococcus aureus [49] by inhibiting its growth and replication through tight 
regulation of free iron concentrations and by lysing S. aureus through the release 
of bactericidal substances [49]. Conversely, infections with other pathogens 
including bacteria (Burkholderia cenocepacia, Mycobacterium smegmatis, 
Haemophilus influenzae, and Staphylococcus aureus), viruses (Respiratory 
syncytial virus), fungi and certain yeast strains (Aspergillus, Candida, Exophiala 
dermatitidis and Lomentospora prolificans) have been shown to promote 
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infections and colonization with PA by directly altering the micro-environment and 
disturbing the immune response against PA [50-54]. 
 
Altered CFTR channels also favor PA acquisition in patients with cystic fibrosis 
[55-59]. CFTR channels act as receptors for the uptake of PA by the airway 
epithelium; therefore, the inability to internalize PA can evade its clearance and 
the antigen presentation for incoming immune cells [60-62].  This strong 
adherence to mutated CFTR channels contributes to chronic and prolonged 
infections with PA [55-57]. Epithelial cells with mutated or deleted CFTR are also 
prone to increased activation of the pro-inflammatory transcription factor, NF-κB 
when stimulated with PA in-vitro compared to normal epithelial cells [57, 58]. 
Increased NF-κB activation is associated with significantly lower levels of IFNγ 
release by the cystic fibrosis epithelial cells challenged with PA. IFNγ is an 
essential pro-inflammatory cytokine required for an efficient activation of the 
inflammatory response. Thus, dampening the IFNγ response is a unique tool by 
which PA can evade its immune recognition and clearance [59]. 
 
Additionally, PA forms biofilms to evade immune response and to cause 
prolonged infections. PA is characterized with biofilm formation and strong 
adherence to the thick mucus which prevents its recognition and phagocytosis by 
neutrophils [63, 64]. Moreover, PA is able to utilize the neutrophil extracellular 
traps (NETs) to favor its own survival. As the name implies, NETs are network-
shaped traps made of extracellular fibers, primarily composed of DNA from 
neutrophils and used to bind pathogens. PA utilizes these neutrophil traps to 
secrete a highly virulent and pro-inflammatory toxin called Pyocyanin [65, 66]. 
Pyocyanin released by PA can kill other competing bacteria and alter the 
activation and function of immune cells. 
 
Finally, PA benefits from the skewed T cells responses to evade clearance and 
to chronically colonize the lungs. The adaptive immune response in cystic fibrosis 
promotes PA infections as it is skewed towards a Th2/Th17 response which is 
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believed to favor and even prime infections with PA [67-70]. Despite all the 
studies about the different variants of PA and the different characteristics related 
to the infection and host-defense mechanisms in cystic fibrosis; the exact 
machinery and environmental characteristics that favor the competition with other 
pathogens and survival of PA are very poorly understood. 
 
II. Inflammation and immune response in cystic fibrosis  
 
The inflammatory response in cystic fibrosis is dysregulated and significantly 
contributes to disease pathology [63]. Epithelial cells and resident macrophages 
lining the airways release pro-inflammatory mediators and chemokines when an 
invading pathogen is sensed. A normal immune system responds to the released 
inflammatory mediators by recruiting innate immune cells (like neutrophils and 
macrophages) which are non-specific but show up early to contain and clear the 
infection. The innate immune cells then activate adaptive immunity in a very well-
coordinated and controlled manner [63]. Adaptive immunity is antigen-specific 
and is highly efficient in clearing infections. However, the immune system in 
patients with cystic fibrosis responds in an abnormally excessive and inefficient 
manner against the invading pathogens. Consequently, altered inflammation fails 
to clear the infection and results in lung injury. Additionally, the non-resolving 
pulmonary inflammation creates niches which favor further chronic infections and 
colonization with highly virulent and opportunistic pathogens. The following 
section discusses the specific alterations in the innate immune response of cystic 
fibrosis (also summarized in Figure 1.1 a and b). The main elements of the innate 
immune response which are altered in cystic fibrosis include the epithelium, the 
NF-κB pro-inflammatory signaling pathway, the neutrophil response, as well as 
the macrophage response.  
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i. Epithelium  
 
The bronchial epithelium is the first line of defense against invading pathogens 
and its physical, chemical, and immunologic functions are disrupted in cystic 
fibrosis. The epithelium functions to physically remove and prevent the spread of 
inhaled microbes by cough, mucociliary clearance, as well as by forming tight 
physical and chemical barriers [63, 71-73]. Appropriate composition, hydration, 
and viscosity of the mucus are essential for the release and transport of mucus in 
the airways. The malfunctional CFTR channels, as mentioned previously, prevent 
chloride and bicarbonate transport. This increases the viscosity and acidity of the 
mucus thus hindering the mucociliary clearance process. Eventually, the thick 
mucus along with the trapped pathogens remain adherent to the epithelium and 
fail to be expelled by cough and mucociliary clearance [13, 74, 75]. Another way 
by which the epithelium prevents invading pathogens from spreading and 
establishing an infection is by the release of antimicrobial products and peptides. 
However, these are inactivated at the acidified airway surface liquid (ASL). The 
ASL pH drops drastically due to ion flux imbalance by the mutated CFTR 
channels [63, 76]. The inactivation of epithelial microbicidal products prevents the 
killing of invading bacteria, viruses, and yeasts. Additionally, the tight epithelial 
barrier is cleaved and digested in the presence of elevated neutrophil elastases 
and proteases [63, 77, 78], thereby increasing paracellular permeability of 
pathogens into the lung interstitium [79, 80]. Collectively, CFTR channel 
dysfunction and the altered inflammatory environment impair the physical and 
chemical functions of the epithelial barrier. 
 
The immunologic function of the epithelium also includes the activation of innate 
immunity via antigen presentation and pro-inflammatory cytokine release. The 
cellular innate immune response is activated when the pathogen-associated 
molecular patterns (PAMPs) are recognized by the Toll-like receptors (TLR) 
expressed on the epithelial cells [81-84]. This primary response occurs when the 
non-self antigens of invading pathogens are presented by the pattern recognition 
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receptors. Several TLRs recognize microbial components of PA, which 
expresses numerous PAMPs, including lipopolysaccharides (LPS) and flagellin. 
TLR2 and TLR4 detect LPS while TLR5 detects flagellin. Along with the cytokine 
stimulation of their corresponding receptors, binding of PAMPs to TLRs activates 
efficient downstream signaling cascades [81]. Activation of the nuclear 
transcription factor NF-κB is one of the main pro-inflammatory singling cascades 
triggered in the stimulated epithelial cells. However, functional CFTR mutations 
are associated with increased NF-κB activation, reduced TLR4 expression and 
stimulation, as well as reduced antigen processing and presentation [85-88]. The 
increased NF-κB activation in epithelial cells is therefore partly responsible for 
the dysregulated immunologic function of the epithelium as it results in excessive 
release of pro-inflammatory cytokines and mediators. Pro-inflammatory 
mediators then act to recruit and activate exaggerated numbers of innate 
immune cells which can lead to inflammatory lung injury [85-88]. 
 
ii. The NF-κB pro-inflammatory signaling pathway 
 
Increased NF-κB activation is a major immunologic alteration in cystic fibrosis. As 
mentioned previously, NF-κB is a nuclear transcription factor in epithelial cells 
and in many other immune cells including macrophages, neutrophils, as well as 
B and T lymphocytes. Disruption of NF-κB activation in the epithelial cells and in 
the macrophages is a very well described pathological factor in cystic fibrosis 
[89-91]. The NF-κB family of proteins includes different transcription factors 
which control genes involved in inflammation, immunity, cell proliferation, 
differentiation, and survival. 
 
The NF-κB family of transcription factors is divided into the canonical vs the non-
canonical pathways. The canonical pathway is mainly involved in inflammation 
while the non-canonical pathway is involved in immune cell differentiation and 
maturation. Each NF-κB transcription factor consists of a heterodimer or a 
homodimer of the five NF-κB subunits: RelA (also named p65), RelB, cRel, p50, 
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and p52 (p50 and p52 subunits are synthesized as precursor proteins, p105 and 
p100) [91]. Activation of the canonical NF-κB pathway mainly involves IκB-α 
degradation and p50/p65 subunits (p50/p65 heterodimers and p65 homodimers). 
Alternatively, activation of the non-canonical NF-κB mainly involves RelB/p52 
subunits and is independent of IκB-α degradation (instead it is dependent on the 
processing of the precursor proteins p100 and p105). Moreover, the activation of 
the canonical pathway frees pre-existing subunits while the non-canonical 
pathway allows the synthesis of new subunits. Finally, the two pathways are 
induced and regulated through independent mechanisms. The canonical 
pathway involves the activation of a NEMO-dependent IKK complex (a trimeric 
complex composed of two catalytic subunits, IKKα and IKKβ, and a regulatory 
subunit, IKKγ) [91]. Conversely, the non-canonical pathway is mediated through 
the activation of a NEMO-independent kinase complex including IKK1 and the 
NF-κB -inducing kinase (NIK) [89]. Inappropriate activation of the canonical 
pathway results in inflammatory and auto-immune diseases while the disruption 
of non-canonical NF-κB signaling results in lymphoid malignancies. Since the 
canonical pathway is mainly involved in inflammation and in cystic fibrosis, 
whenever NF-κB is mentioned in this dissertation it refers to the activation of p65 
subunits through the canonical pathway unless otherwise specified [91]. 
  
In the absence of TLR and cytokine receptor stimulants, NF-κB activation is 
suppressed by an inhibitory subunit (IκB-α, IκB-β, or IκB-ɛ) which binds the NF-
κB subunits (p50 or p65) and prevents them from translocating to their site of 
action in the nucleus. Stimulation through TLR allows the phosphorylation and 
activation of the IκB kinase (IKKβ) which phosphorylates the inhibitory IκB-α 
subunits. Once phosphorylated, the IκB-α subunits undergo rapid ubiquitination 
and proteasomal degradation, thus releasing p50/p65 from the inhibited state. 
Free p50/p65 subunits undergo further phosphorylation in the cytoplasm, 
dimerize, and translocate to the nucleus where they bind to the NF-κB DNA 
promoter region. This promoter region controls several genes for pro-
inflammatory cytokines and mediators including TNF-α, IL-1β, IL-6, IL-8, IL-12, 
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iNOS, IFNγ, adhesion molecules (VCAM1, ICAM1), as well as many other 
immune and non-immune related genes [81, 92-95]. The release of those 
inflammatory cytokines and mediators results in the recruitment and 
chemoattraction of neutrophils and macrophages to the site of infection. 
 
NF-κB activation in epithelial cells plays an essential role in initiating and 
modulating the immune response. In addition to recruiting innate immune cells, 
the inflammatory cytokines also polarize different inflammatory signaling 
cascades in the recruited immune cells including further activation of the NF-κB 
pathway in the recruited neutrophils and macrophages. Thus, any deviation from 
the normal NF-κB activation levels can result in serious pathology [96]. For 
instance, regulation of NF-κB activation mainly involves tight control of the 
activity and synthesis of the IκB-α and IKKβ proteins as well as controlling 
subunit nuclear translocation and DNA binding [91]. Synthesis of IκB-α subunits 
and IKKβ are sensitive to NF-κB activation through a negative feedback 
regulation. Binding of p50/p65 subunits to the DNA shuts down the IKKβ 
synthesis and stimulates the synthesis of new IκB-α subunits thus critically 
controlling the duration of the NF-κB response. IκB-α controls the nuclear 
translocation of p50/p65 subunits by masking the nuclear localization sequence 
(NLS) of p65. Therefore, terminating the NF-κB response is disrupted in the case 
of IκB-α deficiency [91]. Alternatively, IKKβ activation requires phosphorylation of 
two serines; thus, regulation of IKKβ activation involves tight control of its trans-
autophosphorylation as well as its phosphorylation by the upstream kinases [91-
94]. IKKβ deficiency abolishes the activation of an NF-κB response while IKKβ 
accumulation shuts down other signaling pathways which release pro-
inflammatory cytokines including the STAT-1 pathway [91]. Additionally, post-
translational modifications of NF-κB subunits affect their nuclear translocation, 
dimerization, and DNA binding. For instance, several modifications have been 
described like Ser276 phosphorylation of p65 which facilitates its DNA binding, 
while Ser536 phosphorylation affects its nuclear translocation [91]. Other 
modifications like methylation, acetylation, and phosphorylation of additional sites 
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affect p65 interaction with other enzymes and NF-κB subunits as well as 
inhibiting the transcriptional activity of p65. In fact, abnormal NF-κB activation 
has been described in many diseases like cancer, Alzheimer’s disease, multiple 
sclerosis, and cystic fibrosis [96]. 
 
Increased NF-κB activation in epithelial cells is well described in cystic fibrosis 
and is caused by mutated CFTR channels as well as changes in the 
inflammatory environment. Continual NF-κB activation in cystic fibrosis 
contributes to chronic infection, neutrophil inflammation, and lung injury [97]. 
Unopposed NF-κB activation is attributed to the significantly high levels of IL-8 
and the suppressed levels of IL-10. Carrabino et al. found that in the absence of 
any stimulation, isolated cystic fibrosis nasal epithelial cells release high levels of 
IL-8 [98]. Under basal conditions, cells from cystic fibrosis nasal epithelium 
express significantly higher activity of NF-κB compared to normal epithelial cells. 
Co-stimulation of epithelial cells from cystic fibrosis patients with PA and IL-1β 
produced a two-fold increase in NF-κB activation and at least six-folds greater 
increase in IL-8 levels compared to normal epithelial cells [98]. Additionally, 
CFTR mutations in epithelial cells and macrophages are related to increased NF-
κB activation. Specifically, the most common CFTR mutation is the deletion of 
phenylalanine 508 (ΔF508), which results in its endoplasmic reticulum associated 
degradation (ERAD) by the ubiquitin-proteasome system. The inability of ΔF508-
CFTR to translocate to the cell surface is associated with exaggerated NF-κB 
activation [97]. According to Chanson et al., the ΔF508 mutation enhances NF-
κB activation due to lack of gap junctional communication (GJIC) of CFTR with 
inflammatory receptors [97]. Additionally, CFTR binds to and colocalizes with 
TRADD (the key adaptor molecule in TNF-α signaling) while ΔF508 CFTR cannot 
bind TRADD thus preventing the degradation of TRADD, an event that is 
necessary for turning off TNF-α-induced NF-κB activation [99].  
 
Additionally, appropriate CFTR localization within the lipid-rafts formed in 
response to infection is essential for raft clustering and regulated signaling 
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through the NF-κB pathway [100].  Mutated CFTR disrupts lipid-raft formation 
and clustering thereby inducing uncontrolled activation of the NF-κB signaling 
pathway. Tabary et al. also show that disrupted calcium signaling is associated 
with increased NF-κB activation in cystic fibrosis epithelial cells [100]. They show 
that cells with mutated CFTR channels respond to IL-1β stimulation with a 
significant increase in calcium concentrations along with increased NF-κB 
activation. This effect was reversed with thapsigargin treatment which prevents 
calcium release from the endoplasmic reticulum. Tabary et al. suggest that 
epithelial cells with mutated CFTR are endogenously primed for excessive 
release of calcium which results in abnormal lipid-raft formation and disrupts NF-
κB signaling [100].  Finally, Saadane and colleagues infected normal and cystic 
fibrosis mice with PA intratracheally [101]. Although infection is cleared in both 
groups with similar kinetics; cystic fibrosis mice have greater neutrophil influx 
along with higher levels of pro-inflammatory cytokines compared to wild-type 
mice. Saadane found that cystic fibrosis mice lack the ability to re-synthesize 
new IκB-α once it was degraded resulting in prolonged and excessive activation 
of NF-κB which lasted for 6 days compared to normal mice which had 
significantly lower levels of NF-κB which rapidly decreased by day 4 post-
infection [101]. Collectively, aberrant activation of the NF-κB pathway is a 
hallmark of cystic fibrosis pathology. 
 
iii. Neutrophilic inflammation 
 
The third element of the disrupted innate immunity in cystic fibrosis is the 
excessive recruitment and influx of neutrophils. Neutrophils are thought to greatly 
contribute to morbidity and mortality in cystic fibrosis. This is due to the 
overwhelming numbers of neutrophils which migrate to the lungs in large 
numbers due to persistent infection and continuous stimulation. Inflammation in 
cystic fibrosis is characterized by elevated concentrations of neutrophil 
chemokines including IL-17, IL-8, and IL-6 [8]. Neutrophils exert their pro-
inflammatory function by releasing powerful antimicrobial substances, free 
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radicals, and antioxidants which the cystic fibrosis lungs are unable to clear. This 
is aggravated by the death of neutrophils which further releases its granular 
contents resulting in inflammatory lung injury and damage. The resultant lung 
injury and oxidative stress eventually recruit more neutrophils thus causing an 
excessive inflammation that is characteristic of cystic fibrosis [102-105].  
 
CFTR channels are also expressed on the neutrophil cell surface and CFTR 
mutations impair the degranulation of important neutrophil microbicidal products 
from the secondary and tertiary granules (lysozyme, lactoferrin, and cathepsins) 
[102]. Additionally, there is an excessive amount of neutrophil elastases and 
proteases that overwhelm the antiproteases that protect the lungs. In fact, even 
milder forms of cystic fibrosis are associated with greater than 1000 times the 
concentration of α1-protease inhibitors compared to healthy individuals [103-
105]. Thus, neutrophils contribute to lung injury by releasing excessive amounts 
of neutrophil elastases which break down the connective tissues and matrix 
proteins leading to a structural loss in the small airways [106-110]. Additionally, 
unopposed neutrophil elastases are also capable of cleaving non-structural 
proteins like essential immune cell surface receptors (CFTR, CD4, CD8, 
complement receptors, and antigen presentation receptors) [8, 111, 112]. Also, 
elastases can cleave the macrophage phosphatidylserine receptors which 
prevents compensatory anti-inflammatory mechanisms due to impaired 
efferocytosis, the process by which macrophages clear dead and apoptotic 
neutrophils [113-115]. 
 
The changes in the lung microenvironment and the ion imbalance result in 
decreased phagocytic and degranulation capacities of neutrophils. New studies 
suggest that neutrophils express CFTR in their phagolysosomes. Thus, 
mutations in CFTR impair neutrophils ability to kill engulfed pathogens. This 
occurs due to impaired chlorination of the internalized pathogen [111, 112, 116]. 
So, there is an excessive number of neutrophils in the cystic fibrosis lungs that 
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are unable to clear the invading pathogens and simultaneously contribute to 
excessive inflammatory injury.  
 
Additionally, unregulated death of neutrophils contributes to severe inflammatory 
lung injury. The excessive numbers of neutrophils in cystic fibrosis is associated 
with failure of some neutrophils to undergo regulated cell death or apoptosis. 
Large numbers of recruited neutrophils undergo necrosis which releases massive 
intracellular contents like inflammatory mediators and cytokines, oxidants and 
proteases, in addition to large DNA fragments and actin [117]. Neutrophils also 
form chromatin traps called NETs. The purpose of these traps is to facilitate the 
catching and killing of bacteria. However, these NETs contain high amounts of 
DNA which are released upon death of the neutrophils and the released DNA 
further increases the mucus viscosity and reactivity [118]. Thus, the death of 
neutrophils releases tremendous amounts of intracellular contents that are 
extremely harmful to the lungs. 
 
Neutrophils in cystic fibrosis can also undergo metabolic changes which affect 
their pro-inflammatory functions and half-life. According to Ingersoll and his 
colleagues, neutrophils in cystic fibrosis can develop metabolic adaptations 
which contribute to their altered function [119]. Changes in metabolic cycles 
affect the ability of neutrophils to engulf and phagocytize pathogens. It also 
results in additional production of toxic metabolites and prolongs the other-wise 
short half-life of neutrophils. In fact, neutrophils are short-lived immune cells with 
a lifespan ranging from a few hours to 5 days. In cystic fibrosis, several factors 
prolong the neutrophil lifespan including the prolonged pro-survival signals and 
the delayed apoptosis signal (due to mutated CFTR) [120]. These changes 
impair the neutrophil phagocytic capacities and extend their half-life while 
enhancing the neutrophil chemotaxis and migratory abilities. 
 
Neutrophils also control T cell responses in cystic fibrosis. One mechanism 
through which neutrophils can regulate T cell proliferation is by controlling 
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arginine concentration. Arginine is a conditionally essential amino acid required 
for T cell function and proliferation. In cystic fibrosis, neutrophils release 
excessive amounts of arginase-1 which depletes arginine and renders the airway 
lumen a highly inhibitory milieu for T cells. Additionally, neutrophil arginase-1 
cleaves T cell receptors and prevents their activation [119-125]. Conversely, 
neutrophils in cystic fibrosis can exert positive regulation of T cell responses by 
increasing the neutrophil expression of T cell activation receptors, major 
histocompatibility complex II, co-activator CD80, and prostaglandin D2 receptor 
(CD294). Neutrophils have been shown to particularly promote the expansion of 
Th2 and Th17 lymphocytes [119, 123]. Th17 lymphocytes will then recruit more 
neutrophils by releasing IL-17, the major cytokine involved in neutrophil 
chemotaxis and cystic fibrosis pathology (to be discussed in later sections). 
Thus, excessive influx if neutrophils in cystic fibrosis also impact the 
development and function of other immune cells, mainly T lymphocytes [119]. 
  
In summary, neutrophils constitute a major threat in the cystic fibrosis 
inflammatory process as they release toxic substances, reactive oxygen and 
nitrogen species, as well as DNA [82, 119]. Along with proteinases, these toxic 
neutrophil substances result in progressive inflammatory lung injury. 
 
iv. Macrophage alterations 
 
Macrophage function is an important element of innate immunity and is disrupted 
in cystic fibrosis. Changes in lung micro-environment affect macrophage 
polarization, phagocytic function, and antigen presentation. In normal 
circumstances, macrophage subpopulations are recruited to the lungs at different 
timepoints during the infection. These macrophage populations are essential for 
initiation, control, coordination, and resolution of inflammation [126]. Therefore, 
any disruption of a specific macrophage population can drastically affect the 
initiation and control of the immune response against infections. In this section, 
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changes in macrophage polarization and functions in patients with cystic fibrosis 
will be discussed. 
 
a. M1 and M2 macrophage activation 
 
Macrophage populations are separated into two distinct subpopulations based on 
their role in inflammation. Classically activated macrophages (designated M1 
macrophages) are inflammatory while alternatively activated macrophages 
(designated M2 macrophages) are regulatory. M1 macrophages produce high 
levels of pro-inflammatory cytokines and mediate resistance to pathogens by 
releasing reactive nitrogen and oxygen intermediates, phagocytizing invading 
organisms, and promoting Th1 responses. In contrast, M2 macrophages control 
parasitic and helminth infections, express scavenger mannose receptor and anti-
inflammatory cytokines, promote tissue remodeling and immune regulation, clear 
apoptotic cells and debris, and promote Th2 responses [127, 128].  Activation of 
M2 macrophages inhibits M1 macrophage proliferation and function and 
suppresses Th1-type cell-mediated immune responses. The latter is achieved 
through a characteristic pattern of gene up-regulation that includes the 
production of the type II cytokine TGFβ and the effector molecule arginase-1. By 
functioning to orchestrate remodeling and repair mechanisms, arginase-1 and 
TGFβ are also important in controlling lung homeostasis, inflammation, and 
subsequent damage [128-132]. It is important to note that M2 macrophages have 
recently been further characterized into M2a, M2b, M2c and M2d subsets based 
on their distinct gene expression profiles [127, 128]. However, in this dissertation 
we refer to the M2a subtype elicited by IL-4 and IL-13 as M2 macrophages. In 
cystic fibrosis, both macrophage populations are required. M1 macrophages are 
essential for protecting against infections and intracellular pathogens, while M2 
macrophages are essential for inflammation resolution and for tissue 
regeneration and airway remodeling. 
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The activation of M1 and M2 macrophages are governed by distinct signaling 
mediators. M1 macrophages are activated by TNF-α or IFN-γ when stimulated by 
non-self foreign antigens (such as LPS in the case of Gram-negative bacteria) 
[127, 128]. Conversely, M2 macrophages are activated by IL-4, IL-13, or IL-10. 
Signaling through the interferon regulatory transcription factor and the signal 
transducer and activator of transcription proteins (IRF/STAT) is the central 
governing mechanism of macrophage M1–M2 polarization [118, 127-129]. LPS 
signaling through TLR4 activates several signaling cascades which involve two 
adaptors, MyD88 and TRIF. MyD88 signaling activates several kinases including 
IRAK4, TRAF6, and IKKβ which ultimately activate NF-κB, the main M1 
macrophage transcription factor [127, 128]. Alternatively, TRIF signaling 
promotes the secretion of type I interferons through IRF3 activation. 
Consequently, secreted interferons bind receptors on macrophages and 
stimulate the phosphorylation and activation of the second M1 transcription 
factor, STAT-1. STAT proteins form dimers and translocate to the nucleus [128]. 
While NF-κB activation depends on IκB-α and IKKβ regulation, STAT signaling is 
mainly controlled by the suppressor of cytokine signaling (SOCS) family. SOCS 
modulates the sensitivity of cytokine receptors and alters the signaling pathways 
induced in response to TLR stimulation [127-129].  
 
In contrast to M1 macrophages, M2 macrophages are activated upon IL-4, IL-13, 
or IL-10 binding to their receptors, IL-4R, IL-13R, or IL-10R [108, 128, 129]. 
Binding to the receptors activates JAK1 and JAK3. Activation of JAK signaling 
through IL-4Rα activates STAT-6 while IL-10 stimulation through IL-10R activates 
STAT-3 transcription factor. The activation of STAT-6 and STAT-3 induce their 
phosphorylation, dimerization, and nuclear translocation which results in an anti-
inflammatory M2 macrophage phenotype [108, 127]. STAT-6 and STAT-3 
activation is regulated via SOCS proteins and protein inhibitors of activated STAT 
(PIAS). SOCS proteins form a negative feedback loop whereby SOCS genes are 
induced following cytokine stimulation and inhibit cytokine signaling. Conversely, 
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PIAS regulate STAT signaling by binding the activated STATs and preventing 
them from binding to the DNA [108, 128]. 
 
M1 and M2 macrophages have distinct effectors and secrete different cytokines 
and mediators upon stimulation. Activation of STAT-1 and NF-κB signaling in M1 
macrophages promotes the release of TNF-α, IL-1, IL-6, IL-12, Type I IFN, 
CXCL1-3, CXCL-5, and CXCL8-10.  TNF-α and IL-1β are pro-inflammatory 
cytokines responsible for inducing fever, tissue destruction, hematopoiesis, 
leukocyte chemotaxis, and interferon secretion [108, 127, 128].  IL-6 is a 
pleiotropic cytokine with a wide range of pro-inflammatory effects and some 
regenerative and anti-inflammatory activities. IL-12 is a potent pro-inflammatory 
cytokine and it promotes the activation of cytotoxic T lymphocytes and natural 
killer cells. CXCL-8 is also called IL-8 and it is the major neutrophil chemotactic 
factor. Last but not least, IFNγ promotes type 1 T helper cell responses (Th1 
immunity). The other cytokines mediate inflammation, recruitment and migration 
of immune cells, and release of pro-inflammatory mediators [127, 128, 133]. 
 
Alternatively, activation of STAT-6 and STAT-3 promotes the release of anti-
inflammatory mediators. This includes the expression of IL-10, YM1, and FIZZ1 
by M2 macrophages. Additionally, activation of STAT-6 and STAT-3 upregulates 
the expression of Dectin-1, DC-SIGN, mannose receptor, scavenger receptor A, 
scavenger receptor B-1, and CD163 [128]. IL-10 is an anti-inflammatory cytokine 
which suppresses the expression of pro-inflammatory cytokines, inhibits NF-κB 
signaling, suppresses Th1 immunity and promotes a regulatory T cell phenotype. 
Ym1 and FIZZ1 promote Th2 cytokine expression, wound healing, and allergic 
airway inflammation.  Moreover, mannose receptor functions as a pattern 
recognition receptor, plays a role in antigen uptake and presentation, mediates 
phagocytosis, scavenges unwanted mannoglycoproteins, and clears pro-
inflammatory mediators during inflammation resolution. Additionally, scavenger 
receptors remove debris and waste materials [108, 127-130, 133, 134]. 
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M1 and M2 macrophages also express distinct enzymes which are believed to 
play important immunomodulatory functions [127, 131, 132, 135, 136]. M1 
macrophages release nitric oxide and reactive oxygen byproducts due to the 
upregulation of iNOS enzyme which metabolizes arginine into nitric oxide and 
citrulline. M2 macrophages express arginase instead which leads to the 
production of prolines and polyamines through arginase conversion of arginine 
into ornithine and urea [128]. The iNOS/arginase paradigm has been studied for 
its role in modulating the immune response. This hinges upon the competition 
between iNOS and arginase for the same substrate, arginine, as well as the 
distinct immunomodulatory effects of arginase [127-132, 135, 136]. 
 
b. Arginase-1 immunomodulatory properties 
 
Arginase is a unique effector of alternative macrophages believed to have an 
immunomodulatory function, particularly through its competition with iNOS for 
their common substrate, arginine. iNOS induced by LPS and Th1 cytokines 
generates tremendous amounts of nitric oxide (NO). This results in an 
aggravated inflammatory response, contributes to bacterial clearance, and 
causes tissue injury [129-132]. Thus, the protective role of arginase-1 was initially 
expressed in terms of its competition with iNOS for arginine to limit the NO-
derived inflammatory damage. This hypothesis has recently been challenged 
because of the important role of NO in macrophage cytotoxic function and 
bacterial clearance [132, 135]. Hopkins and colleagues addressed this issue by 
distinguishing the role of NO in chronic and acute PA lung infection [136]. 
Acutely, the exaggerated generation of NO, the reactive nitrogen species, 
peroxynitrite, and superoxide radicals does not only contribute to the clearance of 
pathogens but also results in serious lung injury and fibrosis. NO is essential for 
angiogenesis, smooth muscle relaxation, and inhibition of neutrophil and 
leukocyte chemotaxis and migration to the lung [136].  
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The anti-inflammatory role of arginase-1 is believed to be far beyond limiting NO 
generation. In fact, increased arginase-1 expression is associated with down-
regulation of the immune response in several conditions including solid and 
hematological tumors, leishmaniasis, schistosomiasis, autoimmune 
encephalomyelitis, sepsis, pregnancy, trauma and experimental 
glomerulonephritis [137-150]. The immunomodulatory effects of arginase have 
been described in these disease models and they include: (1) suppressing Th1 
mediated pathology; (2) modulating the interplay of Th1/Th2 cytokines; (3) 
shifting the macrophage/neutrophil balance; (4) suppressing immune recognition 
and rejection of tumor cells; (5) reducing CD8+ and CD4+ T cell proliferation; and 
(6) decreasing NO-mediated injury [137-150].  
 
The most commonly described immunomodulatory property of arginase-1 
includes the induction of T cell hyporesponsiveness through arginine depletion 
[151-161]. Arginine depletion results in decreased T cell proliferation, decreased 
T cell effector function, and significantly decreased cytokine release (IFNγ, IL4, 
IL5, and IL10) [151, 152, 154-156, 157 2004, 158-161]. Activated T cells under 
arginine depleted conditions fail to express CD3ζ and CD3ε which results in 
decreased receptor-mediated tyrosine phosphorylation [162]. CD3ζ, CD3ε, and 
CD3δ form the CD3 co-receptor essential for T cell activation and transduction of 
intracellular signaling pathways upon antigen stimulation. Decreased expression 
of CD3 impairs the immune response and impairs T cell development, lineage 
determination, and activation [153 2004, 154, 155, 156 2004, 158-161].  
Decreased CD3ζ expression in arginine-depleted conditions is associated with 
decreased cyclin D3 mRNA stability and expression which in turn prevents 
progression in the cell cycle and arrests T cells in the G0-G1 phase [157]. 
Impairment of T cell activation under arginine depleted conditions is T cell 
receptor (TCR) independent and is not mediated via inhibitory effects of CTLA4, 
IL10, PDL1, or TGFβ [144]. Moreover, the decreased T cell proliferation is not 
associated with an increase in apoptosis or T cell death [151]. Additionally, 
arginase-1 promotes a regulatory T cell phenotype independent of IL2, TGFβ, 
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IL10, CTLA4, or PDL1 [144]. Although arginine depletion results in decreased 
expression of T cell activation markers (CD28, CD62L, and CD25), it does not 
affect macrophage activation [160]. Arginine depletion by arginase-producing M2 
macrophages does not affect the expression of other M2 macrophage effectors 
(IL-10, Ym1, and Fizz1) [144, 160]. In most cases, arginase-mediated T cell 
suppression is localized to the site of infection and does not affect naïve T cells 
in lymph nodes and other secondary lymphoid organs [138-144]. Importantly, 
arginine depletion does not affect the expression of iNOS or arginase. Finally, 
this T cell suppression has been demonstrated to be reversible with arginase 
inhibition or with L-arginine supplementation in a variety of disease models [137-
150].  
 
Arginase-1 also plays an essential role in wound healing and protection against 
inflammatory injury [135, 163]. Arginase is thought to promote its effects on 
tissue remodeling by metabolizing arginine into prolines and polyamines thereby 
promoting collagen synthesis, cell proliferation, and tissue regeneration [163]. 
Inhibiting or deleting arginase is associated with delayed wound healing along 
with defects in matrix deposition in several disease models. Campbell et al. show 
a macroscopic increase in cutaneous wound area along with decreased 
reepithelization in arginase conditional knock-out mice (Tie2-cre-mediated 
deletion from endothelial cells) [163].  In cystic fibrosis, the increased risk for 
chronic bacterial colonization along with the exaggerated inflammation result in 
progressive airway wall thickening and lumen dilatation along with permanent 
scarring of the lungs. Arginase is thought to protect against the resultant scarring 
and to mediate airway remodeling [135, 163]. 
 
Collectively, arginase-1 is an effector of M2 macrophages which exerts 
immunomodulatory and anti-inflammatory properties. Arginase-1 was evaluated 
in different diseases where is it shown to suppress T cell immunity and to 
promote a regulatory phenotype. Thus, it is critical to define the role of arginase-1 
in the setting of dysregulated immunity in cystic fibrosis. It is reported that 
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patients with cystic fibrosis express significantly high levels of arginase in their 
sputum along with decreased levels of NO. The increased arginase expression in 
patients with cystic fibrosis is believed to be mainly of neutrophil origin. 
Moreover, increased sputum arginase activity is reported in patients with end-
stage disease, patients with disease exacerbations, and in patients with severe 
lung disease and bronchiectasis [109, 119, 123-126, 135, 143, 164]. According to 
Grasemann et al., patients with stable disease have significantly lower levels of 
arginase expression and arginase activity is significantly increased upon hospital 
admission for exacerbation. Thus, arginase activity negatively correlates with 
lung function [109]. Current clinical studies link arginase expression with cystic 
fibrosis pathology due to significantly reduced levels of NO required for bacterial 
clearance [109, 119, 123-126, 135, 143, 165]. However, the immunomodulatory 
properties of arginase in cystic fibrosis and its ability to regulate the immune 
response in chronic infections have not been investigated.  
 
c. Altered macrophage polarization 
 
Proportional and balanced macrophage polarization is essential for effective 
control of inflammation. In response to any infection, different populations of 
macrophages are activated to play specialized roles in clearing bacteria and 
dead cells by phagocytosis, recruiting neutrophils and antigen presenting cells to 
the site of infection, as well as establishing and coordinating an efficient adaptive 
immune response. 
 
In patients infected with PA, there are increased levels of M2 macrophages in 
their bronchoalveolar lavage fluids while M1 macrophages predominate in the 
nasal cavities of these patients [166, 167]. Similarly, macrophages in sputum 
samples of cystic fibrosis patients show reduced expression of M2 markers and 
tend to be predominantly M1 polarized [168, 169]. Additionally, Tarique et al. 
show that macrophages from cystic fibrosis patients as well as macrophages with 
inhibited CFTR fail to respond to IL-4 and IL-13; therefore, they fail to polarize to 
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an M2 phenotype [27]. However, polarization to an M1 phenotype is unaffected 
[27]. Thus, CFTR mutations contribute to the altered macrophage phenotype and 
promote an M1 predominant polarization. According to Levi, stimulation of cystic 
fibrosis macrophages with IFN-γ and LPS induces a significantly greater increase 
in STAT-1 phosphorylation and activation compared to normal macrophages. 
This was also associated with significantly greater levels of pro-inflammatory 
cytokine release compared to normal macrophages [27, 167, 169]. Importantly, 
several studies report excessive and dysregulated stimulation of NF-κB 
transduction pathway in macrophages and epithelial cells [170].  
 
Additionally, the lung environment in cystic fibrosis skews macrophage 
polarization depending on the stability of the disease and the nature of infections 
at specific timepoints. The regulatory environment in stable disease and the Th2 
mediated immune responses drive macrophage polarization towards an M2 
phenotype. Infections which favor a Th1 response are associated with an 
aberrant polarization of M1 macrophages [171]. These macrophages are 
recruited in excessive numbers and are more sensitive to external stimuli, 
resulting in robust signal transduction and excessive release of their 
characteristic cytokines. Gao and colleagues show that alveolar macrophages 
with mutated or inhibited CFTR have exaggerated activation of NF-κB and 
increased release of TNF-α [25]. Gao also shows increased chemotaxis and 
migratory abilities of macrophages with mutated CFTR [25]. Therefore, skewing 
macrophage polarization in cystic fibrosis is uncontrolled and results in an 
exaggerated immune response [134, 170-172]. 
 
d. Altered macrophage functions 
 
Macrophage phagocytic function is affected by the absence or mutation of CFTR 
receptors normally expressed on the cell surface. Malfunctional CFTR receptors 
impair the ability of cystic fibrosis macrophages to clear engulfed pathogens 
[134, 172, 173]. CFTR is essential to control phagosomal pH which is critical for 
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macrophage bactericidal functions. This was demonstrated in CFTR knock-out 
mice as alveolar macrophages from these animals fail to acidify their 
phagolysosomes and therefore lack the ability to efficiently kill internalized 
microbes [174]. Additionally, cystic fibrosis causes a disruption in macrophage 
lysosome function and the ability to recognize PAMPs. Bruscia and colleagues 
show that cystic fibrosis macrophages are characterized by defective endosomes 
with delayed endosome/lysosome maturation during LPS challenge [106, 170]. 
This prevents trafficking of TLR4 from the plasma membrane to the lysosome 
resulting in profound stimulation of these macrophages and increased release of 
inflammatory mediators compared to wild-type macrophages [170]. Additionally, 
this defect contributes to long-term colonization of the cystic fibrosis lungs by PA 
which is able to mutate their recognition sequences in order to escape the 
recognition by macrophage TLRs [25, 175, 176].  
 
Macrophages in cystic fibrosis also have decreased ability to clear dead 
neutrophils. Dead neutrophils are normally cleared from the airways by being 
expelled in the coughed mucus or through phagocytosis by alveolar 
macrophages. However, the impaired macrophage signaling pathways, the 
increased intraphagosomal pH, as well as the impaired trafficking of recognition 
receptors to the surface of macrophages render these cells inefficient in clearing 
the excessive number of dead neutrophils [134, 170-172]. Neutrophils also form 
extracellular traps which interact with macrophages and further impair the 
macrophage functions. Therefore, clearance of dead neutrophils is impaired in 
cystic fibrosis leading to accumulation of highly toxic substances [20, 25, 63, 133, 
134, 170-175]. 
 
e. Altered alveolar and interstitial macrophages 
 
Two major macrophage populations are normally present in the lungs, the 
alveolar macrophages and the interstitial macrophages. Alveolar macrophages 
are found in the airway lumen while interstitial macrophages reside in the lung 
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parenchyma [63, 133, 134, 172-174]. When alveolar and interstitial macrophages 
are activated they release mediators to recruit other macrophages from the 
circulation to assist in pathogen clearance. Alveolar macrophages are inherently 
suppressive and maintain homeostasis by clearing debris, recycling surfactant 
molecules, and preventing inflammation. However, they are the first line of 
defense which is initiated by the release of pro-inflammatory cytokines upon 
encountering a pathogen [63, 133]. Conversely, interstitial macrophages are very 
heterogeneous with versatile regulatory functions including the activation of IL-10 
mediated adaptive responses. Alveolar and interstitial macrophages in cystic 
fibrosis are intrinsically modified with metabolic hyperactivity, excessive cytokine 
release, as well as the production of ciliary dyskinesia and tissue-damaging 
substances [63, 133, 177-182]. Additionally, several reports describe a 
remarkable increase in the numbers of tissue macrophages in cystic fibrosis and 
strongly correlate their altered functions with increased mucus accumulation and 
pulmonary exacerbations [63, 133, 134, 172-174, 183-185]. Moreover, tissue 
macrophages are very sensitive to CFTR mutations. A single allelic CFTR 
mutation is sufficient to exacerbate macrophage pro-inflammatory functions. 
Alveolar macrophages in cystic fibrosis have reduced ability to secrete IL-10 
while they release tremendous amounts of IL-6, IL-8, IL-1, and TNF-α. Therefore, 
alveolar macrophages in cystic fibrosis are unable to exert their regulatory 
functions and they fail to establish homeostasis in the lungs. Additionally, 
alveolar and interstitial macrophages in cystic fibrosis express high levels of TLR-
4 which is associated with significantly elevated and sustained signal 
transduction and activation of the NF-κB and MAPK pathways [63, 133, 177, 186, 
187]. Tissue macrophages in the cystic fibrosis lungs also have impaired 
phagocytosis, impaired autophagy, impaired lipid raft composition, impaired 
vesicle trafficking, as well as impaired pH in the trans-Golgi, endosome, and 
lysosome [63, 133, 184, 185]. Collectively, these impairments render the tissue 
macrophages unable to engulf and clear pathogens [63, 133, 178-182]. 
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In summary, macrophages present in the cystic fibrosis lungs fail to exert the 
essential functions required for pathogen clearance while coordinating an 
inflammatory response that is excessive and dysregulated. These changes are 
evident even before any signs of infection and continue to accumulate with non-
resolving infections. The phagocytic and regulatory functions of these 
macrophages are impaired and thus are drastically deleterious to the host. 
 
III. Adaptive immunity in cystic fibrosis  
 
The activation of an efficient and specialized adaptive immune response is 
crucial to completely clear and eradicate infections. There are two main 
categories of cells which carry out adaptive immunity: B cells and T cells. Both 
are antigen-specific and selectively expand in lymphoid organs after recognition 
of foreign antigens presented to them by antigen presenting cells (APC). Similar 
to the innate system, adaptive immune cells exert regulatory functions which 
terminate the inflammatory response. Additionally, adaptive immunity provides 
long-lasting immunological memory. Disruption of adaptive immune responses in 
patients with cystic fibrosis is associated with disease pathology and is a result of 
the disturbed communication with the innate immune cells, environmental factors 
which skew T and B lymphocyte responses, as well as intrinsic factors like CFTR 
mutations and altered signaling [63, 133, 182]. The following section discusses 
the main elements of the adaptive immune response and how they are altered in 
patients with cystic fibrosis.  
 
i. Impaired communication between innate and adaptive immunity 
 
In cystic fibrosis, innate immune cells display a decreased efficiency in antigen 
presentation and to provide necessary costimulation for B and T cell selection. 
The communication, whether direct or indirect, between the innate and adaptive 
immune cells is essential to selectively induce the expansion of antigen-specific 
B and T lymphocytes. Positive selection requires antigen presentation through 
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the MHC receptors on APC. Macrophages and dendritic cells process antigens 
from the site of infection and present them for lymphocyte selection in the 
lymphoid organs. When T or B cells get activated, they require costimulation by a 
second signal in order to expand and differentiate. Costimulation involves 
cytokine signaling for lymphocyte differentiation and proliferation (like IL-2, IL-4, 
IFN) as well as costimulatory receptors (like B7 and CD28) that govern cognate 
interactions between cells [182]. In cystic fibrosis, non-CFTR genetic mutations 
disrupt the communication between innate and adaptive immunity. In fact, Wright 
and colleagues show that disease severity is directly correlated with the MHC 
gene polymorphisms in cystic fibrosis [182]. These polymorphisms are related to 
the failure of appropriate antigen processing and presentation. For instance, 
dendritic cells from cystic fibrosis patients express lower levels of MHC-II on their 
surface compared to dendritic cells from healthy volunteers [63, 133, 183]. 
Specific mutations were also associated with increased infections with PA 
including the DR7/DQA*0201 mutation while HLA-DQB1*0201 increases the risk 
for diabetes in cystic fibrosis patients. Additionally, genetic variations of MHC 
alleles predict susceptibility to PA infections. Expression of HLA-DR7 in cystic 
fibrosis patients is associated with increased risk for PA colonization while HLA-
DR4 expression is associated with reduced frequency of PA colonization [188]. In 
addition, neutrophil elastases are capable of cleaving MHC receptors from 
antigen-presenting cells. Additionally, B lymphocytes are essential for antigen 
presentation required for effector and memory T cell priming and induction. B 
cells from cystic fibrosis patients are characterized with an inefficient uptake, 
processing, and antigen presentation on their B-cell receptors [189-191]. 
Additionally, T and B cells with mutated CFTR lose the appropriate membrane 
polarization potential due to abnormal ion flux across the CFTR channels thus 
losing the essential ion clustering along the membrane for stabilizing the 
interaction between these lymphocytes and the antigen presenting cells.  
 
While immune cells fail to present antigens effectively, costimulatory signals are 
also altered in cystic fibrosis lungs [133, 182, 183, 188-192]. Evidence suggests 
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that PD-L1/PD-1 interaction between airway epithelial cells and T cells is 
suppressed with reduced PD-L1 expression on cystic fibrosis epithelial cells. 
Additionally, epithelial cells control costimulation by intrinsically modulating their 
cytokine release. They skew T lymphocytes into a Th2 response by releasing IL-
4 and they control T cell proliferation by releasing IL-2. Finally, the local release 
of different pro- and anti- inflammatory cytokines, as well as growth factors, by 
different immune cells directly influence the clonal selection and the 
differentiation of T and B lymphocytes [189-192]. Collectively, genetic and 
inflammatory factors contribute to the failure of coordinated activation of the 
adaptive immune response in cystic fibrosis. 
 
ii. Skewed T cell responses 
 
Differentiation of T lymphocytes into different effector cells is altered in cystic 
fibrosis due to CFTR mutation, intrinsic alterations, and environmental factors 
(summarized in Figure 1.1b). T cell responses involve the activation of T helper 
(Th) lymphocytes which are divided into different subpopulations. Type-1 or Th1 
lymphocytes are pro-inflammatory and are polarized by IFN-γ predominantly 
produced by natural killer (NK) and natural killer T (NKT) cells and by Th1 and 
cytotoxic T lymphocytes [192-194]. Th1 cells are involved in clearance of 
intracellular pathogens and they polarize macrophages into an M1 phenotype 
thus promoting their microbicidal function [192-194]. Th1 lymphocytes are 
stimulated through IFN-γ mediated activation of the STAT-1 signaling pathway 
which activates T-bet, the main Th1 transcription factor. Th1 lymphocytes release 
IL-2, IFN-γ, TNF-α, macrophage inflammatory protein-1 alpha (MIP-1α), and MIP-
1β [192-194]. Additionally, IL-12 from M1 macrophages can activate STAT-4 
which binds and activates T-bet. Conversely, Type-2 or Th2 lymphocytes are 
polarized by IL-13 or IL-4 and release anti-inflammatory cytokines, mediate 
humoral immunity, and clear extracellular bacteria and parasites. IL-4 activates 
the STAT-6 signaling pathway which stimulates GATA3 activation, the Th2 
transcription factor. Additionally, IL-4 is a negative regulator of STAT-4 while IFN-
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γ is a negative regulator of STAT-6; thus, the polarization into a specific Th cell 
subset negatively regulates the other [192-194]. 
 
A third population of T helper cells includes the Th17 lymphocytes which are 
strongly associated with morbidity in cystic fibrosis. Th17 lymphocytes are 
polarized in the presence of IL-6, IL-23, and TGF-β and are responsible for the 
production of neutrophil chemokines, IL-17 and IL-8 [193]. TGF-β along with IL-6 
activate STAT-3 which stimulates the Th17 transcription factor, RORγt. IL-23 
also activates STAT-3 by stimulation of IL-23R. Th17 lymphocytes are 
considered pro-inflammatory due to the potent ability of IL-17 to induce the 
release of TNF-α, IL-1β, and MCP-1 [194]. Th17 lymphocytes and their 
contribution to inflammatory lung injury and pathogenesis in cystic fibrosis are 
discussed in later sections. However, Th17 lymphocytes are the main source of 
neutrophil chemoattractant factors. IL-17A and IL-17F are elevated in the sputum 
of patients with cystic fibrosis and correlate with the excessive neutrophil 
recruitment [164, 194-207]. Chronic infections with PA and other Gram-negative 
bacteria skew the T cell responses towards a Th17 predominant response [194]. 
 
The fourth subset of T helper lymphocytes is referred to as regulatory T cells 
(Tregs). Tregs naturally exist in the thymus and can be polarized peripherally in 
the presence of TGF-β [195]. Tregs express CD25 (IL-2rα) and FoxP3, both of 
which are essential for the suppressive activity of these lymphocytes. Tregs 
release anti-inflammatory mediators upon activation including IL-10, IL-35, and 
TGF-β. Tregs are significantly decreased in the peripheral blood and airways of 
patients with cystic fibrosis compared to healthy individuals. Moreover, patients 
with chronic infections like PA have reduced numbers of Tregs [195, 205] and the 
numbers of Treg lymphocytes in cystic fibrosis lungs positively correlate with lung 
function [195, 205-207]. Additionally, Treg lymphocytes with mutated CFTR fail to 
suppress T cell responses and promote regulated immunity. According to Hector 
et al., infections with PA promote suppressed Treg numbers, impaired Treg 
regulatory functions, and impaired Treg memory development [207].  
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T lymphocytes exhibit unique plasticity and are able to convert from one 
phenotype to another [164, 194-207]. For instance, IL-6 can downregulate FoxP3 
expression in Tregs and increase their secretion of IL-17 thus converting them 
into Th17 phenotype [164, 194-207].  Additionally, an intermediate phenotype of 
Th17 and Th1 lymphocytes has been described where cells co-express IFN-γ 
and IL-17 [194].  Th2 lymphocytes stimulated with IFN-γ also co-express GATA3 
and T-bet. It is important to note that two new subsets of Th lymphocytes were 
discovered, and they include Th9s which release IL-9 and Th22s which release 
IL-22 [194]. Th9 lymphocytes mediate immunopathology and mitigate allergic 
inflammation and fibrosis in patients with cystic fibrosis. Th22 lymphocytes 
observed to play a role are in bacterial infections and help in microbe clearance 
[164, 194-208]. 
 
In cystic fibrosis, T helper lymphocyte populations contribute to pulmonary 
pathology and excessive inflammation. The specific role of each population and 
the different environmental factors that alter these responses are discussed in 
the following sections. 
 
a. CFTR in lymphocytes 
 
CFTR is expressed on B and T lymphocytes and its mutation contributes to the 
alteration of B and T cell responses. Lack of functional CFTR expression on B 
cells is associated with suppressed ability to produce λ light chain upon 
stimulation [196]. Lack of λ light chain significantly affects B cell response against 
PA and the clearance of this pathogen [164, 196-206]. Additionally, lack of 
functional CFTR expression on T cells is associated with exaggerated IgE levels 
and a skewed proallergic Th2 response [164, 197-199]. Increased IL-4, IL-13 and 
IgE levels in CFTR deficient T cells results in a Th2 dominated response which is 
effective against parasites but cannot clear PA infections [164, 196-199]. Several 
studies in CFTR knock-out mice and in CFTR-deficient lymphocytes show the 
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direct correlation between CFTR mutations and allergic inflammation in cystic 
fibrosis [164, 197-199]. CFTR knock-out mice infected with PA produce defective 
Th1 lymphocytes which can release IL-12 but do not exhibit other Th1 properties. 
This was explained by the altered calcium flux in T cells which lack CFTR [196, 
200-202]. Increased calcium signaling alters the expression of calcium-sensitive 
genes including those involved in Th1/Th2 differentiation. According to Mueller, 
increased calcium signaling in T cells activates NFAT transcription factor which 
increases Th2 cytokines (IL-4, IL13, and IL-6) along with increased IgE synthesis 
in B cells leading to suppression of Th1 cytokines and therefore creating an 
allergic inflammatory environment in the cystic fibrosis lungs [200, 201]. 
Moreover, the altered ion flux across the CFTR deficient T cells results in 
membrane depolarization due to retention of intracellular chloride concentrations 
thus altering the surface signaling pathways and resulting in abnormal gene 
expression [202]. Collectively, CFTR mutation in cystic fibrosis skews 
lymphocytic responses by altering the different signaling pathways and 
machineries in B and T cells.  
 
b. Intrinsic and environmental lymphocyte alterations 
 
Lymphocytes in cystic fibrosis are skewed into a Th2 and T17 predominant 
immune response due to inherent predisposition as well as abundance of 
inflammatory signals and cytokines which polarize these cells. Inherent 
predisposition is described by the ability of naïve T cells isolated from cystic 
fibrosis patients to be polarized into Th2 and Th17 phenotypes [203-206]. 
Moreover, there is a significant imbalance between driving and opposing signals 
and cytokines involved in Th2 and Th17 polarization. In fact, Th2 and Th17 
lymphocytes are present in excessive amounts and are believed to mediate 
pathology in cystic fibrosis [203, 204]. Kushwah et al. provide evidence on the 
intrinsic tendency of naïve T cells from cystic fibrosis patients to polarize towards 
the Th17 phenotype [205]. Naïve T cells were isolated from mice and humans 
and examined in response to different polarizing cytokines and stimulants [205]. 
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They found that T cells, with or without mutated CFTR channels, can equally 
differentiate under the influence of appropriate cytokines into Th1 and Treg 
phenotypes. However, when T cells with CFTR mutation were polarized with 
Th17 stimulants, there was at least a 2 times higher and faster shift into the Th17 
phenotype compared to wild-type lymphocytes. Similarly, at least double the 
number of naïve lymphocytes from cystic fibrosis patients polarized into Th17 
phenotype compared to lymphocytes from healthy volunteers. Simultaneously, 
there was equal differentiation of naïve T lymphocytes into Th1 and Treg 
phenotypes from healthy and diseased populations [205]. Interestingly, a case 
report from a 16 year old female diagnosed with cystic fibrosis shows T cell 
unresponsiveness despite the fact that she was not receiving steroids or any 
other immunomodulatory therapy. T cells isolated from her blood failed to 
produce IFN-γ and ex vivo stimulation of naïve T cells failed to differentiate into 
either Th1, Treg, or Th17 phenotypes [206]. This patient had greater severity and 
faster progression of her disease. While intrinsic impairment in T cell 
differentiation might be in part related to CFTR mutations, the exact intrinsic 
mechanisms by which naïve T cells from cystic fibrosis patients polarize to a 
specific phenotype are yet to be elucidated [206].    
 
Several other factors drive lymphocyte polarization in patients with cystic fibrosis 
including the suppressed Treg numbers and the exaggerated release of 
cytokines released by epithelial cells and macrophages. The numerous Th2 and 
Th17 lymphocytes are attributed to the fact that there are minimal numbers of 
Tregs [207]. The deficiency in Tregs creates an imbalance in the pro- and anti- 
inflammatory cytokines. Thus, the lack of IL-10 from Tregs and the pro-
inflammatory lung environment in cystic fibrosis promote polarization of T 
lymphocytes into the Th17 subtype [205-207, 209]. Additionally, lower numbers 
of Tregs in cystic fibrosis patients are associated with increased Th2 
lymphocytes and reduced lung function. M2 macrophages and epithelial cells 
release TGF-β and IL-6 which further polarize T cells towards a Th17 phenotype. 
Moreover, excessively elevated levels of IL-1β, TNF-α, and IL-21 in the cystic 
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fibrosis lungs, along with TGF-β, strongly drive Th17 polarization [67, 207, 209-
219]. Th17s also secrete IL-21 which results in a vicious cycle of continual Th17 
stimulation. IL-6 by itself upregulates IL-23R expression, the latter is stimulated 
with IL-23 binding which further promotes the expansion and maintenance of 
Th17 lymphocytes. Other environmental factors which contribute to increased 
Th17 polarization include the change in lung microbiota and prolonged infections 
[209]. In fact, high concentration of antigen and microbial stimuli synergistically 
stimulate Th17 differentiation by upregulating CD40 expression on T cells and 
increasing IL-6 release by dendritic cells. Strong CD40/CD40 ligand interaction in 
this way preferentially drives Th17 polarization [209-214].  Collectively, intrinsic 
and environmental alterations skew the T lymphocytes in cystic fibrosis towards 
Th2/Th17 phenotype. 
 
Th17 lymphocytes and IL-17 production are associated with poor prognosis and 
play an early role in disease pathology. In fact, IL-17 has been found to be 
involved in several inflammatory diseases including multiple sclerosis, rheumatic 
diseases, inflammatory bowel disease, asthma, and atopic dermatitis [210]. In 
cystic fibrosis, human lung lavage and sputum samples show elevated 
concentrations of IL-17 and IL-23, especially in patients infected with PA 
infections [211-213]. IL-17 is strongly associated with disease pathology via 
upregulation of mucin-producing genes [214, 215]. Th17 cells provide a 
continuous signal for sustained neutrophil inflammation which further aggravates 
lung injury [216-220]. Th2 and Th17 lymphocyte populations also predict disease 
progression. In a study of T cell phenotypes in 57 cystic fibrosis patients, stable 
patients had augmented numbers of Th1, Th2, and Th17 lymphocytes compared 
to normal individuals. Cystic fibrosis patients with PA colonization had 
significantly higher numbers of Th17 lymphocytes compared to non-cystic fibrosis 
patients [67]. Moreover, symptomatic patients with PA or fungal infections had 
significantly higher concentrations of IL-17, IL-13, and IL-5 compared to 
asymptomatic patients. Immune responses in symptomatic patients were 
Th2/Th17 skewed and correlated with increased neutrophils and high-resolution 
 35 
computed tomography changes (fibrosis) [67]. These changes, interestingly, 
were independent of IFN-γ levels. There were higher levels of Th2 and Th17 
cytokines in the bronchoalveolar lavage fluids of patients prior to infections with 
PA and the levels of these cytokines positively predicted the development of PA 
infections [67]. Moreover, decreased IFN-γ levels and defective Th1 responses 
were also predictive of increased PA infection frequency [67]. Another study 
shows increased Th17 cytokines in the lungs of PA infected cystic fibrosis 
patients, and the authors report a strong negative correlation between Th17 
levels and lung function. This relationship remained significant even after 
antimicrobial treatment [221].  
 
It is important to note that Th17s and IL-17 are key elements of cystic fibrosis 
pathology as they are present very early in the disease and are maintained and 
remain elevated throughout the course of the disease. As the disease reaches 
the end stages, high IL-17 concentrations persist. This is partially explained by 
the fact that Th17 cells exhibit immunological memory and that other immune 
cells secrete IL-17 [222]. Non-Th17 cells which secrete IL-17 are thought to play 
a role in later more progressive stages of the disease and include the NKT cells 
and the γδ T-cells [211-213]. IL-17 producing γδ T-cells result in 
hyperinflammatory granulomatous disease and are associated with severe and 
fatal lung damage [209]. Cystic fibrosis patients infected with PA have increased 
numbers of γδ T-cells which release large amounts of IL-17, TNF-α and IFN-γ 
thereby aggravating inflammation and lung injury [67, 223, 224]. Similarly, NKTs 
are pro-inflammatory cells which function to maintain a profound activation of the 
immune response by attracting other immune cells. NKT cells express RORγt 
and recruit large numbers of neutrophils by releasing IL-17. In cystic fibrosis, a 
significant decrease in the Treg/NKT ratio is observed. This further relates to the 
constantly activated inflammatory response with persistent neutrophilia and 
airway hyperresponsiveness [209, 225, 226]. 
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In summary, adaptive immunity is altered in cystic fibrosis and is directly related 
to CFTR mutations as well as to intrinsic T and B cell alterations. Changes in ion 
flux and signaling transduction along with changes in the lung microenvironment 
and the predominance of specific cytokines drive lymphocyte polarization and 
dysfunction. Th2 and Th17 lymphocytes predict lung function and acquisition of 
PA infections while they contribute to cystic fibrosis pathology and lung damage. 
 
 
IV. Dysregulated inflammation  
 
There is evidence that inflammation exists in cystic fibrosis even before any signs 
of infection or lung disease [186]. Scientists originally thought of excessive 
inflammation in cystic fibrosis as a consequence of chronic and repetitive 
infections. However, in a review of primary literature and clinical studies by Rao 
et al., the authors propose that the cause of inflammation in cystic fibrosis 
extends far beyond infection [186]. Rao presents inflammation as an important 
pathological component of cystic fibrosis. Inflammation in cystic fibrosis is 
exaggerated, results in lung injury, persists after pathogen clearance, and is 
present even before the first pulmonary infection [186]. Human sputum and 
bronchoalveolar lavage samples reflect an established pro-inflammatory state in 
cystic fibrosis lungs independent of the presence of an active infection. Several 
clinical studies show at least 10 fold more neutrophils in uninfected cystic fibrosis 
lungs compared to normal humans with or without lower respiratory tract 
infections. Moreover, there is an elevated presence of pro-inflammatory 
cytokines including TNF-α, IL-6, IL-8, and LTB-4 in un-infected cystic fibrosis 
lungs as well [173, 227, 228]. There is an increased number of macrophages in 
un-infected cystic fibrosis lungs. These macrophages are believed to have a 
more profound ability to release mediators and to induce an inflammatory state 
compared to macrophages from non-cystic fibrosis lungs [186]. Studies show 
that in the absence of any infection, macrophages in cystic fibrosis lungs are 
polarized towards a pro-inflammatory M1 phenotype [173, 184]. Naïve human 
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macrophages from cystic fibrosis patients stimulated with LPS show significantly 
higher stimulation of the NF-κB and MAPK signaling pathways, higher levels of 
pro-inflammatory cytokine release, and a decreased ability to produce the anti-
inflammatory cytokine IL-10 [134, 172-174, 181, 229-232]. Similarly, T 
lymphocytes from cystic fibrosis lungs have an increased pro-inflammatory 
potential in culture when compared to T lymphocytes from healthy volunteers 
[231].  
 
In addition, cells that makeup tracheal and epithelial tissues are also capable of 
producing dysregulated inflammation. In a study by Tirouvanziam et al., naïve 
tissues from newborns with cystic fibrosis were grafted into immunocompromised 
mice to investigate the inflammatory potential of cystic fibrosis lung tissues [233]. 
When fetal tracheal tissues were transplanted into severe combined 
immunodeficient mice, there was an eight-fold greater increase in IL-8 secretion 
as compared to mice which received non-cystic fibrosis tracheal grafts. When 
these mice were infected with PA, there was a rapid increase in leukocyte 
migration and spread of PA into the lamina propria within 3 hours in mice which 
received grafts from diseased neonates [233]. In mice with grafts from normal 
neonates, the inflammatory response occurred later and at a slower rate after 6 
hours of infection. The inflammation in mice grafted with tissues from cystic 
fibrosis neonates was associated with severe exfoliation of the lung epithelium 
along with damage in the mucosa which was not otherwise observed in mice with 
normal grafts. These pulmonary changes are believed to create a niche for PA 
growth and replication which is thought to resemble the chronic infection in 
humans [233]. This study supports the idea that CFTR mutations predispose to 
an inflammatory state in cystic fibrosis patients independent of infection. And that 
in the presence of an infection, the already primed and inflamed lungs of cystic 
fibrosis patients respond in an exaggerated manner to invading pathogens.  
 
Additionally, Khan et al. analyzed lavage fluids from the lungs of 16 human 
newborns with cystic fibrosis whose cultures were negative for any possible 
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infection (bacterial, viral, or fungal) [234]. In comparison with normal infants, the 
lavage fluids of the diseased population had significantly higher levels of 
neutrophils, neutrophil elastases, anti-protease inhibitors, and IL-8. Collectively, 
this study by Khan, in addition to many similar studies, confirm the inverse 
relation between neutrophil counts and lung function in cystic fibrosis which is 
again independent of the infection state [185, 234-240]. 
 
Cystic fibrosis patients also have a reduction in the typical anti-inflammatory set 
point of the pulmonary environment, represented by a decrease in the 
concentrations of IL-10, nitric oxide, and lipoxin-A4. IL-10 acts to stop the 
inflammatory response by suppressing the pro-inflammatory transcription factors, 
shutting down the synthesis of inflammatory mediators, and inducing the 
regulated-cell death of neutrophils. The reduction in nitric oxide prevents 
bacterial killing and relaxation of the airways. And finally, lipoxin-A4 is essential 
to limit the neutrophil-mediated inflammatory response [228, 241-250]. These 
changes exist along with the pre-described pro-inflammatory state. Thus, there is 
a disrupted balance of the inflammatory state in patients with cystic fibrosis. 
 
Another factor that clearly relates to the inflammatory picture of cystic fibrosis 
which is independent of infection is the presence of reactive airway (asthma-like) 
signs and symptoms. In fact, smooth muscle cells express CFTR receptors. 
When the latter are mutated they are believed to impair the smooth muscle 
contractility due to impairment of ion flux [248]. Additionally, smooth muscle cells 
in children and adults with cystic fibrosis were observed to be affected with 
hyperplasia and hypertrophy which impairs their contraction [12, 249]. The airway 
hyper-responsiveness and the asthma-like phenotype are also attributed to 
inflammatory mediators which induce smooth muscle contractions. In response 
to these inflammatory cytokines, smooth muscle cells can release IL-8 which 
further contributes to the inflammatory process. Additionally, the excessive 
release of IL-4 and IL-13 by T lymphocytes with mutated CFTR (Th2s) drives 
airway hyper-responsiveness directly and through the increased production of 
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IgE [68]. This presents an inflammatory pulmonary disease overlapping with 
cystic fibrosis pathology and independent of infection state [248-250]. 
 
Collectively, the evidence presented distinguishes the inflammatory process as a 
unique pathological element of cystic fibrosis. This is supported by the facts that 
inflammation is (1) present prior to any infection; (2) is excessive compared to 
the number of infective microbes; (3) contributes to lung injury and damage; (4) 
and is innately skewed towards a pro-inflammatory response. This further 
emphasizes that dysregulated inflammation is a key factor in cystic fibrosis 
pathology to be closely considered for therapeutic targeting and treatment. 
 
V. Current treatments for cystic fibrosis 
 
Current treatment options for patients with cystic fibrosis include supportive 
treatment to improve breathing and lung function, as well as symptomatic 
treatment targeting the infections and pulmonary inflammation. Most of the 
currently available anti-inflammatory and immunomodulatory therapies fail to 
effectively resolve the dysregulated inflammation without drastically impairing the 
immune response [84 2001, chmiel, 1999, 97, 250-279]. Several elements of the 
disrupted inflammation and the dysregulated innate and adaptive immune 
responses have been considered for development of new therapeutic targets. 
 
i. CFTR based therapies 
 
Novel therapeutic approaches aim at targeting CFTR function. As discussed 
earlier, CFTR mutations contribute to altered inflammation in several aspects 
[250-256]. Patients with cystic fibrosis have 2 mutated CFTR alleles which result 
in decreased number and malfunction of the CFTR channels. Genotype-directed 
therapies use genetic approaches to restore expression and function of CFTR 
channels. The personalized approaches have been successful in restoring 
epithelial and phagosomal functions; however, they are of limited usefulness in 
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advanced disease stages [250-253]. Additionally, small molecules have been 
developed as CFTR modulators. These modulators target specific CFTR variants 
and mutations that are associated with a minimum level of CFTR protein 
expression. Therefore, these CFTR modulators potentiate and improve the 
function of CFTR expressed on cell surface level [250-253]. Ivacaftor, 
lumacaftor/ivacaftor, and tezacaftor/ivacaftor are FDA approved CFTR 
potentiators. They improve ion flux across the channels, improve lung function, 
and reduce morbidity and mortality. However, the use of these CFTR modulators 
remains limited for patients with a particular mutation [254-256]. 
 
ii. Anti-inflammatory therapies 
 
a. Corticosteroids 
 
Corticosteroids are the main anti-inflammatory agents used in cystic fibrosis 
patients [81, 257]. They are widely available and efficiently dampen airway 
inflammation in a global and non-specific way. There are several oral, inhaled, 
and intravenous corticosteroid formulations that are extensively used in patients 
with cystic fibrosis [81, 256]. Corticosteroids are effective in slowing disease 
progression and suppressing excessive inflammation. However, long-term 
steroid use is associated with many adverse events including growth retardation 
and even decline in lung function [256-259]. Nonetheless, steroids are broadly 
used in cystic fibrosis as targeted anti-inflammatory drugs are not available. 
 
b. Therapies targeting neutrophil recruitment 
 
Multiple approaches aim to correct specific alterations of the immune response 
[8]. Clinicians and immunologists are attempting to target the signaling pathways 
involved in neutrophil recruitment. For instance, a human monoclonal antibody 
against IL-8 is proving to be promising in clinical trials [260]. Besides targeting IL-
8, studies in mice show that neutralizing IL-17 is also promising and it effectively 
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reduces neutrophil influx in response to PA [260-262]. However, targeting IL-17 
with neutralizing antibodies is challenging due to the importance of this cytokine 
in the clearance of pathogens [8, 260-262]. 
 
Other therapies directed against neutrophils include the attempt to deliver or 
stimulate the endogenous release of anti-proteinases (α1-proteinase inhibitor) 
[105, 263-267]. Several studies are evaluating the potential to formulate 
appropriate dosage forms or genetic approaches to achieve therapeutic levels of 
these proteinase inhibitors [105, 263-266]. A recent study just passed phase-II 
clinical trials where they show limited toxicity with an inhaled form of α-1 
antitrypsin (a human anti-protease) [267]. 
 
Moreover, new therapies are directed to clear the pathogenic DNA released from 
dead neutrophils and bacteria [268, 269]. The release of DNA fragments results 
in increased mucus thickness and activation of several inflammatory cascades. 
Recombinant DNase was evaluated in several human trials where it proved to 
reduce mucus thickness, decrease neutrophil influx and recruitment, improve 
lung function, and decrease exacerbations [268, 269]. In fact, some DNases are 
FDA approved for use in cystic fibrosis.  
 
c. Therapies against NF-κB signaling pathway 
 
Several approaches target specific pathways involved in exaggerated 
inflammation including that governed by NF-κB [84 2001, chmiel, 1999, 97, 257-
259, 270, 271, 279]. Recombinant IL-10 succeeds in regulating inflammation by 
inhibiting NF-κB activation in murine models of PA pneumonia. However, it has 
not yet been assessed in humans [280]. A phase-II clinical trial is currently 
evaluating the efficacy of Genestein which is a tyrosine kinase inhibitor that 
stimulates CFTR and inhibits NF-κB activation [270, 271]. Other therapies in 
development which target NF-κB activation in cystic fibrosis include (1) HE3286, 
which is currently in phase I/II clinical trials; (2) azithromycin, which passed a 
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phase III clinical trial and is suggested to inhibit NF-κB and AP1 activation; (3) 
curcumin, which is proven to block NF-κB activation and rescue mutated CFTR 
from degradation; (4) and ibuprofen and fenretinide/docosahexaenoic acid (in 
phase II clinical trial), which are shown to regulate NF-κB activation and lipid-raft 
formation and clustering [97].  
 
A major concern for developing an NF-κB inhibitor is the threat to suppress 
immunity and pathogen clearance. Attempts are being made to target NF-κB 
activation locally in the lungs by developing dosage forms that deliver the 
inhibitors to the lungs directly. Alternative approaches include screening for 
specific molecular targets that would provide controlled inhibition of NF-κB 
without global inhibition. Therefore, optimizing currently available therapies by 
identifying specific pathways by which they exert their beneficial effects is 
essential to overcome the failure and adverse drug effects of the current 
therapies. 
 
d. Cell-based therapies 
 
Cellular therapy is also an interesting and promising venue for cystic fibrosis 
treatment [272-274]. Clinical studies show a significant reduction of bacterial 
replication and infectivity along with increased soluble bactericidal substances in 
the airways of cystic fibrosis patients treated with human mesenchymal stem 
cells. Other cellular therapies include the restoration and transfer of engineered 
epithelial cells, monocytes, or macrophages [272-274]. Some of these 
approaches made it into clinical trials while others are still at the level of 
experimental animal models [272-274].  
 
iii. Antimicrobial therapies 
 
Scientists are developing new antimicrobial molecules and evolving better ways 
to deliver the currently available antibiotics [275-277]. New dosage forms deliver 
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high concentrations of antibiotics locally into the lungs which can allow the 
compounds to reach into the inaccessible areas of infection in the cystic fibrosis 
airways. Rapamycin and azithromycin can be successfully delivered in high 
concentrations packed in engineered nano-particles [275, 276]. Other therapies 
directed against the infecting microorganisms include the development of viral 
phages to kill the colonizing bacteria [277]. However, resolution of chronic 
infection is promising, no evidence is available on how helpful it would be 
because inflammation is dysregulated independent of the infection status. 
 
In summary, cystic fibrosis pathology is based on the chronic infections and the 
non-resolving pulmonary inflammation. Our increased understanding of the 
different components of cystic fibrosis pathology and the specific alterations in 
the immune system and the lung microenvironment identifies novel therapeutic 
targets. In fact, many therapies in development are targeting these specific 
alterations including (1) therapies which restore CFTR function; (2) therapies 
which control neutrophil inflammation; (3) therapies which control NF-κB 
activation; (4) therapies which restore functional immune cells; (5) and therapies 
which clear non-resolving infections. Additionally, the advancement in therapeutic 
options necessitates the consideration of combination therapy that would target 
infection, inflammation, genetic, and symptomatic components of this complex 
disease [84 2001, chmiel, 1999, 97, 250-278]. 
 
VI. Azithromycin use in cystic fibrosis 
 
Macrolide antibiotics constitute a unique therapeutic option proven to be 
tremendously effective in cystic fibrosis patients colonized with PA [281-285]. 
Macrolides exhibit anti-inflammatory properties and are used to control 
dysregulated inflammation. Macrolide antibiotics include azithromycin, 
erythromycin, clarithromycin, and roxithromycin. Macrolide antibiotics inhibit 
bacterial growth by binding and inhibiting the 50s ribosomal subunit thereby 
inhibiting protein synthesis by blocking the translation of mRNA into proteins in 
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bacteria [281]. However, the beneficial effects of macrolide antibiotics in cystic 
fibrosis are independent of their antibacterial activity. In fact, several studies 
evaluated the anti-inflammatory properties of the four macrolides mentioned. In a 
study by Ianaro et al., treatment with either macrolide reduced leukocyte 
infiltration, exudate volume, as well as reducing the pro-inflammatory cytokine 
burst in an acute pleuritic model in rats. The four macrolides reduce TNF-α, IL-
1β, IL-6, and nitric oxide levels in normal and in inflamed lungs [282]. The four 
macrolides were also evaluated in several inflammatory diseases in humans 
where they proved to control neutrophil migration, oxidative burst in phagocytes, 
as well as pro-inflammatory cytokine release [281-285]. Additionally, the four 
macrolides share the ability to accumulate intracellularly in macrophages and 
neutrophils suggesting a possible interaction with leukocytes to control 
inflammation [282-285]. However, the specific mechanism underlying the anti-
inflammatory properties remains unclear. In cystic fibrosis, azithromycin received 
special attention and it proved to exert clinically beneficial effects without 
considerable adverse reactions. This section summarizes the clinical studies 
which evaluate azithromycin anti-inflammatory properties in cystic fibrosis and 
presents the cellular and molecular mechanisms involved. 
 
i. Azithromycin antimicrobial spectrum and pharmacokinetic properties 
 
Azithromycin is effective against some Gram-positive, some Gram-negative, and 
some atypical bacteria [281-295]. The drug’s spectrum of activity covers some 
strains of Staphylococcus, Streptococcus, Haemophilus, Chlamydia, 
Mycoplasma, Neisseria, Moraxella, Legionella, and Prevotella. Additionally, 
azithromycin is orally bioavailable and peaks within 2-3 hours in adult humans 
[281, 282]. Azithromycin accumulates in tissues and intracellularly- particularly in 
macrophages. Thus, tissue levels are at least 50 fold greater than plasma 
concentrations. Additionally, azithromycin is characterized with a very long half-
life estimated to be about 35-40 hours and can be as high as 68 hours following 
a single 500 mg dose [286-289]. Despite its large therapeutic window, 
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azithromycin can cause gastrointestinal toxicity and cardiotoxicity (including QT-
prolongation and arrhythmias). The FDA has issued a warning concerning the 
cardiotoxicity with azithromycin which indicates that the risk is very low in 
patients with no coexisting risk factors [289-293]. However, the use of 
azithromycin should be closely monitored in patients with pre-existing cardiac 
problems, arrhythmias, baseline QT prolongation, electrolyte disturbances, and 
kidney problems [290-295].  
 
ii. Anti-inflammatory effectiveness of azithromycin  
 
Several clinical studies have evaluated the effectiveness of azithromycin in lung 
infection and inflammation [296]. Azithromycin is particularly beneficial in 
inflammatory lung diseases with non-resolving infections. In fact, azithromycin 
was used in 1982 against panbronchiolitis where patients suffer from chronic 
pulmonary inflammation and PA infections. Azithromycin has proven in 
randomized clinical trials in patients with panbronchiolitis to improve lung function 
and outcomes in patients infected with PA. PA virulence was shown to be 
reduced with long-term azithromycin treatment, primarily its ability to form 
biofilms [297, 298]. However, it is important to note that azithromycin does not 
inhibit or kill PA. Thus, these studies provided early evidence of an alternative 
mechanism involved with azithromycin beneficial effects which is independent of 
azithromycin antibacterial activity [296]. 
 
In patients with cystic fibrosis, five large clinical trials have evaluated the safety 
and anti-inflammatory efficacy of chronic azithromycin administration. Southern 
et al. performed a meta-analysis of these clinical trials comparing azithromycin 
therapy against placebo and including at least 959 patients from different ages 
[296]. The following section presents the main outcomes of the five clinical trials. 
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a. Improved lung function 
 
Chronic azithromycin administration in patients with cystic fibrosis improves lung 
function. Three of the clinical trials show a significant improvement in lung 
function in patients on azithromycin (measured by forced expiratory volume, 
FEV1) [299-301], while the other two trials reported that azithromycin treatment 
did not alter the FEV1 in patients with cystic fibrosis [302-305]. Nevertheless, the 
grouped meta-analysis of all the data from the above-mentioned trials supports 
the fact that azithromycin improves lung function in adults and children with cystic 
fibrosis at a 6-month treatment timepoint [296]. Additionally, there was a 
significant improvement in the forced vital capacity (FVC) in patients who 
received azithromycin. However, these studies did not distinguish the effects of 
azithromycin on FEV1 or FVC in the context of chronic PA infections. The five 
trials either excluded the patients with PA infections or included them randomly 
along with other patients not infected with PA [296]. Therefore, there are no 
studies that directly compare the effects of azithromycin vs placebo in cystic 
fibrosis patients infected with PA.  
 
b. Reduced exacerbations and improved quality of life 
 
Another endpoint evaluated in these trials include the effects of azithromycin on 
the exacerbation frequency [296]. Exacerbations recorded in these trials were 
either protocol defined or physician determined and they were reported in terms 
of frequency and time to exacerbation. In the five clinical trials mentioned above, 
there was a significant reduction in the number of exacerbations and hospital 
visits in patients who were on azithromycin [299-305]. 
 
Additionally, chronic azithromycin use in patients with cystic fibrosis improved 
quality of life [296]. There were slight differences among the five clinical trials as 
the quality of life (QOL) endpoint was analyzed using different QOL assessment 
questionnaires.  However, each trial showed improvement in certain measurable 
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components including the physical performance, body image, mental health, and 
social involvement [299-305]. 
 
c. Reduced need for antibiotics 
 
Although long-term antibiotic use could lead to antimicrobial resistance and other 
issues of collateral damage, the chronic use of azithromycin reduced the need for 
antibiotics and infection risk [296]. According to the five clinical trials, there was a 
significant reduction in the need for initiation and duration of oral and IV 
antibiotics in the azithromycin group. Patients on azithromycin acquired PA 
infections at a minimal rate similar to the placebo arm. Moreover, patients in the 
azithromycin group had a significantly lower rate of Staphylococcus aureus 
infections [299-305]. Conversely, the azithromycin group was at higher risk for 
infections with macrolide-resistant Staphylococcus aureus while the infection rate 
with MRSA was not different. Additionally, the risk for acquiring other infections 
was similar between the two groups in all the trials [299-305]. 
 
d. Reduced inflammatory parameters 
 
The five clinical trials evaluated the anti-inflammatory effects of chronic 
azithromycin use in patients with cystic fibrosis [296]. There was a significant 
reduction in pulmonary inflammation with azithromycin use. For instance, there 
was a significant drop in C-reactive protein (CRP) levels at 3, 6, and 12 months 
intervals. Additionally, the trials reported reduced neutrophilia and pro-
inflammatory cytokine concentrations with azithromycin treatment [299-305]. 
 
e. Adverse events 
 
Chronic azithromycin administration in patients with cystic fibrosis was safe and 
well tolerated [296]. Although patients on azithromycin had reduced fever, cough, 
and other respiratory symptoms, they had a higher incidence of gastrointestinal 
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side effects compared to the placebo group [299-305]. None of the patients on 
azithromycin developed any severe side effects while a few patients had 
moderate side effects that required treatment discontinuation (in the 5 trials 
0,1,1,5, & 12 dropouts were recorded for an overall percentage of 0.5–11% of the 
total number of subjects enrolled). Finally, there were no deaths reported in any 
of the studies [296, 299-305].  
 
In summary and despite the heterogeneity of the study populations, the meta-
analysis supported the use of azithromycin treatment in cystic fibrosis patients. 
The improved lung function, reduced exacerbations, reduced need for antibiotics, 
and the decreased inflammatory parameters (CRP) were all clinically significant. 
However, these studies had some limitations including: (1) none of the studies 
evaluated the effects of azithromycin in patients with PA infections; (2) only one 
study evaluated azithromycin use at a 12-months timepoint and the remaining 
were for 6-months treatment durations; (3) different daily and weekly doses of 
azithromycin were evaluated in different age groups; (4) and none of the studies 
stratified the effects of azithromycin based on the CFTR mutation category [296, 
299-305]. Therefore, more studies are required to distinguish the beneficial 
effects of azithromycin among patients with PA infections and patients within 
specific age groups.  
 
iii. Current treatment guidelines for azithromycin use in cystic fibrosis 
 
In Europe, and based on this meta-analysis by Southern et al., the off-label use 
of azithromycin in cystic fibrosis patients was added to the National Institute for 
Health and Care Excellence (NICE) antibiotic treatment guidelines [306]. A 6-
month treatment in patients with deteriorating disease or as determined by 
physician judgment is suggested. The regimen for the off-label use as per the 
NICE clinical guidelines suggests a 3 times weekly dose of azithromycin [306].  
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In the United States, and according to the Cystic Fibrosis Pulmonary Guidelines, 
azithromycin long-term use in cystic fibrosis is divided into two recommendations 
[307, 308]. The guidelines suggest “high” benefit in patients with PA infections 
who are 6 years of age and above. The Cystic Fibrosis Foundation recommends 
the “chronic use of azithromycin to improve lung function and reduce 
exacerbations” in these patients chronically colonized with PA. Alternatively, the 
guidelines suggest “moderate” benefit in patients not infected with PA. The Cystic 
Fibrosis Foundation recommends for these patients, 6 years of age and above, 
without evidence of PA in their lungs to consider long-term azithromycin 
treatment to reduce exacerbations [308]. 
 
iv. Anti-inflammatory cellular and molecular mechanisms of 
azithromycin 
 
The mechanisms underlying the clinical benefits of azithromycin and the 
substantial improvement in lung function and inflammatory parameters are yet to 
be elucidated. As discussed in sections (i) and (ii), macrolides and specifically 
azithromycin exert a clinically beneficial role in cystic fibrosis patients by 
regulating the pro-inflammatory cytokine release and the oxidative burst and 
migration of phagocytes [309]. Additionally, azithromycin has unique 
pharmacokinetic properties allowing it to accumulate intracellularly in these 
phagocytes. This drove many researchers to believe that the macrolide anti-
inflammatory mechanisms involve specific targets in neutrophils and 
macrophages. Yet, the specific cellular and molecular targets of azithromycin had 
not been described. 
 
In 2008, Murphy et al. successfully advanced our knowledge by demonstrating 
the effects of azithromycin on macrophage polarization [310]. This report by our 
group examined the effects of azithromycin on macrophage phenotype by 
stimulating J774 murine macrophages invitro. Macrophages were polarized into 
an M1 phenotype with IFNγ or into an M2 phenotype with IL-4 and IL-13. After 
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stimulation with LPS, polarized J774 macrophages expressed different surface 
markers that distinguish either macrophage phenotype. Interestingly, 
azithromycin in the presence of IFNγ and LPS was able to shift the macrophage 
polarization away from an M1 towards an M2-like phenotype [310]. This was 
based upon reduced CCR7 expression (M1 marker) and increased MR and 
CD23 expression (M2 markers) compared to IFNγ alone and similar to IL-4 and 
IL-13 treated macrophages. Additionally, azithromycin treated macrophages 
produced significantly less IL-12 and IL-6 pro-inflammatory cytokines and more 
of the anti-inflammatory cytokine IL-10 compared to IFNγ treated cells [310]. 
Moreover, Murphy and his colleagues showed that azithromycin also modulates 
other important effectors of macrophage polarization, iNOS and arginase-1 [166, 
310]. Specifically, azithromycin blunts the increase in iNOS expression observed 
with IFNγ and overcomes the suppressed arginase expression in these otherwise 
M1-polarized macrophages. Azithromycin, in the presence of IFNγ and LPS 
signals, was shown to significantly increase arginase-1 (M2 effector) expression 
and activity similar to IL-4 and IL-13 treated macrophages [310].  In summary, 
this report by our group was the first to show that azithromycin directly affects 
macrophage phenotype and drives macrophages into an alternative M2 
phenotype in-vitro. 
 
To examine the physiological relevance of these findings, azithromycin’s effect 
on macrophage phenotype was then evaluated in a mouse model of PA 
pneumonia [311]. In a 2010 report by Feola et al., C57BL/6 mice were infected 
with a clinical mucoid strain of PA (M57-15) [311].  The PA was incorporated in 
agarose beads prior to intratracheal instillation in anesthetized mice. The PA-
impregnated agarose beads result in a prolonged infection similar to that in cystic 
fibrosis patients. In order to examine the effects of azithromycin, infected mice 
received the drug via oral gavage four days prior to infection and daily thereafter. 
Azithromycin treatment of infected mice did not significantly alter bacterial burden 
while protecting against excessive weight loss and improving survival. 
Importantly, the azithromycin-treated group had significantly higher numbers of 
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CD11b+ immune cells infiltrating into their alveolar spaces, lower number of 
neutrophils in their airways, and higher number of CD4+ lymphocytes [311].  
 
The phenotype of these CD11b+ monocytes migrating into the lungs and alveolar 
spaces was then evaluated. Similar to the in-vitro observations, macrophages in 
the azithromycin-treated mice exhibited higher levels of M2 markers like the 
increased MR surface expression and the increased arginase activity. 
Additionally, CD11b+ monocytes in the azithromycin-treated mice exhibited 
greater production of IL-10 and significantly lower production of TNF-α, CCL2 
and IL-6. Subsequently, the effects of azithromycin on lung fibrosis and 
inflammatory changes were evaluated in H&E stained lung sections. 
Histologically, azithromycin treatment was associated with reduced inflammatory 
infiltrates around the bronchioles of PA infected mice compared to untreated 
mice at day seven post-infection. Additionally, the inflammatory infiltrates in 
infected mice were predominantly monocytes in the azithromycin-treated group 
versus neutrophils in the untreated group [311]. 
 
In summary, azithromycin treatment blunts the neutrophilic inflammation and 
shifts the compartmentalization of monocytes infiltrating the lungs and alveolar 
spaces in response to PA intratracheal infection. Collectively, these data support 
the hypothesis that azithromycin shifts macrophage polarization into an 
alternative anti-inflammatory phenotype in response to PA pneumonia.  
 
The next step was to evaluate the clinical applicability of the developing central 
hypothesis [166]. A pilot clinical study was conducted to evaluate the 
immunomodulatory properties of azithromycin and the role of alternatively 
activated macrophages in the pathophysiology of cystic fibrosis. The study 
objective was to characterize the expression of classical and alternatively 
activated macrophage markers in the context of PA infection, immunomodulatory 
drug therapy and pulmonary function [166]. Sputum and lung lavage samples 
were collected from forty-eight cystic fibrosis patients. Flow cytometry was used 
 52 
to evaluate the expression of surface macrophage proteins. Additionally, analysis 
of arginase activity and cytokine levels were evaluated in the sputum and lavage 
samples [166].  
 
Patients with chronic PA infections had a significant increase in M2 macrophage 
markers. Cystic fibrosis patients infected with PA had higher levels of MR 
expressing monocytes compared to patients with no history of PA. Additionally, 
patients infected with PA had increased arginase activity compared to uninfected 
patients [166]. These observations emphasize the role of alternative 
macrophages in the pathophysiology of PA infections in patients with cystic 
fibrosis and suggest that the cytokine environment in patients with chronic PA 
infections skew the macrophage polarization towards an alternative phenotype. 
However, whether alternative macrophage effectors contribute to improved lung 
function or to pathology is yet to be elucidated [166]. 
 
In this pilot study, there were no significant differences in the pro- and anti- 
inflammatory cytokines between the azithromycin and the PA infected subgroups 
when analyzing gene expression [166]. While patients infected with PA had 
significantly higher levels of IL-8, IL-1, and IL-12, there were no significant 
differences in TNF-α, IL-6, and IL-10 compared to the uninfected group. 
Moreover, the increased expression of alternative macrophage effectors or the 
increased arginase expression were inversely correlated with lung function [166]. 
However, it is hard to correlate these observations with any direct effects of 
azithromycin due to the observational nature of this study and the fact that 
empiric azithromycin therapy is very likely to be prescribed to patients with 
declining lung function. In fact, patients infected with PA had a greater chance of 
being on long-term azithromycin therapy compared to uninfected patients. 
Therefore, it was difficult to separate the effects of azithromycin versus the 
effects of PA infections due to the overlap of these two parameters [166]. 
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Importantly, this pilot study examined the effects of azithromycin on alternative 
macrophages in patients with cystic fibrosis [166]. Azithromycin treatment was 
not associated with significant differences in terms of arginase activity, cytokine 
levels, or expression of alternative macrophage proteins. However, data 
generated in the azithromycin group were analyzed based on the PA infection 
status, a significant relationship between arginase activity and lung function and 
between lung function and the expression of alternative macrophage effectors 
was observed in the azithromycin-treated patients with PA infection and not in 
the other groups [166]. These observations emphasize the potential 
immunomodulatory mechanism of azithromycin which involves suppression of 
exaggerated inflammation rather than promoting anti-inflammatory mediators. 
Additionally, these data validate that patients with chronic PA infections might 
benefit the most from azithromycin therapy [166]. 
 
Finally, a combination of parameters was used to predict lung function. Lung 
function (FEV1) was best interpreted from a linear combination of the patient's 
age, PA infection status, azithromycin treatment status, macrophage MR surface 
expression, and arginase activity [166]. In fact, MR expression and arginase 
activity were significant predictors of lung function in cystic fibrosis patients along 
with azithromycin treatment and PA infection status. These data suggest that 
azithromycin alters macrophage polarization in patients infected with PA and 
emphasize the ability of azithromycin to drive macrophage polarization 
independently of the cytokine environment in the lungs. However, the specific 
mechanisms involved with alternative macrophage polarization with azithromycin 
are yet to be elucidated [166]. 
 
This was a novel study by our group which was the first to show evidence of 
alternative macrophage function and its relation to azithromycin use in cystic 
fibrosis. It is important to note that due to the limitations of this study, it was 
difficult to have definitive answers for the specific anti-inflammatory effects and 
mechanisms of azithromycin in the context PA pneumonia in cystic fibrosis [166]. 
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In summary, the Feola lab group provided evidence that azithromycin polarizes 
macrophages into an alternative phenotype in vitro, and that alternative 
macrophages predominated in the lungs of azithromycin treated mice infected 
with PA and in cystic fibrosis patients with PA pneumonia [166, 310, 311]. 
Azithromycin increases alternative macrophage effectors including MR 
expression and arginase activity while suppressing pro-inflammatory cytokine 
release. However, the specific mechanisms by which azithromycin promotes an 
alternative macrophage phenotype remain unknown. 
 
VII. Summary and specific aims 
 
The previous sections summarize our current understanding of cystic fibrosis 
pathology and the available therapeutic options. Patients suffer from genetic 
abnormalities to the CFTR gene which predispose them for chronic and repetitive 
infections. Infections with PA are the most common in patients 18 years and 
older and they are characterized by a chronic, dysregulated, inflammatory 
response with aberrant T cell immunity and a predominant recruitment of 
neutrophils and pro-inflammatory macrophages [312]. This continual immune 
response lowers patients’ life expectancy by 30 years as a result of lung injury 
and damage, deteriorated lung function, and decreased quality of life [313].  
 
Azithromycin, a macrolide antibiotic, exerts anti-inflammatory and 
immunomodulatory effects in cystic fibrosis patients. We have previously shown 
that azithromycin alters macrophage polarization and shifts the macrophages into 
an alternatively activated phenotype, both in vitro and in a mouse model of PA 
pneumonia [166, 310, 311]. Murine experiments with an early polarization of 
macrophages into an alternative phenotype show decreased neutrophil influx and 
pulmonary injury in mice infected with PA. Conversely, abolishing alternative 
macrophage polarization was associated with a profound acute immune 
response along with exaggerated neutrophil influx and an altered T cell 
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phenotype. The absence of alternative macrophages was also associated with 
increased morbidity and mortality in our model of murine PA pneumonia [166, 
310, 311]. 
 
These findings from in vitro, murine, and human experiments were the basis for 
the central hypothesis that the alternatively activated macrophages decrease 
pulmonary inflammation in PA infection, an effect that is dependent upon 
production of TGFβ and arginase-1. The objective is to determine whether 
alternative macrophages induced with azithromycin are essential to regulate the 
exaggerated inflammatory response against PA pneumonia. Additionally, our 
objective is to determine which specific macrophage effectors are essential for 
immunomodulation and whether this involves control of other immune cells like 
neutrophils and T cells. The second objective of our research is to define the 
specific mechanisms by which azithromycin modulates these macrophages. The 
long-term goal is to utilize these mechanisms to optimize the current therapeutic 
options and to identify new therapeutic targets for patients with non-resolving 
pulmonary inflammation. 
 
Work presented in this dissertation is based on our previous findings and aims to 
identify the specific effectors of alternative macrophages that are crucial for 
regulating inflammation and modulating T cell disposition. Closely examining the 
different effectors of alternative macrophages revealed an important role of 
arginase-1. Arginase-1 expression and activity are increased in alternative 
macrophages polarized with azithromycin. Preliminary experiments using 
arginase-1 conditional knock-out mice verified that arginase deficiency is 
associated with greater morbidity in terms of more significant weight loss. 
Additionally, arginase-1 has unique immunomodulatory properties (discussed 
earlier) and include controlling NO-mediated injury, suppression of T cell function 
and proliferation, as well as promoting a Treg phenotype [151, 152, 154, 157, 
312-316]. In cancer, myeloid suppressor cells producing arginase inhibit T cell 
responses against tumor cells [317, 318]. In pregnancy, arginase is essential to 
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prevent maternal immune reactions against the fetus [319]. Arginase also plays 
an important role in sepsis, trauma, surgery, certain infections, and some 
inflammatory and autoimmune diseases [151, 152, 154, 157, 314-316]. However, 
arginase-1 mediated modulation of the inflammatory response against PA 
pneumonia has not been investigated. 
 
The work presented here also investigates the specific pathways involved with 
azithromycin macrophage polarization. It is unknown how azithromycin 
modulates the expression of different pro- and anti- inflammatory macrophage 
effectors. The expression of these inflammatory cytokines and mediators is 
controlled via different transcription factors induced in response to distinct stimuli. 
Th1 cytokines can induce M1 macrophage activation by stimulation of the STAT-
1 and NF-κB transcription factors. Alternatively, Th2 cytokines activate alternative 
M2 macrophages through STAT-6 activation. While some reports suggest that 
azithromycin can inhibit NF-κB activation and polarize macrophages into an M2 
phenotype, a link between these effects has not been established. Theodore 
Cory, a previous graduate student in the Feola lab, conducted a preliminary 
study of azithromycin using an in-vitro model of J774 murine macrophages. He 
showed that azithromycin affects non-canonical NF-κB activation. He showed 
that azithromycin increases the level of inactive NF-κB p105 subunit while the 
active p50 subunit was down-regulated. The work in this dissertation ties the 
preliminary data that Dr. Cory generated with specific regard to the effects of 
azithromycin on the canonical NF-κB subunit, p65. Additionally, the research in 
this dissertation evaluates cross-talk between the canonical NF-κB pathway and 
the STAT-1 pathway. 
 
The purpose of the work presented in this dissertation is to specifically 
investigate the role of arginase-1 in the immunomodulatory functions of 
alternative macrophages and to define the molecular anti-inflammatory 
mechanism of azithromycin. In addition to evaluating my hypotheses in murine 
models of PA pneumonia, I also address the translatability of my observations by 
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evaluating the immunomodulatory properties of azithromycin in cystic fibrosis 
patients. 
 
The long-term goal is to define key regulators of the exaggerated immune 
response that can be of therapeutic value for immunotherapy in cystic fibrosis. 
The objective of this project is to investigate the regulatory role of arginase-1 in 
the immune response to PA pneumonia and its modulation of T cell immunity. 
Additionally, this project examines the effects of azithromycin on the transcription 
factors involved with macrophage polarization, specifically NF-κB and STAT-1. 
 
The central hypotheses to be tested in the following chapters are: 
 
I- Decreases in inflammation in response to PA pneumonia achieved by 
polarizing macrophages to an alternatively-activated phenotype is 
dependent upon the production of arginase-1. 
 
II- Azithromycin polarizes macrophages to an M2 phenotype via inhibition 
of STAT1 through cross-talk from NF-κB signaling mediators. 
 
 
III- The ability of azithromycin-induced M2 macrophages to control 
inflammation in response to PA pneumonia is dependent on arginase-1 
expression. 
 
I found that decreases in inflammation in response to PA pneumonia are 
dependent upon the production of arginase-1. Arginase-1 deletion resulted in 
exaggerated neutrophil influx and in skewing of the T cell responses towards a 
Th1 and Th17 responses.  
 
Additionally, azithromycin polarized macrophages to an M2 phenotype via 
inhibition of STAT1 through cross-talk from the NF-κB signaling mediators. 
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Azithromycin inhibited p65 nuclear translocation which resulted in IKKβ 
accumulation due to suppressed negative feedback. Thus, inhibiting the NF-κB 
signaling pathway cross-inhibited the STAT-1 pathway. 
 
Finally, azithromycin regulated the immune responses in PA pneumonia via 
mechanisms independent of arginase.  Azithromycin protected against excessive 
morbidity and exaggerated inflammation by controlling the influx of neutrophils 
and inflammatory macrophages in mice with macrophages that could not express 
arginase-1. Additionally, azithromycin balanced the Th17/Treg responses in mice 
infected with PA, an effect that was also independent of arginase production.
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Figure 1.1a 
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Figure 1.1b 
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Figure 1.1. Cystic fibrosis pathology.  
Cystic fibrosis patients suffer from a defective and dysregulated immune 
response. (a) The main alterations of the cystic fibrosis epithelium, macrophages, 
neutrophils, and adaptive immune cells. (b) Figure depicts the progression of 
cystic fibrosis pathogenesis from a functional CFTR mutation (1) to the 
development of end-stage bronchiectasis (11). 
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Chapter 2: Methods 
 
I. Mice 
 
i. Arginase-1 conditional knock-out mice 
 
The function of macrophage arginase was studied by genetically modifying 
C57BL/6 mice to delete arginase-1 expression in myeloid cells. To generate 
arginase-1 conditional knock-out mice, C57BL/6-Arg1 tm1Pmu/J (or Arg1flox) mice 
were utilized along with B6.129P2-Lyz2 tm1(cre)Ifo/J (or LysMcre) mice (The 
Jackson Laboratory, Bar Harbor, ME). Arg1flox are floxed mutants with LoxP sites 
flanking exons 7 and 8 of the arginase-1 gene. When these mice are bred with 
the LysMcre mice expressing Cre recombinase under the control of Lyz2 
promoter, floxed arginase-1 gene in myeloid cell lineages is deleted. All animals 
were bred in-house starting with the homozygous loxP mice (Arg1flox) and the 
transgenic Cre mice. These generate heterozygous loxP, hemizygous Cre mice; 
the latter were backcrossed with the homozygous loxP mice to generate 
homozygous loxP, hemizygous Cre mice (arginase-1 conditional knock-out mice 
or Arg1Δm), and homozygous loxP, non-carrier mice (littermate controls that do 
not have Cre recombinase to excise the flanked allele, Arg1flox/flox). All studies 
were approved by the University of Kentucky Institutional Animal Care and Use 
Committee. The mice were housed under conditions of pathogen-free isolation 
and were transferred to a biosafety level 2 housing unit after infection. All mice 
utilized in the infection experiments were about 6-8 weeks of age and were 
randomized into different treatment groups with comparable weight and sex. 
Arginase deletion from different immune cells is shown in Figure 2.1 
 
ii. BALB/cJ mice 
 
BALB/cJ mice were utilized in experiments with pharmacological arginase 
inhibition. The rationale behind using BALB/cJ mice is that they are 
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immunologically modified and demonstrate a Th-2 biased immune response with 
a significant expression of arginase-1 post infection. BALB/cJ females 4-6 weeks 
of age were purchased from Jackson Laboratory (Bar Harbor, ME). Mice were 
allowed to acclimate after shipment for 1 week prior to use. All mice utilized in the 
infection experiments were 6-8 weeks of age and were randomized into different 
treatment groups. 
 
II. Murine infection and drug dosing 
 
i. PA-laden agarose beads 
 
Mice were infected with PA incorporated into agarose beads to cause a 
prolonged infection similar to that in cystic fibrosis patients. PA M57-15 is a 
clinical mucoid strain of PA isolated from a patient with cystic fibrosis and 
obtained as a generous gift from Anna Van Heeckeren from Case Western 
University. 
 
PA M57-15 were frozen in glycerol stocks at -80 °C. Prior to each infection, a 
fresh batch of beads was prepared. A sterile inoculating loop was used to scrape 
bacteria off the frozen bacterial stock. The scraped bacteria (1, 2, and 3 loops) 
were allowed to grow overnight in three 125 mL flasks with 30 mL of sterile 
Trypticase soy broth (TSB). The bacterial cultures were allowed to grow for 18 
hours (to reach the late log phase or early stationary phase) in a shaking 
incubator at 37 °C and 220 RPM. According to the growth curves and the optical 
density (OD) analysis of the PA M57-15 cultures, the starting OD of the bacterial 
culture to be incorporated into the beads for optimal infective beads is 1.0 – 2.0.      
The OD of each bacterial culture was measured using the spectrophotometer at 
620 nm wavelength and by normalizing the OD to that of TSB. After determining 
which bacterial culture to use, two stirring hot plates were placed in a hood. 
Agarose powder (0.5 g) was dissolved in 25 mL of sterile phosphate buffered 
saline solution (PBS) by microwaving for 1 minute. The agarose solution was 
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placed on a hot plate with a slow stirring magnet bar and a thermometer. 
Simultaneously, 40 mL of mineral oil was heated on the second hot plate with a 
slow stirring magnet bar and a thermometer. The temperatures were monitored 
closely to assure that the agarose solution cooled down to 50 °C and the mineral 
oil heated up to the same temperature of 50 °C. Once the target temperature was 
reached, 15 mL of the bacterial culture was slowly added to the agarose solution 
and allowed to mix for 3-5 minutes. Subsequently, the stirring speed of the 
mineral oil was increased, and 10 mL of the bacteria-glycerol mixture was 
transferred to the mineral oil- 1 mL at a time. The mineral oil flask was then 
cooled immediately by adding ice to the secondary beaker and allowing the 
mixture to stir at maximal speed for 10 minutes. The rapid speed allows the 
agarose to break into beads trapping the bacteria inside. Different sizes of 
agarose beads form, each containing different amounts of PA. After cooling the 
oil-agarose-bacteria mixture and mixing briskly, a milky and frothy mixture forms. 
This mixture was collected into 50 mL canonical tubes and several washes were 
done by centrifuging with different buffers at 600 RCF for 4 minutes. Two initial 
washes with 0.5% and 0.25% deoxycholic acid (DCA) were performed to remove 
the mineral oil. Two more washes with PBS were then performed to remove the 
DCA. Four more washes with PBS were used to settle the large beads and 
collect the floating smaller beads. The latter constitutes the bead stock. A sample 
of the bead stock was then homogenized on ice to break the beads. The 
homogenized beads were serially diluted and plated on dry TSA (Trypticase soy 
agar) plates using a spiral plater. Inverted plates were incubated overnight at 37 
°C. The concentration of PA in the bead stock was then determined by counting 
the colonies growing on the incubated plates using a QCount Colony Counter. 
The bead stock was then diluted to make the infecting solution with the desired 
inoculum of 2 × 10^5 CFU in 100 μL for C57BL/6 mice and 2 × 10^6 CFU in 100 
μL for BALB/c mice.  This inoculum was determined to result in significant murine 
pneumonia without causing severe morbidity or mortality in each mouse strain. 
The target inoculum was calculated as the 10% of the lethal CFU or LD10. 
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ii. Infection 
 
Mice were lightly anesthetized in a chamber connected to an isoflurane vaporizer 
and an oxygen source. Mice were then placed on the infection stand and the 
tongue was pulled out gently with forceps to visualize the trachea. A curved and 
blunted 24-gauge needle was used to infect the mouse by introducing 100 μL of 
the infecting bead solution intratracheally. Importantly, the infecting bead solution 
was allowed to mix on a stirring plate during the infection procedure and each 
100 μL was pulled individually to make sure an even bead sample was used to 
infect each mouse. The infecting bead solution was then homogenized and 
platted on Pseudomonas isolation agar (PSA) plates and the colony count was 
determined after 24 hours of incubation at 37 °C to confirm the concentration of 
PA that was instilled into the mice. Experimental designs for each infection 
experiment are depicted in Figures 2.2 a, b, and c. 
 
iii. Animal dosing 
 
a. Azithromycin 
 
To evaluate azithromycin effects in arginase-1 conditional knock-out mice, the 
drug was dosed via oral gavage starting four days prior to infection and daily 
thereafter. Azithromycin was dosed based on murine body weight at 40 mg/Kg. 
The murine dose of azithromycin was prepared by suspending crushed 
azithromycin tablets (Teva, Petah Tikva, Israel) in 2% methylcellulose. 
Alternatively, the control group was dosed with the vehicle (2% methylcellulose). 
To administer the drug, the head of each mouse was gently restrained and kept 
in an upright position. A stainless-steel bulb-tipped gavage needle was then 
gently rolled along the back of the tongue into the esophagus and towards the 
stomach. The drug was then delivered orally by instilling 150 μL of the 
azithromycin suspension into the stomach of each mouse. 
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b. L-norvaline and BEC 
 
In select experiments, the arginase inhibitors L-norvaline or S-(2-Boronoethyl)- L-
cysteine hydrochloride (BEC) were given to mice to evaluate the 
immunomodulatory effects of pharmacological arginase inhibition in PA 
pneumonia. L-norvaline and BEC were dosed via oral gavage starting 1 day prior 
to infection and daily thereafter.  
 
BEC was synthesized in the lab of our collaborator Dr. Sylvie Garneau-Tsodikova 
lab. The thiol-ene reaction strategy was used to synthesize S-(2-boronethyl)- L-
cysteine. The single step reaction between di-(n-butyl)-vinylboronate and L-
cysteine in the presence of a radical initiator 2,2′-azobis(2-methylpropionitrile) 
resulted in the formation of BEC at a 53% yield [320]. Detailed synthesis 
procedure is described in Figures 2.3 and 2.4. 
 
The BEC dose was calculated based on the daily water consumption of BALB/cJ 
mice and the suggested dosing of 0.2% BEC in water. A dose of 0.2% represents 
0.2 g of BEC per 100 mL of water intake. The reported volume of water 
consumption in BALB/cJ mice is about 6 mL per day [321]. Therefore, the daily 
volume of water consumed by each mouse contains about 0.012 g of BEC. To 
ensure each mouse receives an equivalent dose of the arginase inhibitor, a daily 
dose of 0.012 g of BEC was administered in 100 μL of water via oral gavage 
(same as described in II.iii.a). 
 
L-norvaline was purchased from Sigma-Aldrich (St. Louis, MO). The murine dose 
of L-norvaline was calculated from the rat dose of 50 mg/kg [322]. Animal 
equivalent dose calculation based on body surface area resulted in an estimated 
dose of 100 mg/kg in mice [323]. Appropriate L-norvaline dose was administered 
daily in 100 μL of water via oral gavage (same as described in II.iii.a). 
 
 
 67 
III. Tissue harvest and processing 
 
Murine body weight was monitored daily to assess morbidity post infection. Mice 
were euthanized and excluded from the experiment if they lose 20% or more of 
their body weight prior to infection along with 1 sign of morbidity (immobility, 
hunched posture, or lack of response to handling). If mice suffered from 
cyanosis, dyspnea, or loss of righting reflex, they were euthanized immediately.  
 
Mice which survived and lost at least 5% of their body weight were included in 
the analysis. A representative sample of the infected mice was humanely killed at 
different timepoints post-infection (select experiments had timepoints at different 
days post-infection. Death was ensured using two methods (intraperitoneal 
injection of pentobarbital and aortic exsanguination).  
 
i. Murine lung lavage 
 
Lung lavage was performed on each mouse to collect cells from the airway and 
alveolar spaces. Lavage was performed by connecting two 5 mL syringes to a 
three-way stopcock with a lavage catheter inserted into a small puncture in the 
exposed trachea. Each lung was then lavaged with 5 mL of PBS (with 30 μM 
EDTA) in 1 mL aliquots. The lavage samples were then centrifuged at 1200 RPM 
for 7 minutes at 4 °C. The supernatants were saved while the cells were 
incubated for 2 minutes with a lysis buffer to lyse the red blood cells. The lysis 
buffer was then washed away by centrifuging the samples with fresh PBS (for 2 
times). The final pellet was suspended in 1 mL of PBS and cells were counted 
prior to being aliquoted into 5 mL flow cytometry tubes for processing for flow 
cytometry analysis. 
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ii. Tracheobronchial lymph nodes 
 
Tracheobronchial lymph nodes draining the site of infection were excised and 
placed in 1 mL of PBS. Lymph nodes were then pushed through a 70 μm cell 
strainer with a syringe plunger to create a single cell suspension. Similar to the 
lavage samples, the lymph nodes were centrifuged and the pellet was incubated 
with red blood cell lysis buffer for 2 minutes. After washing away the lysis buffer 
with PBS, the final pellet was suspended in 1 mL of PBS and the cells were 
counted prior to being aliquoted into 5 mL flow cytometry tubes for processing for 
flow cytometry analysis. 
 
iii. Interstitial lung tissues  
 
To collect cells from the interstitial spaces, the lung tissues were collected after 
being lavaged and the lymph nodes harvested. Each lung was collected in 2 mL 
of RPMI with 5% Fetal Bovine Serum (FBS). Lungs were then minced with 
scissors and incubated with 1 mg/mL of collagenase and 50 U/ml of DNase for 1 
hour at 37 °C. After digestion, the lungs were then pushed through a 70 μm cell 
strainer with a syringe plunger to create a single cell suspension. The lung 
samples were centrifuged, and the pellet was incubated with red blood cell lysis 
buffer for 2 minutes. The lysis buffer was then washed away by centrifugation 
with PBS (twice). The final pellet was suspended in 1 mL of PBS and the cells 
were counted prior to being aliquoted into 5 mL flow cytometry tubes for 
processing for flow cytometry analysis. 
 
IV. Histology 
 
Lungs from infected mice were collected for histologic analysis. Importantly, the 
lung lavage procedure was not performed when the lungs were to be sectioned. 
Lungs were sectioned using two different methods, cryosectioning and paraffin-
embedding. 
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i. Tissue cryosectioning 
 
Lungs for cryosectioning were insufflated with 2-3 mL of formalin- optimal cutting 
temperature (OCT) solution (50% OCT and 50% formalin (10%)). The lungs were 
inflated to the appropriate degree so as to not cause bursting of the alveoli. The 
formalin-OCT solution was slowly and gently infused into the lungs after the 
trachea was cannulated with an 18G catheter needle. When the lungs were fully 
inflated, the trachea was tied with a suture and the lungs were carefully removed 
and placed in 25 mL of 5% formalin overnight. The next day, lungs were 
transferred into a 15% sucrose solution and incubated overnight. Finally, the 
lungs were transferred to a 30% sucrose solution and incubated overnight. 
Subsequently, lungs were placed in a tissue mold and submerged OCT. Tissue 
molds were then snap frozen at -80 °C. Frozen tissues were cryosectioned at the 
Biospecimen Procurement & Translational Pathology Shared Resource Facility of 
the University of Kentucky Markey Cancer Center (P30CA177558). Specimens 
were sectioned on a cryostat at 8 μm. Hematoxylin and eosin stain (H&E) was 
performed according to the standard Harris’ hematoxylin protocol on a Leica XL 
Autostainer and mounted with permanent mounting media [324]. 
 
ii. Sectioning of paraffin-embedded tissues 
 
Lungs for paraffin embedding were collected after the mice were euthanized. 
Harvested lungs were gently inflated with 2-3 mL of 10% formalin. Excised lungs 
were then kept overnight in 25 mL of 10% formalin. Lungs were then transferred 
into 70% ethanol. Tissues were processed and paraffin embedded according to 
standard procedures described by Morton et al. [325].  Lungs were trimmed in 
from the ventral face until all 5 lobes were visible. H&E staining was performed 
according to the standard Harris’ hematoxylin protocol. Paraffin embedding and 
staining were performed at the COBRE Pathology Core of the University of 
Kentucky which is supported by an Institutional Development Award (IDeA) from 
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the National Institute of General Medical Sciences of the National Institutes of 
Health under grant number P20GM103527. 
 
iii. Lung injury scoring 
 
Histologic analysis of sectioned lungs was performed to evaluate acute 
inflammatory lung injury after infection. Lung injury scoring was calculated 
according to the American Thoracic Society guidelines [326]. Briefly, 20 random 
high-power fields were independently and blindly scored. The scoring system 
takes into consideration the number of neutrophils in the alveolar and interstitial 
spaces, the presence of hyaline membranes and proteinaceous debris, as well 
as septal wall thickening. The scoring system is summarized in Table 2.3. To 
generate a lung injury score, the sum of each of the five independent variables 
shown in Table 2.3 were weighted according to the significance factor of each 
variable and then normalized to the number of fields evaluated. The following 
formula was used to calculate the lung injury score: Score = [(20 x A) + (14 x B) + 
(7 x C) + (7 x D) + (2 x E)] / (number of fields x 100). Scoring was performed by 
an independent pathologist, Dr. Therese Bocklage, MD. 
 
V. Flow cytometry 
 
i. Surface staining 
 
Samples of the processed lung lavage, lung digest, and lymph nodes were 
counted using the TC10 Automated Bio-Rad Cell Counter with Tryptan Blue to 
determine viability. Aliquots of 1 x 10^5 - 1 x 10^6 cells were transferred into 
each flow cytometry tube (5 mL polystyrene round-bottom tubes). Cells were 
then washed with PBA (PBS with bovine serum albumin and sodium azide) by 
centrifuging at 1200 RPM for 7 minutes at 4 °C. Tubes were then decanted and 
the pellets were incubated with 20 μL of the appropriately diluted fluorochrome-
conjugated antibodies. The latter were diluted according to the manufacturer 
 71 
instructions or as determined by the antibody titter experiments. Cell-antibody 
mixtures were incubated on ice and in the dark for 20 minutes. Subsequently, 
unbound antibodies were washed away with PBA. When fixation was required for 
some experiments, the stained cells were fixed by incubating with 200 μL of 5% 
formalin for 20 minutes in the dark. Excess formalin was then removed by 
washing with PBS and fixed cells were suspended in PBS for flow cytometry. 
 
ii. Intracellular staining 
 
After tissue processing and cell counting, samples for intracellular staining were 
aliquoted into flow cytometry tubes (5 mL polypropylene round-bottom tubes). 
Cells were then incubated in 2 mL of RPMI (with 5% FBS and 1% 
Penicillin/Streptomycin). Ionomycin (1 μg/mL final concentration) and PMA 
(Phorbol 12-myristate 13-acetate, 50 ng/mL final concentration) were added to 
the media for stimulation of intracellular cytokine expression. Cells were 
incubated for 2 hours at 37 °C. After 2 hours, Brefeldin A was added into each 
tube (2 μL of 1000x) in order to enhance intracellular cytokine staining by 
blocking protein transport. Cells were incubated with Brefeldin A for additional 2 
hours at 37 °C after which they were centrifuged and washed with PBA. Staining 
for surface markers was performed similarly to the procedure described in (a) 
followed by fixation with 5 % formalin when required. After washing away the 
excess formalin with PBA, cells were incubated with permeabilization buffer (PBA 
+ 0.5% saponin) for 10 minutes at room temperature. Cells were then centrifuged 
and the pellet was incubated with Fc block (10 μL of 1:10 diluted stock) for 10 
minutes at room temperature. This was followed by adding 20 μL of the 
appropriately diluted fluorochrome-conjugated antibodies specific for intracellular 
proteins. Unbound antibodies were washed away by centrifuging twice with 
permeabilization buffer followed by a third wash with PBA. Cells were then 
suspended in PBA for flow cytometry analysis. 
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iii. Flow cytometry analysis 
 
Surface and intracellularly stained cells were analyzed using either the Attune 
Flow Cytometer (Applied Biosystems, Foster City, CA) at the Feola lab or the BD 
LSR II Flow Cytometer (BD Biosciences, Franklin Lakes, NJ) at the UKY flow 
core facility. Attune Performance Tracking Beads were used to run a 
performance test prior to each experiment in order to define the baseline 
performance of each laser and to set the intensity level of each detection 
channel. Unstained and single-stained control tubes were used to adjust the 
instrument settings by running a compensation for each set of antibodies used in 
a multicolor panel. During compensation setup, the threshold and voltages of the 
fluorescence channels were adjusted to visualize the desired populations. Proper 
compensation is necessary to correct for spillover due to the overlap of the 
emission spectra of the used fluorochromes. Subsequently, each sample was run 
according to the collection criteria set during the compensation setup in order to 
record a minimum of 50,000 events per sample. Further analysis of the recorded 
events was performed using FlowJo software (FlowJo, LLC, Ashland, Oregon). 
FlowJo allows analysis of single live cells and performs statistics on the desired 
populations. Additionally, FlowJo allows analysis for multiple surface and 
intracellular markers in single cells. Therefore, FlowJo was used to generate 
percentages and counts of specific cells that were gated by selecting on the 
positively stained versus the negatively stained events for specific markers within 
the identified parent populations and sub-populations. For graphs with cell 
counts, the FlowJo percentages were multiplied by the number of cells added 
into each tube. Table 2.4 illustrates the specific markers of different immune cell 
populations analyzed. 
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iv. Flow panels  
 
a. Surface staining panels 
 
Immune cells recruited into the lungs and lymph nodes were identified by staining 
for surface markers. The antibodies listed below were used to identify these 
specific cell markers. Importantly, in certain experiments the antibody panels or 
fluorochromes varied from the list below as will be indicated in the Results 
section. 
Table 2.1. Surface staining panels  
Tissue Sample Antibody- Fluorochrome  
Lung lavage and lung digest F4/80- APC 
CD11c- PE/Cy7 
CD11b- PerCP/Cy5.5 
Ly6G- APC/Cy7 
CD68- FITC 
MR- PE 
Lung lavage, lymph nodes, and 
lung digest 
CD4 PE/Cy7 
CD44- FITC 
CD62L- PE 
CD69- APC 
CD25- PerCP-Cy5.5 
Lung lavage, lymph nodes, and 
lung digest 
LIN- FITC 
CD90.2- APC 
IL33R- PE 
CD127- PE/Cy7 
CD25- PerCP-Cy5.5 
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b. Intracellular staining panels 
 
Cytokine production and expression of lineage transcription factors by immune 
cells in the lungs and lymph nodes were identified by staining for intracellular 
proteins. The antibodies listed below were used to identify surface and 
intracellular proteins. Importantly, in certain experiments the antibody panels or 
fluorochromes varied from the list below as will be indicated in the Results 
section. 
Table 2.2. Intracellular staining panels 
  
Tissue Sample Antibody-Fluorochrome  
Lung lavage and lung digest F4/80- PerCP-Cy5.5 
CD11c- PE/Cy7 
TNF-α- FITC 
CCR7- APC 
iNOS- PE 
Lung lavage and lung digest F4/80- PerCP-Cy5.5 
CD11c- PE/Cy7 
IL10- PE 
ARG1- APC 
Ly6G- APC/Cy7 
Lung lavage, lymph nodes, and 
lung digest 
CD4- PE/Cy7 
IFNγ- APC 
IL17- PE 
RORγt- PerCP-Cy5.5 
CXCR3- FITC 
Lung lavage, lymph nodes, and 
lung digest 
CD4- PE/Cy7 
CD25- FITC 
FOXP3- PE 
TGFβ- PerCP-Cy5.5 
ARG1-APC 
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VI. Macrophage polarization 
 
Invitro assays used to study azithromycin’s mechanism of action were performed 
using the murine macrophage cell line J774A.1 (ATCC, Manassas, VA). J774 
macrophages were allowed to grow and reach confluency in appropriate media 
(Dulbecco's Modified Eagle's Medium (DMEM) + 10% FBS + 1% Sodium 
Pyruvate + 1% penicillin/streptomycin).  
 
Confluent cells were scrapped, counted, and plated in 24-well plates at a 
concentration of 2.5x10^5 cells per 1ml of media. Cells were allowed to adhere 
for 4-6 hours and then polarized to an M1 phenotype with IFNγ (final 
concentration 20 ng/mL) or to an M2 phenotype with both IL-4 and IL-13 (final 
concentration 10 ng/mL of each). Additionally, azithromycin was added to select 
wells along with IFNγ at concentrations ranging from 5 to 100 μM. Additionally, 
IKK-16, an IKKβ inhibitor, was added to select wells with azithromycin and IFNγ 
(final concentrations 50 or 100 nM). Cells were then incubated overnight at 37 °C 
with 5% CO2.  
 
Polarized cells were then stimulated with LPS (final concentration 100 ng/mL). 
The duration of LPS stimulation ranged from 0, 2, 5, 10, 15, 30, and 60 minutes 
up to 24 hours depending on the experimental goals. LPS and other cytokines 
were then washed away with PBS. Cells were scraped, enumerated, and lysed in 
0.1% (v/v) Triton X-100 (protease and phosphatase inhibitors were added to the 
lysis buffer prior to use). Protein concentrations were quantified utilizing the 
Pierce BCA reaction kit. Alternatively, in some experiments, stimulated cells were 
fractionated into nuclear and cytoplasmic contents; or, homogenized with trizol 
for RNA extraction (procedures described in the following sections). 
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VII. RNA isolation and quantitative RT-PCR.  
 
RNA isolation was performed using trizol reagent (Invitrogen, Carlsbad, CA) and 
RNeasy Mini Kits (QIAGEN, Valencia, CA). Polarized cells were homogenized 
with 1 mL of trizol reagent by pipetting up and down several times to lyse the 
cells. Lysates were allowed to incubate at room temperature in trizol, then 0.2 mL 
of chloroform was added. The lysate-trizol-chloroform mixture was vortexed and 
incubated for 2-3 minutes. The mixture was then centrifuged at 12,000 g for 15 
minutes at 4 °C. The last step separated the mixture into 2 fractions: an aqueous 
transparent layer and a pink phenol-chloroform layer. The aqueous (top) layer 
containing the RNA was transferred to a new tube. Subsequently, RNA was 
purified using Spin technology. Briefly, the isolated RNA was mixed with 245 μL 
of 100% ethanol. The mixture was then transferred to the spin columns provided 
by the RNeasy Mini Kit. Columns were centrifuged at 8,000g for 30 seconds 
which allows the isolated RNA to be trapped in the columns. The columns were 
then washed twice by centrifuging for 30 seconds with 700 μL of RW1 and 500 
μL of RPE buffers respectively. A third wash with 500 μL of RPE buffer was 
performed by centrifuging from 2 minutes. After the 3 washes with RW1 and RPE 
buffers, the flow-through eluents were discarded and the columns were 
transferred into new tubes. RNA was eluted from the columns by adding 40 μL of 
RNase-free water and by centrifuging the columns at 8,000g for 1 minute. 
Isolated RNA was quantified using Nanodrop 2000 spectrophotometer (Thermo 
Fisher Scientific, Wilmington, DE).  
 
Equal amounts of RNA were then reverse transcribed into cDNA using the iScript 
cDNA Synthesis Kit (Bio-Rad, Hercules, CA) according to manufacturer's 
protocols. cDNA samples were then used for quantitative real-time PCR using 
the TaqMan gene expression arrays for murine Arg1 (arginase-1), Ikbkb (IKKβ) 
and GAPDH. An epMotion 5070 robot was used to accurately pipette the PCR 
reaction components (cDNA template, forwards and reverse primers, TaqMan 
Gene Expression Master Mix, and RNase-free water) into 384-well plates. Plates 
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were centrifuged briefly and transferred into the ABI Prism 7900HT Fast Real 
Time-PCR System (Applied Biosystems, Foster City, CA) set for 40 standard 
thermal PCR cycles. The generated cycle threshold (CT) values were used to 
quantify gene expression. ΔCt values were calculated by normalizing the target 
gene expression (Arg1 and Ikbkb) to the housekeeping gene expression 
(GAPDH).  ΔΔCt was then calculated by comparing the expression of the 
experimental condition to the control condition. Power analysis of the generated 
ΔΔCt values was then used to interpret the fold change in gene expression. 
 
VIII. RelA translocation assay.  
 
Analysis for cellular localization of p65 subunit reflects on the activation of the 
NF-κB signaling pathway. Therefore, a nuclear translocation assay was used to 
interpret NF-κB activation by quantifying the amount of translocated subunit in 
the nucleus versus the cytoplasmic levels. Polarized and stimulated J774 
macrophages (as described in VI) were washed with PBS to remove polarizing 
cytokines and then scraped manually using sterile well scrapers. Cells were then 
counted and fractionated into nuclear and cytoplasmic fractions using the NF-κB 
Assay Kit (FivePhoton Biochemicals, San Diego, CA) and according to the 
manufacturer protocol. Briefly, collected cells were treated with ice-cold 
Cytoplasmic Fractionation Reagent (CFR) containing protease inhibitors and 
centrifuged at 2500 RPM for 4 minutes at 4 °C. The supernatant was then 
collected as the cytoplasmic fraction. The pellet was then washed a second time 
with the CFR by centrifugation. The washed pellet was resuspended in ice-cold 
Nuclear Fractionation Reagent (NFR) containing protease inhibitors. The pellet 
was allowed to incubate in the NFR for 10 minutes on ice and then centrifuged at 
maximum speed for 10 minutes. The final supernatant containing the nuclear 
fraction was then collected. RelA (or p65 subunit of NF-κB) was then quantified in 
the nuclear and cytoplasmic fractions by Western blot. 
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IX. Immunofluorescence staining and analysis 
 
Immunostaining was used to visualize the NF-κB subunit localization in 
stimulated cells. Macrophages were polarized as described in VI except that 
round glass coverslips (12 mm) were added to each well of the 24-well plates. 
Cells were allowed to attach to the glass coverslips overnight. After polarization 
and stimulation, the coverslips were washed three times with PBS++ (PBS with 
0.5 mM CaCl2 and MgCl2). Cells were then fixed and permeabilized by adding 1 
mL of ice-cold methanol and incubating for 5 minutes. Methanol was then 
aspirated, and the coverslips were washed three times with PBS++. Primary and 
secondary antibodies were diluted at appropriate concentrations in 3% BSA as 
determined by the titration experiments. A humidified chamber was used for the 
antibody incubations. Coverslips were removed using thin tip forceps and 
incubated over a 50 µL drop of the primary antibody for 45 minutes at room 
temperature. Unbound primary antibodies were washed away by repeating the 3 
washes with PBS++. Subsequently, coverslips were incubated over a 50 µL drop 
of the fluorochrome-conjugated secondary antibody for 45 minutes at room 
temperature and in the dark. Excess secondary antibodies were washed away 
with PBS++ and the coverslips were finally incubated in DAPI nucleic acid stain 
to visualize the nuclei. About 300 µL of the 300 nM DAPI stock solution 
(Invitrogen, Carlsbad, CA) were added to completely cover each coverslip. After 
5 minutes incubation with the DAPI stain, the coverslips were washed with 
PBS++ several times and mounted using an antifade reagent.  
 
Stained cells were visualized using a Zeiss fluorescent microscope (Oberkochen, 
Germany) at the 100X objective. The scoring system described in Table 2.5 was 
used to interpret the activation of the NF-κB signaling pathway based on the 
localization of the subunits. The scoring system gives each cell a number based 
on the location of the subunit relative to the DAPI stained nuclei. At least 100 
cells were scored per each replicate coverslip. Scores were then averaged and 
compared to the control condition. 
 79 
X. Arginase assay.  
 
Arginase enzymatic activity was assessed using the urea assay. Arginase is an 
enzyme which metabolizes arginine into ornithine and urea; therefore, urea 
concentrations directly correlate with the activity and expression level of 
arginase. J774 murine macrophages were polarized and lysed with 0.1% Triton 
X-100 (containing protease and phosphatase inhibitors) as described in VI. The 
enzyme was activated by incubating 50 µL of the cell lysate with 50 µL of the 
arginase activation solution (10 mM MnCl2 in 50 mM Tris HCl, pH 7.5) for 10 
minutes at 55 °C. Subsequently, 25 µL of the previous reaction mixture was 
added to 25 µL of the arginase substrate solution (0.5 M L-arginine in water, pH 
9.7). This mixture was allowed to incubate at 37 °C for 6 hours. The reaction was 
then terminated by adding 400 µL of the acid mixture (H2SO4, H3PO4, water at a 
ratio of 1:3:7) followed by the addition of 25 µL of alpha-isonitrosopropiophenone 
(9% w/v). The reaction mixture was heated at 100 °C for 45 minutes. Optical 
density was then read at 540 nm wavelength using a spectrophotometer (the 
intensity of color change of the urea-chromogen complex was measured). A 
standard curve was used to interpret the results by repeating the assay 
described above using standard stock solutions with known urea concentrations.  
 
Readings were normalized to the optical density of blank sample and water. 
Arginase activity was then calculated in units where 1 unit of arginase activity is 
equal to the conversion of 1 µmole of L-arginine to ornithine and urea per 1 
minute; arginase activity was then normalized to the protein concentrations of 
each sample. 
 
XI. Western blot analysis.  
 
Western blot analysis was performed to determine the effect of macrophage 
polarization on the protein mediators of NF-κB and Stat1 signaling pathways. Cell 
lysates obtained from the polarization assay described in VI were quantified. 
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Samples of 20-30 µg of protein were denatured by heating for 5 minutes at 95 °C 
in loading buffer (Bio-Rad, Hercules, CA) containing β-mercaptoethanol. 
Denatured samples were loaded onto 4-15% precast polyacrylamide gels (Bio-
Rad, Hercules, CA). Proteins were then separated by electrophoresis at 100 V 
for 1-2 hours and transferred onto a methanol-activated and wetted Immobilon®-
FL PVDF membrane at 100-200 V for 90 minutes (LI-COR Biosciences, Lincoln, 
NE). The membranes were rinsed with PBS and then blocked for 1 hour at room 
temperature with Tris-buffered saline (TBS) based Odyssey® Blocking Buffer (LI-
COR Biosciences, Lincoln, NE). Membranes were then incubated overnight at 
4°C with primary antibodies specific for p65, IκB-α, IKKβ, phospho-IKKβ (Abcam, 
Cambridge, UK), phospho-Stat1 (Santa Cruz, Dallas, TX), Stat1 (ThermoFisher, 
Wilmington, DE), or actin (LI-COR Biosciences, Lincoln, NE) at recommended 
dilutions. Unbound primary antibodies were washed away with PBS + 0.1% 
Tween 20 (repeated 3 times with gentle shaking). Subsequently, membranes 
were incubated with the appropriate IRDye Subclass Specific secondary antibody 
for 1 hour at room temperature (IRDye 680RD Goat anti-rabbit or IRDye 800CW 
Goat anti-mouse, LI-COR Biosciences, Lincoln, NE). Excess secondary 
antibodies were washed away with PBS + 0.1% Tween 20. Membranes were 
finally rinsed with PBS to remove residual detergents and then imaged and 
analyzed using the Odyssey® CLx Imaging System (LI-COR Biosciences, 
Lincoln, NE). 
 
XII. Human study protocol 
 
i. Study design  
 
To evaluate azithromycin anti-inflammatory mechanisms in cystic fibrosis 
patients, a prospective, unblinded, non-randomized study was designed in which 
each patient served as his or her own control. The study was approved by the 
Institutional Review Board of the University of Kentucky. Patients with cystic 
fibrosis who were on chronic azithromycin therapy and meet the 
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inclusion/exclusion criteria were consented (alternatively children were assented) 
and instructed to stop azithromycin use for 60-90 days.  After informed consent 
was obtained, sputum was induced voluntarily or via inhalation of hypertonic 
saline. Samples were collected at 3 regular clinician visits which were scheduled 
every 1-3 months.  At the 1st visit, samples were collected, and patients started 
their 60-90 day azithromycin holiday. At the 2nd visit and by the end of the 60-90 
day drug holiday period, sputum was collected again and patients re-initiated 
azithromycin therapy. Finally and at the 3rd visit, samples were collected again 
60-90 days after azithromycin re-initiation.  During the drug holiday and re-
initiation periods, patients were encouraged to report any illness and potential 
adverse reactions to the pulmonologist on call. In addition, check-up calls were 
done every 2 weeks during the azithromycin holiday to make sure there were no 
adverse effects that require medical attention.  
 
Demographic information, CFTR mutation type, pulmonary function status, 
current medication regimen, blood glucose measurements, culture data, and any 
comorbidities were recorded via chart review for each subject (Data collection 
form in appendix 1).  
 
ii. Study population 
 
The University of Kentucky Children's' Hospital pulmonology group provides care 
for a cystic fibrosis population of approximately 300 patients in our targeted age 
range between 12 to 50 years.  The target of this study was to recruit up to 25 
subjects during the period starting from January 2018 until December 2019 (if 
necessary).  Subjects were included without regard to gender, race, or ethnic 
background according to the following criteria: 
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a. Inclusion criteria 
 
• Age from 12 to 50 years 
• Confirmed diagnosis of CF  
• Stable disease with FEV1 > 40 % (no CF pulmonary exacerbation, no 
intravenous antibiotics, no hospitalization, and stable clinical symptoms for 
past 1 month) 
• Chronically colonized with Gram-negative bacterial pathogens based on 1 
previous infection and 2 positive cultures on regular visits in the absence 
of an exacerbation. 
• Able and willing to provide the induced sputum clinical samples 
• Clinically stable and is on azithromycin for at least 1 year 
 
b. Exclusion criteria 
   
• History of cancer 
• HIV infection 
• Pregnancy 
• Breastfeeding 
• Any other major illness/disease like heart failure, liver failure  
• Systemic corticosteroid treatment   
• Participation in other clinical studies 
• Undergoing change of therapy during the 4-month study period (including 
immunomodulatory therapy or steroids) 
 
The above criteria were selected to minimize variability in immune function due to 
parameters including age, medication exposure, and other disease states.  
Aspects of pulmonary immune function have been demonstrated to decline at 
older ages.  Additionally, the above immunomodulatory disease states affect the 
parameters that were measured; therefore, exclusion of these patients was 
necessary. 
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iii. Human sample processing 
 
Fresh samples were transported on ice to the laboratory for analysis of 
inflammatory cell populations and their function. Sputum samples were liquefied 
and homogenized with an equal volume of Sputasol (Thermo Fisher Scientific, 
Waltham, MA) containing dithiothreitol. Samples were then filtered using a 48-µm 
nylon mesh and centrifuged to separate cells from the fluid phase. Cells were 
then enumerated and divided for different experimental purposes. 
 
a. TaqMan microfluidic cards for gene expression assays  
 
RNA was isolated as described in section VII and used for microarray analysis to 
compare expression of inflammatory genes at different treatment timepoints. 
Microarrays were performed using TaqMan® Array Micro Fluidic Cards (Life 
Technologies, Grand Island, New York).  Life Technologies Corporation 
manufactured gene microarrays that are specific to a given cellular function, 
pathway, or disease state.  These arrays each consisted of 47 genes associated 
with expression of the inflammatory immune reactions.   
RT-qPCR reactions were performed using cDNA reverse transcribed from the 
purified RNA to amplify the specific genes of interest (as described in VII). When 
the 3 samples are obtained from each patient, genetic information will be 
compared between different timepoints to determine if alterations exist in relative 
expression levels as a result of azithromycin treatment.  Scatter plots will be 
generated to analyze fold differences in relative expression levels for each gene 
when patients are on and off azithromycin.  A list of genes included in the 
assessment can be found in Appendix 2. 
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b. Flow cytometry analysis of immune cells in the sputum 
 
Single-cell suspensions from processed sputum were stained and analyzed with 
flow cytometry as described in V. Cells were stained for multiple surface and 
intracellular markers listed below: 
• TLR 
• CD25 
• CD19 
• CD11c 
• CD4 
• CD8 
• Foxp3 
• RORγt 
• CD11b 
• ARG1 
• ARG2 
 
c. Cytometric Bead Array (CBA) 
 
Cytokine concentrations in cell lysates from sputum samples were evaluated 
using CBA kits. After sputum processing, cells were lysed in a hypotonic buffered 
solution, and the lysates were frozen at -80°C for simultaneous analysis of all 
samples within 6 months.  Concentrations of the cytokines listed below were 
quantified using BD CBA Kits (BD Biosciences, San Jose, CA) according to the 
manufacturer protocol.  Briefly, the CBA Kit contains bead populations with 
distinct fluorescence intensities that are coated with capture antibodies specific 
for each cytokine to be measured.  These beads were incubated with 
fluorochrome-conjugated detection antibodies and then incubated with 50 μL of 
each sample for 3 hours at room temperature.  Sandwich complexes formed, 
after which the beads were washed, and the fluorescence intensity was assayed 
by flow cytometry.  These intensities were then compared to a standard curve 
generated for each cytokine to determine the concentration in each sample. 
 
• TNF-α 
• IL-1β 
• IFNγ 
• IL-2 
• IL-4 
• IL-6 
• IL-10 
• IL-12p40 
• IL-5 
• IL-8
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XIII. Statistical analysis.  
 
Statistical analysis was performed utilizing GraphPad Prism (GraphPad 
Software, La Jolla, CA). Comparison between groups was made via one-way 
ANOVA with Tukey’s test multiple comparisons, paired sample T-test with 
McNemar's test, or via two-way ANOVA with Sidak's multiple comparisons test. 
Repeated-measures ANOVA with Tukey's multiple comparison tests were utilized 
for time course experiments. Kaplan-Meier survival curves were compared using 
Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests. The trend of survival 
curves was also compared using Log-rank test. 
 
Gene and protein expression levels in sputum samples were analyzed through 
principal component analysis. The expression levels were compared among 
paired samples from the 3-collection time-points when patients are on and off 
azithromycin. Results were then correlated to clinical outcomes (demographic 
information, pulmonary function tests, requirement for hospitalization, 
requirement for antibiotics, etc.) acquired through retrospective review of the 
chart. Paired sample T-test with McNemar's test and two-way ANOVA were used 
to perform statistical analysis for paired human samples and among groups.  
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Table 2.3. Lung injury scoring guide 
 
Parameter Score per field 
0 1 2 
A. Neutrophils in the alveolar space None 1-5 >5 
B. Neutrophils in the interstitial space None 1-5 >5 
C. Hyaline membranes None 1 >1 
D. Proteinaceous debris filling the airspaces None 1 >1 
E. Alveolar septal thickening <2x 2x-4x >4x 
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Table 2.4. Key markers for different immune cell populations. 
 
  Immune Cell Populations Key Markers 
Infiltrating Monocytes F4/80 +, CD11c -, CD11b+ 
Alveolar Macrophages F4/80 +, CD11c +, CD11b- 
Interstitial Macrophages F4/80 +, CD11c +, CD11b+ 
Neutrophils F4/80 -, Ly6G + 
Type 2 innate lymphoid cells (ILC2) LIN -, CD90.2 +, CD127 +, IL33R + 
Activated CD4+ T cells CD4 +, CD44 Hi, CD62L lo 
Th1 lymphocytes CD4 +, CXCR3 +, IFNγ + 
Th17 Lymphocytes CD4 +, RORγt +, IL-17 + 
Treg Lymphocytes CD4 +, FOXP3 +, TGFβ + 
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Table 2.5. P65 nuclear translocation scoring scale. 
 
 
 
 
 
 
 
 
 
 
Table 2.5. P65 nuclear translocation scoring scale.  
Polarized J774 murine macrophages were immunostained on glass coverslips 
and visualized using Zeiss fluorescent microscope. Different fields were 
evaluated to score at least 150 cells per each replicate coverslip by 2 blinded 
investigators. Each cell was evaluated to determine the localization of the p65 
signal with respect to the nucleus.  
Score Location of p65 in a single cell 
0 Cytoplasmic signal only 
1 Evenly distributed signal (nuclear and 
cytoplasmic) 
2 Mainly nuclear with faint cytoplasmic signal 
3 Nuclear signal only 
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Figure 2.1 
  
Arg1flox/flox mice Arg1Δm mice 
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Figure 2.1. Arginase deletion from Arg1Δm mice. 
Lungs from Arg1flox/flox and Arg1Δm mice were lavaged with PBS as described and 
the lung tissues were collected. Cells were then processed into single cell 
suspensions for flow cytometry analysis. Figure shows representative images of 
arginase-1 expression in alveolar macrophages, infiltrating monocytes, 
neutrophils, and lymphocytes from Arg1flox/flox and Arg1Δm mice. 
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Figure 2.2a 
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Figure 2.2b 
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Figure 2.2c 
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Figure 2.2. Murine experimental design. 
(a) and (b) figures depict the experimental design for experiments in chapter 3. 
(c) Experimental design for experiments in chapter 5.  
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Figure 2.3. Synthesis of BEC 
 
Synthesis of BEC. Di-(n-butyl)-vinylboronate (303 mg, 1.65 
mmol) and L-cysteine (200 mg, 1.65 mmol) were mixed in 
MeOH (5 mL) and H2O (3 mL) under N2. 2,2′-Azobis(2-methylpropionitrile) (AIBN) 
(30 mg) was added and the mixture was heated at 80 °C for 1 h. An additional 
portion of AIBN (20 mg) was further added and the mixture was heated for an 
additional 6 h at 80 °C. The solvents were evaporated and the crude product was 
purified by flash column chromatography (SiO2 gel, 1:4:0.5/CH2Cl2:MeOH:NH4OH) 
to afford BEC as white solid (170 mg, 53%): 1H NMR (400 MHz, D2O, Figure 2.3b) 
δ 3.74 (dd, J1 = 7.6 Hz, J2 = 4.2 Hz, 1H), 2.96 (dd, J1 = 14.8 Hz, J2 = 4.2 Hz, 1H), 
2.84 (dd, J1 = 14.8 Hz, J2 = 7.6 Hz, 1H), 2.54 (t, J = 7.9 Hz, 2H), 2.84 (td, J1 = 7.9 
Hz, J2 = 2.4 Hz, 2H); 13C NMR (100 MHz, D2O, Figure 2.4c) δ 172.9, 53.4, 31.7, 
26.8, 14.8. 
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Figure 2.3b 1H NMR of BEC in D2O (400 MHz). 
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Figure 2.3c 13C NMR of BEC in D2O (100 MHz). 
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Chapter 3: Requirement of arginase in host protection against excessive 
inflammation 
 
I. Introduction 
 
Macrophages are important sentinel cells of the immune system that play highly 
complex and coordinated functions during inflammatory responses [131]. In 
addition to macrophages that reside in tissues, activated monocytes are recruited 
from the bone marrow and infiltrate tissues in response to injury, infections, or 
other inflammatory stimuli. However, both tissue and infiltrating macrophages are 
not terminally differentiated; they undergo phenotypic changes which can direct 
their functions into killer (M1) macrophages or into repair (M2) macrophages 
[327]. The balance between these two macrophage phenotypes is essential for 
proper activation and termination of the immune response and for maintaining 
tissue homeostasis. In fact, a shift towards M1 macrophage polarization is 
associated with exaggerated inflammation and autoimmune disorders; while a 
shift towards M2 macrophage polarization is associated in some instances with 
suppressed immunity and inability of the immune system to combat infections 
[327]. Therefore, macrophage phenotypic changes are viewed as a spectrum of 
changes which are driven by the two major classes of lymphocytes [327]. Th1 
cytokines (IFNγ) polarized macrophages towards an M1 or classical phenotype 
while M2 or alternative macrophages are polarized in the presence of Th2 
cytokines (IL-4 and IL-13). M1 macrophages are pro-inflammatory, they are 
characterized with bactericidal and phagocytic properties and they release pro-
inflammatory cytokines and mediators. Alternatively, M2 macrophages are 
viewed as anti-inflammatory cells with important functions for limiting the immune 
response and driving wound healing and tissue repair. Additionally, M1 and M2 
macrophages have distinct metabolic properties which drive their different 
immune functions. The two macrophage populations metabolize arginine, a 
unique conditionally essential amino acid, differently through the expression of 
different enzymes. Nitric oxide (NO) is the characteristic inflammatory and 
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microbicidal mediator of M1 macrophages which is generated with the induced 
expression of nitric oxide synthase enzyme (iNOS). Conversely, M2 
macrophages express arginase-1 enzyme which metabolizes arginine into 
proline and polyamines essential for cell proliferation and wound healing [328]. 
 
Thus, arginine metabolomics in macrophages had been evaluated as a key 
regulator of the immune response. While 80% of circulating arginine comes from 
diet and proteolysis, the remaining 15-20% are from citrulline-derived synthesis 
in the kidneys [130]. Under physiological conditions, arginine primarily 
participates in the urea cycle for the elimination of toxic ammonia compounds. 
However, under certain inflammatory conditions, arginine becomes semi-
essential where it is metabolized by arginase-1, arginase-2, or iNOS [130]. Both 
arginase isoforms convert arginine into ornithine and urea. Cytosolic arginase-1 
is predominantly expressed in hepatocytes and certain immune cells, whereas 
mitochondrial arginase-2 is found in renal cells, enterocytes, neurons, and 
mammary gland cells. Constitutive expression of arginase-2 is mainly involved in 
the generation of ornithine precursor for the synthesis of proline (for collagen 
synthesis and repair) and polyamines (for cell proliferation and regeneration). 
Conversely, arginase-1 expression is induced in macrophages, neutrophils, and 
other immune cells where it competes with iNOS thereby regulating NO 
generation and limiting NO-mediated inflammatory injury [129-132, 135, 136, 
317-319]. However, recent studies evaluating the immunomodulatory role of 
arginase-1 suggest that its beneficial properties reach beyond its effects on 
limiting NO generation. In contrast to iNOS which does not deplete the arginine 
pool due to the citrulline recycling pathway, arginase depletion of arginine was 
found to have important effects on T cell function and proliferation [152, 154, 157, 
314, 315, 316 2008, 317]. Arginine depletion by arginase arrests T cell 
proliferation in the G0-G1 phase of the cell cycle, decreases its CD3ζ expression, 
affects the development of memory T cells, and suppresses the T cell effector 
pro-inflammatory functions [151-161]. By this mechanism, arginase suppresses 
the secretion of Th1 cytokines (IFNγ), as well as Th2 cytokines (IL4, IL5, and 
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IL10) [151-161]. Arginine deprived T cells also decrease their expression of 
activation markers (CD25, CD28, and CD62L) [160]. Those changes promote a 
regulatory T cell phenotype and suppress T cell immunity [129-132, 135, 136, 
317-319]. Additionally, arginase expression by M2 macrophages stimulates 
autophagy by increasing the conversion of microtubule-associated protein light 
chain 3 (LC3) from LC3-I to LC3-II [329]. Thus, arginase expression mediates the 
formation of autophagosomes and induces caspase-independent apoptosis. 
Autophagy induction by arginase is cytoprotective and it plays a critical regulatory 
role that downregulates inflammation [329-334]. Collectively, arginase expression 
by macrophages and other immune cells depletes arginine, controls T cell 
responses, prevents inflammatory injury, induces autophagy, and modulates the 
immune response. 
 
The immunomodulatory role of arginase had been evaluated in several disease 
models. In cancer, myeloid suppressor cells producing arginase inhibit T cell 
responses against tumor cells [151-162]. In pregnancy, arginase is essential to 
prevent maternal immune reactions against the fetus [319]. Arginase also plays 
an important immunomodulatory role in sepsis, trauma, surgery, certain 
infections, and some inflammatory and autoimmune diseases (e.g. leishmaniasis, 
streptococcus pneumonia infection, schistosomiasis, autoimmune 
encephalomyelitis, asthma, and experimental glomerulonephritis) [151, 152, 
316]. However, arginase mediated modulation of the inflammatory response 
against Pseudomonas aeruginosa (PA) pneumonia has not been investigated. 
 
About 60% of patients with cystic fibrosis (CF) are infected with PA which 
chronically colonizes the lungs of 80% of the patients older than 18 years [17-19]. 
Infections with PA are characterized by a chronic dysregulated inflammatory 
response with aberrant T cell immunity and a predominant recruitment of 
neutrophils and pro-inflammatory macrophages [312]. Epithelial cells with 
mutated CFTR channels release excessive amounts of cytokines and 
chemokines (IL8, IL1, and TNF-α) recruiting tremendous amounts of neutrophils 
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and pro-inflammatory macrophages which further release more inflammatory 
mediators. Neutrophil death results in the release of proteases and neutrophil 
elastases which digest the structural airway proteins and result in bronchiectasis. 
Death also causes the release of neutrophil intracellular DNA resulting in 
increased mucus viscosity, oxidative stress, and free radical formation. In 
addition to the exaggerated responses of pro-inflammatory neutrophils and 
macrophages, T cell responses against PA pneumonia in CF are also 
dysregulated, with a Th1 predominant response believed to be disproportionate 
to that required to respond to infection [312, 335]. This exaggerated inflammation 
had previously been attributed to abnormal NF-κB activation, decreased negative 
feedback and regulatory responses, disproportional cytokine release, and 
irregular immune cell activation [312].  
 
Our group has previously demonstrated that azithromycin-driven polarization of 
macrophages into an alternative phenotype controls several aspects of the 
immune response in mice infected with PA-impregnated agarose beads [166, 
310, 311]. Previously published data suggest that azithromycin treatment 
polarizes macrophages towards an M2 phenotype, shifts the immune response in 
infected mice into a monocyte predominant response, blunts neutrophil influx, 
and shifts the T cell response away from the Th1 phenotype [166, 310, 311].  
 
Closely examining the different effectors of those M2 macrophages revealed an 
important role of arginase-1. Azithromycin treatment significantly increases 
arginase expression and activity in vitro and in vivo. In mice treated with 
azithromycin, peaks in arginase expression in the lungs at days 3 and 14 post-
infection were consistent with reduced morbidity and decreased airway damage. 
In this chapter, we evaluate the hypothesis that the decreases in inflammation in 
response to PA pneumonia achieved by polarizing macrophages to an M2 
phenotype is dependent upon the production of arginase-1. The possible role 
and mechanism of arginase modulation of inflammation and T cell immunity in 
PA pneumonia have not been previously investigated. Many studies focus on 
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changes in arginase expression and its competition with iNOS in pulmonary 
inflammatory conditions, but to our knowledge, none of the studies previously 
examined the possible protective role of arginase in PA pneumonia. This study 
presents a novel approach for examining the immune-protective role of arginase-
1 in PA pneumonia by utilizing arginase-1 conditional knock-out mice and two 
pharmacological inhibitors of arginase (L-norvaline and S-(2-boronoethyl)- L-
cysteine (BEC)). We show that macrophage arginase-1 is essential for control of 
inflammatory responses in PA pneumonia with potentially different effects of 
other cellular sources as shown with global arginase inhibition.  
 
II. Results 
 
Increased morbidity and acute inflammation in arginase-1 conditional knock-out 
mice. We evaluated the impact of arginase deletion from myeloid cells upon the 
acute inflammatory response against PA pneumonia. We conditionally deleted 
arginase-1 in macrophages and neutrophils of C57BL/6 mice.  Arg1Δm and 
control Arg1flox/flox mice were infected intratracheally with PA-laden agarose 
beads to cause a prolonged infection similar to the chronic infections in patients 
with cystic fibrosis. Morbidity in infected mice was evaluated by measuring their 
body weight daily (Figure 3.1a). Mice were then humanely killed for assessment 
of inflammation and lung injury at different timepoints post-infection (Figure 3.2). 
Lungs were lavaged to collect cells from the alveolar spaces and the lung tissues 
were harvested to collect cells from the lung interstitium. Lavage and lung tissue 
samples were processed for flow cytometry analysis to assess neutrophil 
recruitment, macrophage disposition, as well as macrophage polarization over 
time post-infection. Arg1Δm mice lost more weight compared to their littermate 
controls. There was a significantly faster and greater decline in murine body 
weight at days 1 and 2 post-infection in the arginase conditional knock-out mice 
(Figure 3.1a). Increased morbidity in the Arg1Δm mice was associated with an 
average weight loss of 13.33% of their baseline body weight versus an average 
weight loss of 8.09% in the control mice (Figure 3.1, day 2, p-value < 0.0001). 
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Conversely, control mice recovered faster than the Arg1Δm mice which slowly 
regained their weight over time (Figure 3.1a, day 3, littermate control mice at 
96.02% of their baseline weight vs 90.38% in the conditional knock-out mice, p-
value = 0.0002). 
 
Interestingly, there were no significant differences in terms of bacterial clearance 
and mortality between the two groups (Figure 3.1 b and c). Lung bacterial 
clearance was evaluated at different timepoints post-infection by counting the 
number of viable PA colonies in homogenized lung tissues. Arg1Δm mice cleared 
PA at a comparable rate similar to the Arg1flox/flox mice. Both groups failed to 
completely clear the infection and PA was still present in the lungs by day 10 
post-infection. Similarly, arginase deletion from myeloid cells was not associated 
with increased mortality (Figure 3.1c). Importantly, the infective inoculum used in 
these experiments was selected to cause murine pneumonia without causing 
severe morbidity or mortality in each mouse strain. Mice were euthanized and 
excluded from the analysis if they lose 20% or more of their body weight prior to 
infection along with 1 sign of morbidity (e.g. immobility, hunched posture, or lack 
of response to handling).  
  
Additionally, the impact of arginase production by myeloid cells upon the acute 
inflammatory response to the infection was evaluated (Figure 3.2). Figure 3.2a 
explains the gating scheme used in FlowJo to identify different immune cell 
populations activated in response to the infection. Arg1Δm mice had significantly 
greater recruitment and infiltration of neutrophils into their lung interstitial and 
alveolar spaces. Arg1Δm mice had a greater peak in neutrophil counts at day 3 
post-infection compared to their littermate control mice (Figure 3.2b, p-value = 
0.0033 in the alveolar spaces and lung interstitium). Similarly, there was a 
significantly larger number of macrophages in the lungs of arginase conditional 
knock-out mice (Figure 3.2c). Littermate control mice had significantly lower 
numbers of tissue macrophages at day 3 post-infection in their alveolar spaces 
compared to the Arg1Δm mice (p-value = 0.0042). The latter recruited and 
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maintained a larger number of macrophages into their lung interstitium at days 3 
through 5 post-infection (Figure 3.2c, day 3, p-value = 0.0003; day 5 p-value < 
0.0001).  
 
Macrophage polarization was also evaluated in the arginase conditional knock-
out mice. The expression of different M1 and M2 macrophage effectors was 
assessed to determine the phenotype of macrophages recruited in response to 
the infection (Figure 3.2 d, e, f). Arg1Δm mice recruited larger numbers of all 
macrophage phenotypes. There were significantly higher numbers of TNF-α 
producing macrophages in the lungs of arginase conditional knock-out mice 
(Figure 3.2d, day 5, p-value = 0.0063 (alveolar and infiltrating)). Additionally, 
there was a significantly greater number of IL-10 producing alveolar 
macrophages in the lungs of arginase conditional knock-out mice compared to 
their littermate controls (Figure 3.2e, day 3, p-value = 0.0225). However, the 
number of infiltrating monocytes producing IL-10 were comparable in both groups 
with no significant difference. Similarly, there was no significant difference in the 
number of mannose receptor expressing alveolar macrophages between the 2 
groups (Figure 3.2f). However, the arginase conditional knock-out mice recruited 
significantly larger numbers of mannose receptor expressing macrophages into 
their lung interstitium later at 10 post-infection compared to the control mice 
(Figure 3.2f, day 10, p-value = 0.0493). Interestingly, the ratios of TNF-α and IL-
10 producing cells were comparable in both groups (Figure 3.2g, A). However, 
Arg1Δm had at least 2 times more neutrophils than macrophages in their lungs by 
day 3 post-infection compared to Arg1flox/flox mice (Figure 3.2g, B, day 3, p-value 
= 0.0387).  
 
Arginase conditional knock-out mice respond to PA pneumonia with greater T 
cell recruitment and activation. The impact of arginase production by neutrophils 
and macrophages upon the T cell responses was evaluated in Arg1Δm mice 
infected with PA-laden agarose beads intratracheally. T cell responses and 
activation profiles at different timepoints post-infection were evaluated in the 
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tracheobronchial lymph nodes that drain the site of infection, in the lung lavage, 
and in the lung tissue samples (Figure 3.3). Figure 3.3a and 3.4a explain the 
gating scheme used in FlowJo to identify different T cell populations. Although 
the arginase conditional knock-out mice responded to the infection with a greater 
increase in T cell numbers in their tracheobronchial lymph nodes by day 5 post-
infection, the differences were not statistically significant (Figure 3.3b). Similarly, 
there was a greater increase in T cell activation in the lymph nodes of arginase 
conditional knock-out mice at day 5 post-infection which was not statistically 
significant. Conversely, there were significantly greater numbers of CD4+ T cells 
and activated CD4+ T cells in the alveolar spaces of arginase conditional knock-
out mice compared to their littermate controls (Figure 3.3c, day 5, p-value = 
0.0369 and 0.0092, respectively). However, the arginase conditional knock-out 
mice responded with comparable T cell recruitment and activation in their 
interstitial spaces compared to their littermate controls with no significant 
differences (Figure 3.3d).  
 
Additionally, we analyzed the phenotypes of activated T cells in the lymph nodes 
and lungs overtime post-infection (Figure 3.4). Th1 lymphocytes were defined as 
the CD4+ T cells which express CXCR3 and IFNγ. In the lymph nodes of 
arginase conditional knock-out mice, there was a greater increase in the number 
of Th1 lymphocytes compared to the littermate control mice, but the differences 
were not statistically significant (Figure 3.4b). However, there were significantly 
higher numbers of Th1 lymphocytes in the lungs of arginase conditional knock-
out mice at days 3 and 5 post-infection (Figure 3.4c, p-value = 0.0345 and 
0.0371, respectively). Finally, Th17 lymphocytes were defined as the CD4+ T 
cells which express RORγt and IL-17. There were significantly larger numbers of 
Th17 lymphocytes in the lymph nodes and in the lungs of arginase conditional 
knock-out mice compared to the littermate control mice (Figure 3.4 b and c, day 
3, p-value = 0.0191 and 0.0488, respectively).  
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Additionally, we estimated the ratios of pro- and anti-inflammatory cytokines 
expressed by all lymphocytes. The lymphocyte population contains CD4+ T cells 
as well as other lymphoid cells including the innate lymphoid cells, CD8+ T cells, 
and NK cells. Figure 3.2g shows the ratios of IL-17, IFNγ, and IL-10 cytokines 
from lymphoid origin. The ratio of IL-17 to IL-10 producing lymphocytes was 
significantly higher in Arg1Δm mice at days 3, 5, and 10 post-infection (Figure 
3.2g, C, p-value < 0.0001). However, the ratios and trend of IFNγ to IL-10 
expressing lymphocytes were comparable among the 2 groups with similar 
trends (Figure 3.2g, D). 
 
Pharmacological arginase inhibition is associated with comparable morbidity and 
acute inflammatory response. We evaluated the impact of pharmacologic 
arginase inhibition upon the inflammatory response to PA pneumonia. BALBc/J 
mice were dosed with one of 2 pharmacological arginase inhibitors (BEC or L-
norvaline) via oral gavage starting 1 day prior to infection and daily thereafter. 
Control BALBc/J mice were dosed with water daily. Mice were infected with PA-
laden agarose beads as described in the methods section. Figure 3.5a shows 
morbidity at different tested infective inoculums. No significant morbidity was 
attained at the lowest inoculum of 5 × 10^6 CFU/mL (Figure 3.5a, B) while the 
highest inoculum of 5 × 10^7 CFU/mL resulted in severe morbidity (Figure 3.5a, 
D). Most of the mice infected with the inoculum of 1 × 10^7 CFU/mL lost at least 
10% of the baseline body weight (Figure 3.5a, C).  Therefore, we selected an 
inoculum between 1 × 10^7 CFU/mL and 5 × 10^7 CFU/mL for our experiments. 
Statistical significance was determined using two-way ANOVA ((x) BEC treated 
group significantly different than water treated group; (#) L-norvaline treated 
group significantly different than water treated group; (+) BEC treated group 
significantly different than L-norvaline treated group; p-value < 0.05).  
 
Morbidity post-infection was evaluated by measuring daily weight and evaluating 
weight loss as compared to the baseline prior to infection. There were no 
significant differences in terms of acute weight loss in mice treated with water 
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versus mice treated with the arginase inhibitors. However, control mice 
recovered slowly and incompletely compared to the mice treated with the 
arginase inhibitors (Figure 3.5b). While the BEC and L-norvaline treated mice 
regained their lost weight at day 6 post-infection up to an average of 89.94% and 
91.5% of their baseline body weight respectively, the water treated mice failed to 
recover with an average body weight at day 6 of 83.2% of their original weight 
prior to infection (Figure 3.5b, day 6, (x) p-value = 0.0391, (#) p-value = 0.0187). 
Similarly, BEC and L-norvaline treated mice recovered with an increase in their 
weight up to 98.21% and 99.4% of their baseline body weight at day 10 post-
infection while the water treated mice remained at 88.5% of their original weight 
(Figure 3.5b, day 10, (x) p-value = 0.025, (#) p-value = 0.0161). Interestingly, 
there were no significant differences in terms of mortality or bacterial clearance 
among the 3 groups (Figure 3.5 c and d). 
 
Additionally, we evaluated the impact of pharmacologic arginase inhibition on the 
inflammatory response and recruitment of innate immune cells (Figure 3.6). 
Surface and intracellular staining of lung lavage and lung tissue samples 
collected at different timepoints post-infection were performed and analyzed 
using flow cytometry. While the water treated mice had significantly higher 
numbers of neutrophils recruited into their alveolar spaces compared to the mice 
treated with BEC and L-norvaline (Figure 3.6a, day 2, (x) p-value = 0.0264, (#) p-
value = 0.0221); neutrophil recruitment into the lung interstitium was comparable 
among the 3 groups of mice. Similarly, water treated mice had significantly higher 
numbers of macrophages in their alveolar spaces at day 2 post-infection (Figure 
3.6b, day 2, (x) p-value = 0.0263, (#) p-value = 0.0053). Macrophage infiltration 
into the lung interstitium was comparable with no significant differences among 
the 3 groups (Figure 3.6b).  
 
To evaluate the phenotype of macrophages recruited into the lungs of mice 
treated with pharmacologic arginase inhibitors we stained for different M1 and 
M2 macrophage effectors and cytokines. There were no statistically significant 
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differences in either alveolar or infiltrating macrophages expressing TNF-α, IL-10, 
or iNOS (Figure 3.6c, d, f) among the 3 groups of mice. However, mice treated 
with BEC or L-norvaline had significantly lower numbers of MR expressing 
alveolar macrophages compared to water treated mice (Figure 3.6e, day 2, (x) p-
value = 0.038, (#) p-value = 0.0165). Similarly, mice treated with pharmacologic 
arginase inhibitors presented with significantly lower numbers of infiltrating M1 
macrophages at day 2 post-infection compared to water treated mice (Figure 
3.6g, day 2, (x) p-value = 0.0253, (#) p-value = 0.0349). Conversely, alveolar M1 
macrophages and infiltrating macrophages expressing MR were comparable 
among the 3 groups. Interestingly, the ratio of CCR7 and MR expressing 
macrophages and of TNF-α and IL-10 producing cells were comparable among 
the 3 groups (Figure 3.6h, A and B).  
 
Finally, we stained for type 2 innate lymphoid cells (ILC2) which are a major 
source of arginase in addition to neutrophils and macrophages (Figure 3.6i). 
ILC2s are derived from a lymphoid progenitor, but they lack B and T cell 
receptors. ILC2s are found in the skin, respiratory and gastrointestinal systems 
and they play a role in asthma, allergy, and parasitic infections. They release Th2 
cytokines and express arginase-1 constitutively [336]. Control mice had a greater 
increase in ILC2 recruitment to the alveolar spaces at day 2 post-infection which 
was not significantly different than the ILC2 recruitment in mice treated with 
arginase inhibitors. Similarly, the numbers of ILC2 infiltrating into the lung 
interstitium were comparable among the 3 groups of mice. 
 
Pharmacologic arginase inhibition is associated with increased T cell recruitment 
and activation in the lymph nodes of infected mice with potentially reduced 
chemotaxis to the lungs. We evaluated the impact of arginase inhibition in mice 
infected with PA pneumonia upon the activation of different T cell responses. The 
total number of CD4+ T cells and the number of CD4+ T cells expressing 
activation markers were quantified at different time points post-infection. In the 
tracheobronchial lymph nodes of water treated mice, there was a slightly higher 
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acute recruitment and activation of CD4+ T cells at day 2 post-infection 
compared to mice treated with arginase inhibitors (Figure 3.7a, day 2, p-value > 
0.05). The latter had a significantly increased recruitment and activation of CD4+ 
lymphocytes in their tracheobronchial lymph nodes at day 10 post-infection 
(Figure 3.7a, day 10, Total T cells: (x) p-value = 0.0017, (#) p-value = 0.0066; 
Activated T cells: (x) p-value = 0.0292, (#) p-value = 0.0044). Conversely, water 
treated mice had significantly higher numbers of CD4+ lymphocytes in their 
alveolar spaces at day 2 post-infection compared to the 2 groups treated with 
arginase inhibitors (Figure 3.7b, day 2, (x) p-value = 0.0349, (#) p-value = 
0.0285). However, there were no significant differences in T cell recruitment to 
the alveolar spaces at later timepoints post-infection. Similarly, the number of 
activated T cells in the alveolar spaces were comparable at all timepoints post-
infection with no significant differences among the 3 groups of mice (Figure 
3.7b).  As for the T cell responses in the lung interstitium, the 2 groups of mice 
treated with arginase inhibitors have slightly higher numbers of CD4+ 
lymphocytes compared to the water-treated mice (Figure 3.7c, Total T cells, p-
value > 0.05). However, mice treated with L-norvaline had significantly higher 
numbers of activated T cells in their interstitial spaces compared to both BEC 
and water treated mice (Figure 3.7c, activated T cells, day 2 (+) p-value = 
0.0081, (#) p-value = 0.0016; day 5 (+) p-value = 0.0256, (#) p-value = 0.0179). 
Although no statistical significance was observed, the trend of increased 
numbers of CD4+ T cells observed on day 10 post-infection in the lymph nodes 
holds true for both the airways and the lung interstitium. 
 
Next, we sought to determine the phenotype of T cells recruited and activated in 
the lymph nodes and lungs of mice treated with pharmacologic arginase 
inhibitors. We stained for different surface receptors, lineage-specifying 
transcription factors, and intracellular cytokines. Mice treated with BEC or L-
norvaline had higher recruitment of Th17 lymphocytes in their lymph nodes with 
significantly higher numbers at day 10 post-infection (Figure 3.8a, day 10, (x) p-
value = 0.0079, (#) p-value < 0.0001). However, there were no significant 
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differences in the number of Th17 lymphocytes in the interstitial spaces among 
the 3 groups of mice; whereas, the water treated mice had significantly higher 
numbers of Th17 lymphocytes in their alveolar spaces compared to the L-
norvaline treated mice only (Figure 3.8a, day 2, (#) p-value = 0.0127).  
As for the type 1 T helper lymphocytes, the numbers were comparable in the 
lymph nodes with no significant differences among the 3 groups of mice. 
However, water treated mice had significantly higher numbers of Th1 
lymphocytes in the alveolar and interstitial spaces at day 2 post-infection 
compared to mice treated with BEC and L-norvaline (Figure 3.8b, day 2, lung 
interstitium (x) p-value = 0.0002, (#) p-value < 0.0001; alveolar spaces (x) p-
value = 0.0066, (#) p-value = 0.0165).  
 
Lastly, water-treated mice had higher numbers of regulatory T cells in their lymph 
nodes, alveolar spaces, and lung interstitium (Figure 3.8c). While the number of 
Treg lymphocytes were not significantly different among the groups treated with 
BEC versus the groups treated with L-norvaline, the latter had significantly lower 
numbers of Treg lymphocytes compared to the water treated mice (Figure 3.8c, 
day 2, lymph nodes (#) p-value = 0.0317; lung interstitium (#) p-value = 0.0128).  
 
Additionally, we estimated the ratios of pro- and anti-inflammatory cytokines 
expressed by CD4+ T cells as well as other lymphocytes. Figure 3.6h shows the 
ratios of total IL-17, IFNγ, TGFβ, and IL-10 expressing lymphoid cells in the 
alveolar spaces. The ratio of IL-17 to IL-10 producing lymphocytes was 
significantly higher in water treated mice at day 3 post-infection compared to the 
L-norvaline treated group (Figure 3.6h, C, (#) p-value = 0.0014). However, the 
ratios and trend of IFNγ to TGFβ expressing lymphocytes were comparable 
among the 3 groups (Figure 3.6h, D). 
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III. Discussion 
 
Patients with cystic fibrosis are genetically predisposed for chronic and repeated 
infections against which the immune system responds in an exaggerated but 
inefficient manner. The excessive immune response fails to adequately clear the 
infection while damaging the lungs and aggravating the pathology. The resultant 
lung injury further activates the immune response resulting in a vicious cycle of 
continuous inflammation and decline in lung function. Because of this, pulmonary 
infections are the leading cause of mortality in cystic fibrosis [1]. Despite our 
increased understanding of the altered immune response, life expectancy in 
patients with cystic fibrosis is still limited to 40 years in male patients and 37 
years in female patients. 
 
Several drugs against individual elements of the altered immune response are in 
clinical trials; yet, there is no defined target that can globally modulate the 
multiple mechanisms involved. Arginase-1 is an immunomodulatory enzyme with 
a versatile power in regulating multiple elements of the immune system.  
Additionally, we consistently see increased arginase expression and activity with 
improved inflammatory response and decreased lung pathology. Our group has 
previously shown increased arginase expression in mice treated with 
azithromycin along with improved morbidity and mortality [166, 310, 311]. 
Additionally, we have previously shown increased arginase expression in 
patients with cystic fibrosis and in J774 murine macrophages polarized with 
azithromycin in vitro [166, 310, 311]. Yet, whether arginase plays a role in 
modulating immunity in cystic fibrosis has not been investigated. And if so, the 
specific mechanisms involved in arginase modulation of the immune response 
are yet to be elucidated. The current study investigates the hypothesis that 
regulating excessive inflammation in PA pneumonia is dependent upon arginase 
production. We provide novel evidence concerning the different aspects of the 
immune response modulated with arginase expression, broadening our 
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knowledge of the specific mechanisms involved in regulating the immune 
response against infections in cystic fibrosis patients.  
 
We utilized an arginase-1 conditional knock-out mouse model as well as two 
global pharmacological arginase inhibitors to investigate the impact of arginase 
deletion or inhibition upon the inflammatory response to PA pneumonia. Our 
group has previously developed an effective method for establishing a prolonged 
infection with PA in mice. We incorporate bacteria isolated from cystic fibrosis 
patients into agarose beads which are instilled intratracheally in mice to cause a 
chronic PA lung infection.  
 
We show that arginase deletion from myeloid cells is associated with increased 
morbidity in mice infected with PA-laden agarose beads. Arginase conditional 
knock-out mice got sicker and lost more weight after the infection compared to 
mice whose macrophages and neutrophils can produce arginase. Additionally, 
arginase-1 conditional knock-out mice had a more severe response to the 
infection compared to their littermate controls. Arginase deletion from myeloid 
cells resulted in an excessive recruitment of neutrophils and macrophages into 
the lungs of infected mice. The increased macrophage infiltration into the lungs of 
arginase conditional knock-out mice was predominantly skewed towards an M1 
pro-inflammatory phenotype with excessive numbers of TNF-α producing 
macrophages. These results suggest that arginase production is essential to 
control the acute inflammatory response and that absence of arginase precludes 
regulatory mechanisms essential for limiting the immune response and 
preventing exaggerated activation and recruitment of immune cells. One of the 
possible mechanisms by which arginase could lead to reduced recruitment of 
pro-inflammatory cells into the lungs is by protecting against permeability edema 
[337]. It is suggested that arginase reduces NO concentrations, through 
competition with iNOS, thereby reducing NO-mediated capillary endothelial 
hyperpermeability which is associated with excessive infiltration of neutrophils 
and macrophages from the blood into the alveoli. Therefore, arginase protects 
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against dysfunction of the alveolar-capillary barriers which limit the influx of 
inflammatory cells into the lungs [337]. Moreover, it is very likely that the 
arginase-mediated regulation of T cell responses that we observed in our model 
is responsible for limiting the excessive recruitment and chemotaxis of 
inflammatory cells into the lungs. 
 
The most described immunomodulatory properties of arginase include its 
modulation of T cell responses. Consistently, we demonstrate abruptly increased 
proliferation and activation of CD4+ T lymphocytes in the Arg1Δm mice. The 
deletion of arginase from myeloid cells resulted in increased T cell numbers in 
the lymph nodes and alveolar spaces of infected mice. This can be attributed to 
the increased arginine concentrations in the absence of arginase-mediated 
arginine depletion. These findings are consistent with research showing that 
arginase-1 expression induces T cell hypo-responsiveness through arginine 
depletion by the enzyme [130-132, 135, 136, 338-340]. In fact, arginase-
mediated arginine depletion was shown to be associated with down-regulation of 
the T cell mediated immune responses in several conditions including (1) solid 
and hematological tumors, (2) virus-induced diseases, (3) leishmaniasis, (4) 
dextran sodium sulfate induced intestinal inflammation, (5) Behςet disease, (6) 
streptococcus pneumonia infections, (7)  schistosomiasis, (8) autoimmune 
encephalomyelitis, (9) filarial infections, (10) sepsis, (11) asthma, (12) trauma, 
and (13) experimental glomerulonephritis [137-150, 341, 342]. Arginase-
mediated effects on T cell responses were variable among the disease models 
listed above ranging from suppression of Th1 mediated pathology, to modulating 
the interplay of Th1/Th2 cytokines, shifting the macrophage/neutrophil balance, 
suppressing immune recognition and rejection of tumor cells, reducing CD8+ and 
CD4+ T cell proliferation, and modulating the Treg/Th17 balance [137-150, 341, 
343]. According to Denning et al., arginase expression by lamina propria 
macrophages controls T cell differentiation into Treg and T17 phenotypes [344]. 
Overall our findings are in accordance with findings reported by Denning and 
several other studies which show that arginine depletion by arginase decreases 
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T cell proliferation and T cell effector functions [151-161]. Previous studies show 
that T cells activated under arginine depleted conditions fail to express CD3ζ and 
CD3ε. This results in decreased receptor-mediated tyrosine phosphorylation; 
however, it does not affect Ca2+ flux [162]. The decreased CD3ζ expression is 
not due to protein degradation or decreased mRNA but due to decreased global 
protein synthesis [157]. It is attributed to decreased cyclin D3 mRNA stability and 
expression which in turn prevents forward progression in the cell cycle and 
arrests T cells in the G0-G1 phase [157]. Impairment of T cell activation under 
arginine depleted conditions is T cell receptor (TCR) independent and is not 
mediated via inhibitory effect of CTLA4, IL10, PDL1, or TGFβ [144]. Moreover, 
the decreased T cell proliferation is not associated with an increase in apoptosis 
or T cell death [151]. Previous literature suggests that in most cases the 
arginase-mediated suppression of T cells is localized to the site of infection and 
does not affect naïve T cells in lymph nodes and other secondary lymphoid 
organs ensuring that this suppression is not due to T cell intrinsic defects [138-
143]. Additionally, T cell suppression due to arginine depletion is reversed with 
arginase inhibition or with the L-arginine supplementation [137-150]. Thus, the 
increased arginine availability in Arg1Δm mice is most likely driving increased T 
cell proliferation and contributing to the robust and excessive numbers of T cells 
in infected mice. Additionally, we show that deletion of arginase is associated 
with excessive numbers of activated T cells emphasizing the important role of 
this immunomodulatory enzyme in controlling the expression of T cell activation 
markers and limiting T cell responses in PA pneumonia.  
 
Additionally, our results show that arginase deletion from myeloid cells skews the 
T helper cell responses towards a Th1/Th17 predominant response consistent 
with previous reports of arginase-mediated shift towards a regulatory T cell 
phenotype along with suppression of pro-inflammatory cytokine production [129]. 
We show that in a murine model of PA pneumonia, Arg1Δm mice respond with 
excessive activation of Th1 and Th17 pro-inflammatory lymphocytes in their 
lymph nodes and in their lungs. In addition to the previously discussed evidence 
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of arginase effects on T cell phenotype mediated via arginine depletion, several 
other mechanisms could be involved. According to Obermajer and colleagues, 
iNOS mediates Th17 induction and stabilization via NO mediated pathways 
[345]. NO secretion by myeloid-derived suppressor cells expressing iNOS 
promoted the differentiation of RORγt+ IL-17+ CD4+ T cells from naïve and 
memory human T cells. These effects of NO on T cell polarization were mediated 
via signaling through the canonical cyclic guanosine monophosphate (cGMP)-
dependent protein kinase (cGK) pathway within CD4+ T cells. Inhibition of iNOS 
or cGMP–cGK signaling prevents the polarization towards a Th17 phenotype  
[345]. Obermajer reports that suppression of NO levels significantly reduces IL-
17 concentrations in patients with ovarian cancer  [345]. Therefore, comparing 
our results to the findings by Obermajer et al., it is likely that arginase deletion 
shifts the arginine metabolism towards the iNOS pathway thereby increasing NO 
levels which drive T cell polarization towards the Th17 phenotype. Additionally, it 
is likely that an arginase-mediated shift of T cell response towards a regulatory 
phenotype suppresses Th17 and Th1 responses. Geiger and colleagues suggest 
that arginase controls several metabolic pathways in T cells which promotes their 
regulatory functions [346]. Arginase modulates glycolysis and oxidative 
phosphorylation in activated T cells which shifts their function towards regulatory 
and memory cells by direct effects on several transcription regulators including 
BAZ1B, PSIP1, and TSN [346]. Tregs suppress Th1 and Th17 responses and 
directly inhibiting the secretion of polarizing cytokines [346, 347]. Therefore, it is 
likely arginase deletion shifts the Treg/Th17 balance in Arg1Δm mice by promoting 
Th17 polarization and suppressing Treg numbers. 
 
Skewing of the T cell responses towards a Th17 and Th1 predominant response 
partially explains the increased recruitment of neutrophils and M1 macrophages. 
It is very likely that the excessive amounts of IFNγ and IL-17 released by the Th1 
and Th17 lymphocytes are responsible for polarizing macrophages towards an 
M1 pro-inflammatory phenotype and for recruiting excessive numbers of 
neutrophils. According to Disteldorf et al., Th17 responses attract destructive 
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neutrophils which cause renal tissue injury [348]. In a murine model of crescentic 
glomerulonephritis, authors report that CXCL5 drives the excessive influx of 
pathogenic neutrophils into sites of inflammation via a Th17-dependent pathway 
in later chronic stages of the disease [348]. Similarly, Th17 responses recruit 
neutrophils both of which mediate immunopathogenesis in Leishmaniasis. This is 
mediated via cooperation of IL-17 with other cytokines which recruits neutrophils 
in excessive numbers during Leishmania infection [349]. Therefore, our results 
emphasize the importance of arginase-mediated regulation of Th17 responses 
thereby limiting the pathogenic neutrophil influx into the lungs of patients with 
cystic fibrosis. Our data support that arginase is a mediator which controls Th17-
associated inflammation providing new targets to manipulate Th17 responses in 
cystic fibrosis, cancer, autoimmunity, and other inflammatory diseases. 
 
Additionally, results show significantly increased ratio of IL-17/IL-10 producing 
lymphoid cells at days 3 through 10 post-infection in Arg1Δm mice. We observed 
marked expression of IL-17 cytokine in CD4+ T cells expressing non Th17 
cytokines or lineage markers as well as in non CD4+ lymphoid cells. This reflects 
upon the potential of arginase-1 to control IL-17 production through mechanisms 
additional to Th17 regulation. According to Hayes et al., IL-17 is required to 
control chronic infection with PA and is released by Th17 cells, innate lymphoid 
cells, γδ-T cells, and NK cells [289]. Hayes and colleagues infected IL-17RA 
knock-out mice with PA-laden agarose beads to cause a chronic infection with a 
mucoid PA strain similar to our procedure. Authors found that IL-17RA knock-out 
mice had significantly lower morbidity and faster recovery while the bacterial 
loads in their lungs were higher at 2 weeks post-infection compared to wild-type 
mice. Additionally, there were no significant differences in the number of 
neutrophils and the histologic lung injury scores between wild-type and IL-17RA 
knock-out mice [289]. The decreased morbidity in IL-17RA knock-out mice is 
attributed to the lack of IL-17 direct effects on pro-inflammatory cytokines like IL-
6 and TNF-α. Additionally, they show a CD3+ population expressing both IFNγ 
and IL-17 in the lymph nodes of infected mice. About 90% of the cells expressing 
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IL-17 in the lymph nodes at 2 weeks post-infection had a phenotype consistent 
with ILC3 cells while the remaining 5-10% of the cells had B cell markers [289]. 
However, in the lungs of wild-type mice, there was a significant increase in IL-17 
expressing cells. About 50% of these cells were consistent with Th17 and γδ-T 
cells while the majority of the remaining cells were consistent with ILC3 cells. A 
small fraction of about 3.83% of all IL-17 expressing cells in the lungs had B cell 
markers and was consistent with B1 cell population [289]. Accordingly, our 
results from Arg1Δm mice show significantly increased IL-17 expression along 
with increased morbidity. We observed a significant IL-17 expression by 
lymphoid and non-lymphoid cells. Although we did not specifically stain for ILC3 
cells, it is very likely that ILC3 cells contribute to the increased IL-17 expression 
by non-CD4+ T cells. Group 3 ILCs produce IL-22 and IL-17A and express 
RORγt, they present antigens and control CD+ T cell responses [350, 351]. 
According to von Burg et al., ILC3 cells can regulate lymphoid tissue 
development and can alter the adaptive immune response by directly stimulating 
CD4+ lymphocytes [350]. ILC3 cells prime CD4+ T cells and induce their 
proliferation and activation by directly presenting antigen and secreting cytokines. 
Therefore, regulating IL-17 production by ILC3 cells constitutes a novel approach 
to control T cell immune responses [350, 351]. Accordingly, it is essential to 
closely examine the effects of arginase mediated regulation of IL-17 secretion 
and whether it involves regulation of ILC3 development and subsequent 
regulation of T cell mediated immunity. 
 
Importantly, the absence of arginase does not inhibit anti-inflammatory 
responses, as we see recruitment of IL-10 and MR expressing M2 macrophages. 
The latter are likely to be elevated in the absence of arginase as a regulatory 
feedback that is failing to downregulate the excessive inflammation. Despite the 
increased levels of the anti-inflammatory cytokine IL-10, the anti-inflammatory 
response is still unable to protect against the excessive inflammation caused by 
the deletion of arginase. We have consistently observed this in past experiments 
in mice that lack alternative macrophage activation. Also, in-vitro when TNF-α 
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production increases as a result of increased M1 polarization, IL-10 is also 
increased in a compensatory manner [166, 310, 311]. According to Stenvinkel et 
al., systemic inflammation responsible for pathogenesis in cardiovascular 
disease and end-stage live disease is associated with elevated concentrations of 
IL-10, IL-6, and TNF-α. Authors report that IL-10 secretion is delayed and always 
follows the release of TNF-α with a latency of a few hours. The coupling of 
excessive inflammatory mediators with the delayed secretion of IL-10 ensures 
that inflammation will securely be down-regulated [352]. Additionally, several 
reports describe complex signaling mechanisms involved with TNF-α induced IL-
10 secretion which involves activation of protein kinase C [353-355]. Exclusive 
secretion of IL-10 without preceding secretion of pro-inflammatory cytokines 
seems to be a rare event. Our results were broadly in agreement with the 
previous findings which demonstrate that excessive TNF-α release induces 
increased IL-10 concentrations as a regulatory mechanism to control excessive 
inflammation. However, in our model the increased IL-10 was not enough to 
protect against the increased morbidity in the Arg1Δm mice. 
 
Our model of Arg1Δm mice allowed us to address our hypothesis concerning 
macrophage and neutrophil specific arginase expression. Arginase is expressed 
by many other immune and non-immune cells; therefore, we next sought to 
confirm the results by globally inhibiting arginase by administering pharmacologic 
arginase inhibitors. BALBc/J mice are known to be Th2-dominant compared to 
C57BL/6 mice which are on a Th1-dominant. BALBc/J mice respond to the 
infection with significant expression and activation of arginase. Hence, we 
decided to globally inhibit arginase in these mice to investigate the impact of 
inhibiting arginase from all cellular sources on the immune response to PA 
pneumonia. Mice treated with global arginase inhibitors did not lose more weight 
compared to mice which were dosed with water. However, it is important to note 
that mice with global arginase inhibition lost more weight generally compared to 
mice with conditional arginase deletion from myeloid cells. The maximum weight 
loss in arginase conditional knock-out mice was about 13.33% achieved by day 2 
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post-infection, versus a maximum average weight loss of about 20% in BALBc/J 
mice treated with arginase inhibitors and achieved by day 3 post-infection. This is 
a trend that we observed in our experiments, but we did not directly compare the 
2 strains with simultaneous infection. 
 
Global arginase inhibition with both pharmacologic inhibitors suppressed the 
acute inflammatory response in infected mice. There were significantly lower 
numbers of neutrophils in the alveolar spaces of mice treated with BEC or L-
norvaline compared to mice which were dosed with water only. However, in the 
lung interstitial spaces there was a delayed and slightly elevated influx of 
neutrophils into the lungs of mice treated with arginase inhibitors at day 5 post-
infection. Results suggest that while arginase inhibitors can acutely attenuate 
neutrophil influx in the alveolar spaces, the global arginase inhibition is 
associated with a delay in neutrophil infiltration into the lung interstitium. 
Importantly, the total number of neutrophils recruited in the 3 groups of BALBc/J 
mice were much higher than in the arginase conditional knock-out mice (1.5-9 x 
10^6 versus 0.5-1.5 x 10^6 in the alveolar spaces; 8-9 x 10^6 versus 1-3 x 10^6 
in the lung interstitium). Whether this difference is significant, and if so, whether 
this is due to global inhibition of arginase versus deleting it from myeloid cells is a 
question to be answered. Additionally, this difference might be due to a more 
infective batch of PA-laden agarose beads as we prepare these prior to each 
infection and there is always a chance of the bacteria changing its virulence or 
becoming more or less infective. Moreover, the difference in the weight loss and 
in the inflammatory response to the infection might be solely due to the different 
genetic background of the two strains of mice.  Therefore, a clear and definitive 
assumption about the effect of global arginase inhibition on morbidity and 
neutrophil influx cannot be concluded from these results. 
 
Similarly, global arginase inhibition was associated with different effects on 
alveolar and infiltrating macrophages. While mice treated with BEC or L-norvaline 
had reduced numbers of alveolar macrophages activated in response to the 
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infection, they had higher numbers of infiltrating macrophages in their lung 
interstitium. Again, the total number of macrophages recruited in the 3 groups of 
BALBc/J mice were much higher than in the arginase conditional knock-out mice 
(1 - 4 x 10^6 versus 0.25 - 0.5 x 10^6 in the alveolar spaces; 0.5 - 2 x 10^7 
versus 1 - 5 x 10^6 in the lung interstitium) and this is likely due to the use of 
BALB/c mice, a strain in which we consistently observe higher macrophage 
numbers as compared to neutrophils. Moreover, the numbers of TNF producing 
macrophages were comparable in mice treated with water versus mice treated 
with global arginase inhibitors. As for IL-10 producing macrophages, they were 
slightly lower in the BEC and L-norvaline groups without being statistically 
significant. Similarly, there were lower levels of MR expressing alveolar 
macrophages in the groups treated with arginase inhibitors while the infiltrating 
monocytes were not significantly different among the 3 groups. Moreover, there 
were no significant differences in iNOS expressing alveolar and infiltrating 
macrophages. While the numbers of alveolar M1 pro-inflammatory macrophages 
were comparable among the 3 groups of mice, the numbers of infiltrating M1 
macrophages were significantly lower in mice treated with arginase inhibitors. 
Our results suggest that arginase inhibitors have potentially different effects on 
resident versus infiltrating macrophages. This might be explained by potentially 
different local, anatomical, or cellular effects of the pharmacologic inhibitors. 
Additionally, these observations may be a mere effect of the murine strain used 
in these experiments. According to Loke and colleagues, C57BL/6 mice and 
BALB/c mice have inherent differences in PDL1 and PDL2 expression on the 
surface of macrophages [356]. The expression of these markers, as well as other 
surface receptors essential for migration of leukocytes, is governed by Th1 and 
Th2 cytokines. These differences account for a significant variation in leukocyte 
recruitment and transmigration as well as to differences in T cell activation 
among the 2 strains of mice [356, 357]. Therefore, it is important to consider the 
differences among the 2 strains of mice used in our experiments besides the 
effects of the arginase inhibitors. This urges us to repeat the arginase inhibitor 
experiments in C57BL/6 mice to better draw informative conclusions about the 
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specific effects of these inhibitors on leukocyte recruitment and activation in 
response to PA pneumonia. 
 
Collectively, global arginase inhibition had different effects on alveolar versus 
interstitial macrophages. Our results do not support a definite conclusion as to 
whether arginase inhibition modulates compartmentalization of immune cells 
recruited in response to the infection. Additionally, BALBc/J mice are on a Th2 
background which drives a completely different immune response compared to 
Arg1Δm mice which are on a C57BL/6 background. Stevenson and colleagues 
suggest resistance of BALBc/J to infections with PA whereas the C57BL/6 mice 
were more susceptible to the infection. This group shows increased cellularity 
and a shift towards a neutrophilic response in C57BL/6 while BALBc/J had a 
monocytic predominant influx with less cellularity [358]. However, both groups in 
this report were infected at the same CFU while in our experiments there was a 
10-fold difference in the CFU required to cause a comparable infection in both 
strains. Additionally, a mucoid PA strain was used which is not the same that was 
used in our experiments which might result in differences in the immune 
response activated. Moreover, our BALBc/J were dosed with arginase inhibitors 
which might have contributed to the difference in the inflammatory response 
observed. Furthermore, the difference in susceptibility to the infection is also 
related to the differences in clearance due to altered macrophage activation and 
chemotaxis between C57BL/6 mice and BALBc/J mice. According to Watanbe et 
al., in vitro infection of naïve macrophages from both strains of mice with live 
bacteria shows a significant impairment of bactericidal functions of BALB/c 
macrophages compared to macrophages from C57BL/6 mice [359]. This effect 
was explained by the impaired ability of BALBc/J macrophages to upregulate 
lysosomal enzyme and NO essential for bacterial killing. Authors show that in a 
murine model of septic peritonitis, BALBc/J mice fail to clear the infection despite 
the excessive recruitment of leukocytes. Similar to our observations, BALBc/J 
mice recruited tremendous numbers of macrophages into the peritoneal cavity 
with significantly higher levels of pro-inflammatory cytokines and mediators 
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compared to C57BL/6 mice thereby resulting in exaggerated systemic 
inflammation. Watanbe and colleagues suggest significant differences in innate 
immune responses between C57BL/6 mice and BALB/c mice depicted by 
increased cellularity but decreased functionality of immune cells recruited in 
response to infections in BALB/c mice compared to the C57BL/6 mice [359]. 
Therefore, it is important to distinguish the effects of the pharmacological 
arginase inhibitors on leukocyte activation and migration versus the inherent 
immune differences in the BALBc/J mice. 
 
Additionally, we evaluated the effects of the pharmacologic arginase inhibition 
upon the T cell responses. As expected, mice treated with BEC or L-norvaline 
had a significantly higher number of T cells in their lymph nodes similar to the 
effects with myeloid arginase deletion. This can be explained by the increased 
arginine pool and the lack of arginase-dependent suppression of T cell activation 
as we explained in the Arg1Δm murine experiments. However, in contrast to the 
observations with Arg1Δm mice, there were lower numbers of T cells and 
activated T cells in the alveolar spaces of mice treated with global arginase 
inhibitors (differences not statistically significant). Yet, there was a greater 
infiltration and activation of T cells in the interstitial spaces of mice treated with 
BEC or L-norvaline. Therefore, global arginase inhibition increases T cell 
numbers in the lymph nodes and in the lung interstitium but not in the alveolar 
spaces. This may be explained by the potentially different spatial effects of the 
arginase inhibitors and the potential effects of arginase inhibitors on chemotaxis 
and migration of T cells between the lymph nodes and the different lung 
compartments. It is likely that BEC and L-norvaline modulate effectors involved in 
T cell migration into the alveolar spaces. Future studies will evaluate the effects 
of arginase inhibitors on T cell migration and chemotaxis. This includes looking 
for transmigration effectors and proteins in addition to performing T cell migration 
assays using transwells and Boyden chambers. Additionally, in vivo T cell 
migration assays to evaluate the effects of arginase inhibition of T cell 
recruitment to the lungs involve adoptively transferring T cells into mice as well 
 123 
as tracking radiolabeled T cells according to the methods proposed by 
Campanella and colleagues [360-362]. 
 
Lastly, we evaluated the specific phenotypes of T cells affected by 
pharmacologic arginase inhibition. Similar to the results from Arg1Δm mice, there 
was a significantly higher number of Th17 lymphocytes in the lymph nodes of 
mice treated with BEC or L-norvaline. Conversely, arginase inhibitors did not 
significantly increase the numbers of Th17 lymphocytes in the lungs like in the 
Arg1Δm mice. There were comparable numbers of Th17 lymphocytes in the 
alveolar spaces and lower numbers in the interstitial spaces compared to the 
water treated mice. Similarly, there were higher numbers of Th1 lymphocytes in 
the lymph nodes of mice treated with arginase inhibitors while they were 
considerably lower in the interstitial and alveolar spaces compared to the water 
treated mice. These observations are also different than the effects of arginase 
deletion from myeloid cells in the Arg1Δm mice which promotes Th1 responses 
both in the lungs and the lymph nodes. Additionally, global arginase inhibition 
suppressed the development of regulatory T cells. There were significantly lower 
numbers of Treg lymphocytes in the lymph nodes and interstitial spaces of mice 
treated with arginase inhibitors versus mice treated with water. In the alveolar 
spaces, arginase inhibitors reduced the numbers of Treg lymphocytes; however, 
the differences were not statistically significant. Therefore, results from 
experiments with global arginase inhibition validate our previous hypotheses that 
global arginase inhibition has different effects on the lung compartments versus 
the lymph nodes and that T cell migration and chemotaxis is potentially altered in 
mice treated with BEC or L-norvaline. It is likely that arginase inhibitors prevent 
migration of activated T helper cells (including Th1, Th17, and Tregs) from the 
lymph nodes to the lungs of infected mice. This will be confirmed using the 
chemotaxis assay proposed earlier. However, it is also possible that the arginase 
inhibitors affect local T cell activation in the lungs via effects on leukocyte 
activation and expression of co-stimulatory molecules. It has been reported that 
PDL1 and PDL2 promote peripheral tolerance in viral infections and in cancer. In 
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a murine model of Trypanosoma cruzi infection, peritoneal macrophages 
suppressed proliferation of T cells at the site of infection through a PD-1/PDL1 
dependent mechanism [363]. This effect was mediated by modulation of the 
iNOS/arginase metabolic pathways and it results in suppression of peripheral T 
cell proliferation and cytokine release. Therefore, future experiments will evaluate 
the effects of arginase inhibitors on macrophage expression of T cell inhibitory 
receptors and whether effects of arginase inhibitor are mediated through effects 
on transmigration versus monocyte-mediated peripheral tolerance.  
 
In summary, results from Arg1Δm mice experiments confirm the importance of 
myeloid arginase in the regulation of the inflammatory response, while 
experiments with global arginase inhibition suggest different and broad effects of 
other cellular sources of arginase. Besides neutrophils and macrophages, many 
other immune cells express arginase which can potentially influence our 
observations. Monticelli et al. show that arginase deletion from type 2 innate 
lymphoid cells can suppress Th2 mediated inflammation and reduce cytokine 
release. They suggest that arginase deletion from these cells changed multiple 
metabolic pathways with potential effects on several inflammatory and immune 
responses [364]. Additionally, Bando et al. show that arginase expression in 
ILC2s is governed by distinct signaling pathways as compared to the M2 
macrophages and that ILC2s express arginase at rest and during inflammation. 
Bando’s group show that altered arginase expression affects the development 
and expansion of the ILC2 population besides affecting arginase expression in 
M2 macrophages [365]. Moreover, CD4+ and CD8+ T cells as well as B cells can 
express arginase. In our experiments with BEC and L-norvaline we inhibited 
arginase from all of the above-listed sources and therefore it is difficult to tease 
apart the specific effects of different arginase sources on the immune response 
to PA pneumonia.  
 
Our results confirm that global arginase inhibition has a different effect on 
different elements of the immune response. Our results suggest that arginase 
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inhibition affects compartmentalization of both myeloid and lymphoid cells 
recruited in response to the infection. While arginase inhibition did not result in 
increased weight loss, mice which received BEC and L-norvaline did have 
multiple signs of increased morbidity, reduced motility, and increased 
inflammation. However, comparing these results to the experiments with Arg1Δm 
mice confirms our hypothesis that myeloid arginase is essential in controlling the 
inflammatory response. Therefore, we provide strong evidence that myeloid 
arginase specifically, and not other arginase sources, is important for controlling 
inflammation in PA pneumonia. 
 
Importantly, results were comparable among the two arginase inhibitors used, 
BEC and L-norvaline. Both inhibitors are arginine analogs and they compete with 
the substrate and irreversibly inhibit arginase enzymatic activity. We used 2 
inhibitors to confirm that our observations are due to arginase inhibition rather 
than other pleiotropic effects of the inhibitor. However, some reports suggest that 
L-norvaline and not BEC might have some anti-inflammatory effects independent 
of arginase inhibition [366]. Ming et al. suggest that L-norvaline can have anti-
inflammatory effects by suppressing the S6K1 pathway thereby reducing TNF-α 
secretion. However, their results are from in vivo experiments with endothelial 
cells which might be valid but insignificant in our murine model of PA pneumonia. 
Yet, it is possible that some of our results with BEC and L-norvaline might be 
driven by different alternative mechanisms that either of the inhibitors can exert. 
Moreover, it is possible that the inhibitors act differently on different immune cells 
and in different anatomical compartments and that this difference is responsible 
for our observations in mice treated with either BEC or L-norvaline. Additionally, 
although the doses of both arginase inhibitors used in our study were adapted 
from literature and established to result in comparable enzymatic inhibition, it is 
possible that the potency of these drugs in our mouse model is different and that 
this drives some of our results.  
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The effects of arginase inhibitors on the migration and chemotaxis of myeloid 
cells and T lymphocytes to the lungs might be attributed to the effects on NO 
production. Both BEC and L-norvaline are shown to affect NO production by NOS 
and to modulate the endothelium junctions and affect dilation and relaxation of 
the blood vessels [367]. While arginase inhibition can affect the expression of 
surface markers on immune cells, the changes in the endothelium and blood 
vessels with our inhibitors can potentially be responsible for reduced 
transmigration and trafficking of immune cells across the vessel walls. 
 
Some of the other limitations in our study include the “leaky” LysM cre system 
and the difference in murine strains used in both experiments. The deletion of 
arginase in our murine model is controlled by lysozyme expression. Lysozyme M 
is expressed in neutrophils and macrophages. So, it is hard to delineate the 
difference between neutrophil versus macrophage arginase function as both are 
deleted. Additionally, new reports show different levels of lysozyme expression 
between tissue and infiltrating macrophages thus accounting for different levels 
of arginase deletion from these two populations system [368]. Suggested models 
which may be associated with even deletion of arginase from different 
macrophage population would be the Arg1flox/floxTie2cre system [358]. 
Arg1flox/floxTie2cre mice delete Arg1 in all macrophage populations and they 
are available on both the BALB/c and C57BL/6 genetic backgrounds making it 
possible to examine the influence of Arg1 activity on two distinct backgrounds. 
Tie2cre system is associated with >99% deletion of Arg1 from all macrophage 
populations as the Tie2 endothelial-specific receptor tyrosine kinase promoter 
expression allows the deletion of floxed sequences in endothelial and myeloid 
cells during embryogenesis and adulthood [143, 369]. 
 
Future experiments will define the contribution of arginine to the modulation of T 
cell phenotype. This will be approached by evaluating whether L-citrulline, the 
arginine precursor, can rescue the T cell responses in PA pneumonia. The 
hypothesis is that L-citrulline metabolism in T cells increases CD4+ cell 
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recruitment, proliferation, and Th17 effector function following PA. This is based 
on preliminary data suggesting that L-citrulline rescues T cell proliferation and 
differentiation in arginine-depleted environments. Furthermore, we will test if T 
cells require L-citrulline to L-arginine synthesis to regulate neutrophil recruitment 
and defense to PA. This will be achieved using AslΔTcell mice, a novel mouse 
model in which T cells cannot synthesize L-arginine from L-citrulline. 
 
Moreover, the arginase conditional knock-out mice are on a C57BL/6 background 
which is known to express a lower level of arginase as compared to BALBc/J 
mice as discussed earlier. Therefore, we will examine the effects of conditional 
arginase deletion from myeloid cells in BALBc/J mice. Especially that it is hard to 
make any comparison between the two experiments with obvious differences 
among the two strains of mice. Moreover, global arginase inhibition with 
pharmacologic inhibitors does not provide a clear explanation of the role of 
arginase from non-myeloid cells. Therefore, utilizing different mouse models with 
conditional arginase deletion from other immune cells is essential to answer the 
question of whether myeloid arginase functions differently as compared to other 
cellular sources. Additionally, our models did not specifically distinguish the role 
of different arginase isoforms. Future work aims at examining the 
immunomodulatory effects of different arginase isoforms. Studies to differentiate 
the functions of arginase-1 versus arginase-2 are needed. 
 
Moreover, correlating our results with their applicability in humans is essential. In 
fact, the role of arginase in humans is complex as there is a large discrepancy 
between the cellular sources of arginase in humans. Studies in cystic fibrosis 
suggest that neutrophils may be the predominant source of arginase in these 
patients. Because arginase is consistently elevated during disease exacerbation 
and in end-stage deteriorated and severe disease states, arginase has been 
correlated with pathology [109, 135, 164, 370]. Additionally, many reports 
suggest distinct effects of arginase-1 versus arginase-2 in humans. For instance, 
several studies show that arginase-1 induces autophagy while some reports 
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show that arginase-2 suppresses autophagy [248, 371]. Moreover, some data in 
systemic lupus erythematosus and in sickle cell anemia suggest that arginase 
promotes Th17 responses and neutrophil influx contributing to 
immunopathogenesis [372-375]. However, it is likely that arginase upregulation 
follows the activation of exaggerated inflammation and that arginase induction is 
a regulatory mechanism to downregulate the activated inflammation. Therefore, 
extending our studies to validate the immunomodulatory mechanisms of arginase 
in humans is crucial.    
 
Our results show for the first time that myeloid arginase has a role in regulation of 
the immune response to chronic PA pneumonia. We show that arginase 
production by macrophages and neutrophils is essential to protect against 
excessive morbidity and inflammation. To our knowledge, we are the first to show 
that deletion of arginase from myeloid cells is associated with an acute influx of 
neutrophils and pro-inflammatory macrophages which are likely to be driven by 
the altered T cell response. Our results emphasize the effects of myeloid 
arginase on T cell polarization and skewing the T helper response towards a Th1 
and Th17 predominant response in mice infected with PA pneumonia. 
Additionally, we show that global arginase inhibition has different effects on 
immune cell recruitment, activation, and chemotaxis. We show that 
pharmacologic arginase inhibition might not be the best way to control 
inflammation in chronic infections with PA pneumonia. Results from experiments 
with global arginase inhibition suggest close consideration of the effects of 
different cellular sources on the immune response and how this could potentially 
influence treatment of excessive inflammation and regulation of altered immune 
responses.  
 
We conclude that myeloid arginase is essential for control of inflammatory 
responses in PA pneumonia. 
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Figure 3.1a 
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Figure 3.1b 
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Figure 3.1c 
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Figure 3.1. Arginase conditional knock-out mice lose more weight post 
intratracheal infection with PA compared to their littermate controls.  
Mice were infected with PA-laden agarose beads through intratracheal instillation 
of 2 × 10^6 CFU/ mL as described. Murine morbidity post infection was evaluated 
in terms of weight loss measured at least once daily before and after infection. 
(a) The graph represents percentage weight loss normalized to the baseline body 
weight prior to infection. (b) The graph represents bacterial clearance from the 
lungs. (c) Kaplan-Meier curve represents the survival of mice post-infection. Data 
represents mean ± SD.  Data are representative of 3 independent experiments. 
Statistical significance determined by two-way ANOVA (p-value < 0.05 (*); p-
value < 0.0005 (***); p-value < 0.0001 (****)). Graphs plotted using GraphPad 
Prism 7.  
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Figure 3.2a 
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Figure 3.2b 
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Figure 3.2c 
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Figure 3.2d  
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Figure 3.2e  
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Figure 3.2f 
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Figure 3.2g 
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Figure 3.2. Arginase conditional knock-out mice respond with a profound 
recruitment of innate immune cells.  
Lungs from infected mice were lavaged with PBS to collect cells from the alveolar 
spaces and lung tissues were then harvested to collect cells from the lung 
interstitium. Lavage and lung tissue samples were collected from at least 4 mice 
per timepoint per group. Harvested samples were processed into single cell 
suspensions and stained for flow cytometry analysis as described. At least 
50,000 events per sample were analyzed using the FlowJo software to quantify 
different immune cell populations. Data represent total count of each cell 
population as a fraction of the total number of live cells analyzed. (a) Gating 
scheme representing the FlowJo analysis performed to identify different immune 
cell populations activated in response to the infection. (b) Neutrophil recruitment 
into the alveolar and lung interstitial spaces (c) Total number of tissue and 
infiltrating macrophages. (d, e, f) Total counts of alveolar and infiltrating 
macrophages producing TNF-α, IL-10, or expressing Mannose receptor (MR). (g) 
Bar graphs represent ratios of TNF-α to IL-10 expressing monocytes in the 
alveolar spaces (A); ratios of neutrophils to macrophages in the alveolar spaces 
(B); ratios of IL-17 to IL-10 expressing lymphocytes in the alveolar spaces (C); 
and ratios of IFNγ to IL-10 expressing lymphocytes in the alveolar spaces (D). 
Data represents mean ± SD.  Data are representative of 3 independent 
experiments. Statistical significance determined by two-way ANOVA (p-value < 
0.05 (*); p-value < 0.0005 (***); p-value < 0.0001 (****)). Graphs plotted using 
GraphPad Prism 7. 
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Figure 3.3a 
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Figure 3.3b 
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Figure 3.3c  
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Figure 3.3d 
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Figure 3.3. Greater T cell recruitment and activation in response to PA 
pneumonia in arginase conditional knock-out mice.  
Tracheobronchial lymph nodes draining the site of infection were harvested and 
processed into single cell suspensions by passing through mesh strainers. Lung 
lavage and lung tissue samples were collected and processed as described. 
Single cell suspensions were stained for flow cytometry analysis as described. At 
least 50,000 events per sample were analyzed using the FlowJo software to 
quantify different immune cell populations. Data represent total count of each cell 
population as a fraction of the total number of live cells analyzed. (a) Gating 
scheme representing the FlowJo analysis performed to identify different immune 
cell populations activated in response to the infection (b, c, d) Total number of 
CD4+ T cells recruited and activated in the lymph nodes, alveolar spaces, and 
lung interstitium of infected mice. Data represents mean ± SD.  Data are 
representative of 3 independent experiments. Statistical significance determined 
by two-way ANOVA (p-value < 0.05 (*); p-value < 0.0005 (***); p-value < 0.0001 
(****)). Graphs plotted using GraphPad Prism 7. 
 
  
 146 
Figure 3.4a 
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Figure 3.4b   
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Figure 3.4c 
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Figure 3.4. Arginase conditional knock-out mice respond to PA pneumonia with 
an excessive recruitment of Th1 and Th17 pro-inflammatory lymphocytes.  
Tracheobronchial lymph nodes draining the site of infection and lung tissue 
samples were collected and processed as described. Single cell suspensions 
were stained for flow cytometry analysis as described. At least 50,000 events per 
sample were analyzed using the FlowJo software to quantify different immune 
cell populations. Data represent total count of each cell population as a fraction 
of the total number of live cells analyzed. (a) Gating scheme representing the 
FlowJo analysis performed to identify different lymphocyte populations activated 
in response to the infection (b, c) Total number of Th1 and Th17 lymphocytes in 
the lymph nodes and lung interstitium of infected mice. Data represents mean ± 
SD.  Data are representative of 3 independent experiments. Statistical 
significance determined by two-way ANOVA (p-value < 0.05 (*); p-value < 0.0005 
(***); p-value < 0.0001 (****)). Graphs plotted using GraphPad Prism 7. 
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Figure 3.5a 
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Figure 3.5b 
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Figure 3.5c 
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Figure 3.5d 
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Figure 3.5. Pharmacological arginase inhibition results in comparable acute 
morbidity with faster recovery.  
BALB/cJ mice were infected intratracheally with PA-laden agarose beads as 
described. Murine morbidity post infection was evaluated in terms of weight loss 
measured at least once daily before and after infection. (a) Graph represents 
percentage weight loss normalized to the baseline body weight prior to infection 
at different infective inoculums (A: 0 CFU/mL; B: 5 × 10^6 CFU/mL; C: 1 × 10^7 
CFU/mL; D: of 5 × 10^7 CFU/mL). (b) The graph represents percentage weight 
loss normalized to the baseline body weight prior to infection at the chosen 
optimal infective inoculum of 2 × 10^7 CFU/mL. (c) Kaplan-Meier curve 
representing mortality post-infection in mice infected with 2 × 10^7 CFU/mL. (d) 
The graph represents bacterial clearance after infection with 2 × 10^7 CFU/mL. 
Data represents mean ± SD.  Data are representative of 3 independent 
experiments. Statistical significance determined by two-way ANOVA ((x) BEC 
treated group significantly different than water treated group; (#) L-norvaline 
treated group significantly different than water treated group; p-value < 0.05). 
Graphs plotted using GraphPad Prism 7 (Note: for some points, the error bars 
are shorter than the height of the symbol. In these cases, Prism simply does not 
draw the error bars).  
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Figure 3.6a  
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Figure 3.6c 
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Figure 3.6d 
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Figure 3.6e 
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Figure 3.6f 
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Figure 3.6g 
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Figure 3.6h 
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Figure 3.6i 
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Figure 3.6i (continued) 
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Figure 3.6. BALB/cJ mice with global arginase inhibition respond to PA 
pneumonia with comparable but slightly attenuated recruitment of innate immune 
cells.  
Lungs from infected mice were lavaged with PBS to collect cells from the alveolar 
spaces and lung tissues were then harvested to collect cells from the lung 
interstitium. Lavage and lung tissue samples were collected from at least 4 mice 
per timepoint per group. Harvested samples were processed into single cell 
suspensions and stained for flow cytometry analysis as described. At least 
50,000 events per sample were analyzed using the FlowJo software to quantify 
different immune cell populations. Data represent total count of each cell 
population as a fraction of the total number of live cells analyzed. (a) Neutrophil 
recruitment into the alveolar and lung interstitial spaces (b) Total number of 
tissue and infiltrating macrophages in the lungs of infected mice. (c, d, e, f) Total 
number of alveolar and infiltrating macrophages producing TNF-α, IL-10, 
expressing MR, or expressing iNOS enzyme respectively. (g) The total number of 
M1 macrophages expressing CCR7 receptor and positive for iNOS and TNF-α. 
(h) Bar graphs represent ratios of CCR7 to MR expressing monocytes in A; ratio 
of TNF-α to IL-10 expressing monocytes in B; ratio of IL-17 to IL-10 expressing 
lymphocytes in C; and the ratio of IFNγ to TGFβ expressing lymphocytes in D. (i) 
The total number of type 2 innate immune cells recruited into the alveolar and 
lung interstitial spaces.  Data represents mean ± SD.  Data are representative of 
3 independent experiments. Statistical significance determined by two-way 
ANOVA ((x) BEC treated group significantly different than water treated group; 
(#) L-norvaline treated group significantly different than water treated group; (+) 
BEC treated group significantly different than L-norvaline treated group; p-value < 
0.05). Graphs plotted using GraphPad Prism 7 (Note: for some points, the error 
bars are shorter than the height of the symbol. In these cases, Prism simply does 
not draw the error bars). 
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Figure 3.7a  
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Figure 3.7b  
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Figure 3.7c  
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Figure 3.7. Global arginase inhibition results in greater T cell recruitment and 
activation in the lymph nodes but not the lungs of infected mice.  
Tracheobronchial lymph nodes draining the site of infection were harvested and 
processed into single cell suspensions by passing through mesh strainers. Lung 
lavage and lung tissue samples were collected and processed as described. 
Single cell suspensions were stained for flow cytometry analysis as described. At 
least 50,000 events per sample were analyzed using the FlowJo software to 
quantify different immune cell populations. Data represent total count of each cell 
population as a fraction of the total number of live cells analyzed. (a, b, c) The 
total number of CD4+ T cells recruited and activated in the lymph nodes, alveolar 
spaces, and lung interstitium of infected mice. Data represents mean ± SD.  Data 
are representative of 3 independent experiments. Statistical significance 
determined by two-way ANOVA ((x) BEC treated group significantly different than 
water treated group; (#) L-norvaline treated group significantly different than 
water treated group; (+) BEC treated group significantly different than L-norvaline 
treated group; p-value < 0.05). Graphs plotted using GraphPad Prism 7 (Note: for 
some points, the error bars are shorter than the height of the symbol. In these 
cases, Prism simply does not draw the error bars). 
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Figure 3.8a 
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Figure 3.8b 
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Figure 3.8c 
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Figure 3.8. Global arginase inhibition is associated with increased activation of 
Th1, Th17 and regulatory T lymphocytes in the lymph nodes of infected mice with 
potentially reduced migration into the lungs.  
Tracheobronchial lymph nodes draining the site of infection, lung lavage, and 
lung tissue samples were collected and processed as described. Single cell 
suspensions were stained for flow cytometry analysis as described. At least 
50,000 events per sample were analyzed using the FlowJo software to quantify 
different immune cell populations. Data represent total count of each cell 
population as a fraction of the total number of live cells analyzed. (a, b, c) Total 
number of Th1, Th17, and Treg lymphocytes in the lymph nodes, alveolar 
spaces, and lung interstitium of infected mice. Data represents mean ± SD.  Data 
are representative of 3 independent experiments. Statistical significance 
determined by two-way ANOVA ((x) BEC treated group significantly different than 
water treated group; (#) L-norvaline treated group significantly different than 
water treated group; (+) BEC treated group significantly different than L-norvaline 
treated group; p-value < 0.05). Graphs plotted using GraphPad Prism 7 (Note: for 
some points, the error bars are shorter than the height of the symbol. In these 
cases, Prism simply does not draw the error bars). 
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Chapter 4: Azithromycin polarizes macrophages to an M2 phenotype via 
inhibition of STAT1 through cross-talk from NF-κB signaling mediators 
 
I. Introduction 
 
While the function of alternatively activated macrophages (M2-polarized) has 
been primarily evaluated in host responses to disease processes that elicit Th2-
type immune mechanisms [143, 376-378], little is known of their function in 
regulating inflammation in response to extracellular Gram-negative bacterial 
infections. While primarily functioning to orchestrate remodeling and repair, M2-
polarized macrophages produce effector molecules such as arginase-1 and 
TGFβ that control lung homeostasis, inflammation, and subsequent pulmonary 
damage associated with pneumonia [143, 379]. We have demonstrated that the 
immunomodulatory antimicrobial azalide azithromycin can induce macrophage 
characteristics that are consistent with an M2 polarization, both in vitro and in a 
mouse model of Pseudomonas aeruginosa infection of the lungs [135, 310, 311]. 
The subsequent improvement observed in the mortality and severity of lung 
destruction in this infection model has direct bearing on chronic inflammatory 
lung conditions such as cystic fibrosis, where P. aeruginosa relapsing 
pneumonias contribute to the decline of pulmonary function over time [380, 381]. 
 
Macrophages are polarized to distinct functional phenotypes via signaling from 
two separate pathways. Classical, or M1 activation requires signaling through 
both the cytokine IFNγ and a pattern recognition receptor, which, in the case of 
responses to Gram-negative bacterial pathogens, is mainly toll-like receptor 4 
(TLR4). IFNγ-dependent signaling results in phosphorylation and dimerization of 
STAT-1, allowing for translocation to the nucleus of the cell. Similarly, IFNγ and 
LPS signal through interferon receptors and TLR4 respectively, inducing a series 
of phosphorylation steps which result in NF-κB activation and nuclear 
translocation. NF-κB is the prototypical pro-inflammatory transcription factor 
activated through TLR and inflammatory cytokine signaling. Stimulation through 
TLR, IL1R, or other TNF receptor family members results in a series of 
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phosphorylation reactions activating the canonical pathway kinase IκB kinase 
(IKK)β [382]. Activated IKKβ phosphorylates and releases the NF-κB inhibitory 
subunit, IκB-α, which is subsequently ubiquitinated and degraded. This frees the 
nuclear translocation signal on the NF-κB p65 subunits. After translocating to the 
nucleus, together with the activated subunit of STAT-1, phospho-p65 (RelA) 
induces the transcription of many inflammatory mediators and cytokines [383, 
384]. Nuclear fractions of RelA are representative of NF-κB activation. 
 
Alternative, or M2 polarization, occurs through the binding of either interleukin 
(IL)-4 or IL-13 to their respective receptors leading to the phosphorylation and 
dimerization of STAT-6. Upon activation, STAT-6 translocates to the nucleus of 
the cell and upregulates the expression of genes associated with anti-
inflammatory processes [158, 385-388]. Through our work characterizing the 
effects of azithromycin, we found that the drug is only able to polarize 
macrophages to an M2-like phenotype when they are stimulated with LPS [310]. 
This characteristic provides the basis for our hypothesis that the mechanism of 
the drug’s ability to polarize cells lies in its interference with these signaling 
cascades. Other groups have shown that azithromycin decreases the activation 
of NF-κB signaling and subsequent production of pro-inflammatory cytokines and 
other inflammatory effectors [389, 390]. While these effects may help to explain 
the beneficial effects of azithromycin in patients with CF, the mechanism by 
which azithromycin is able to polarize macrophages towards an M2-like 
phenotype is unknown. Because of work by others that demonstrates a cross-talk 
between the NF-κB and STAT-1 signaling cascades through IKKβ [391], we 
hypothesized that azithromycin polarizes macrophages to an M2 phenotype via 
inhibition of STAT-1 through cross-talk from NF-κB signaling mediators.  
 
In the present study, we demonstrate that azithromycin inhibits the nuclear 
translocation of p65. Concurrently, total IKKβ levels were increased, and through 
this mediator STAT-1 phosphorylation was directly inhibited. In cultured 
macrophages, inhibition of IKKβ resulted in a reversal of M2-macrophage 
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polarization. These results provide insights into the immunomodulatory 
mechanism of azithromycin and support studies by other groups that 
demonstrate a cross-talk between the 2 pathways.  
 
II. Results 
 
Azithromycin prevents p65 nuclear translocation while increasing IKKβ levels. 
We first assessed the effects of azithromycin on the activation of transduction 
proteins involved in the NF-κB signaling cascade. Cells were incubated overnight 
with IFNγ alone or with azithromycin at concentrations ranging from 5 to 100 μM. 
Cells were then stimulated with LPS for durations ranging from 0 to 60 minutes. 
Polarized macrophages were fractionated into nuclear and cytoplasmic fractions 
to assess the effects of azithromycin on the translocation of p65 subunits to the 
nucleus. (Figure 4.1). Importantly, overnight polarization with IFNγ alone prior to 
LPS stimulation (Figure 4.1a, time 0) induced p65 nuclear translocation to a 
lower extent with a peak in nuclear p65 fractions at 30 minutes post LPS 
stimulation (Figure 4.1a, time 30). However, azithromycin treatment in the 
presence of IFNγ completely and significantly prevented p65 translocation to the 
nucleus at all timepoints. Treatment with azithromycin at all concentrations tested 
was associated with accumulation of p65 in the cytoplasm, shown for 
azithromycin concentrations of 5 μM and 30 μM (Figure 4.1a). This was coupled 
with decreased p65 fractions in the nucleus of cells treated with azithromycin 
compared to cells treated with IFNγ only, with the ratios of p65 nuclear to 
cytosolic fractions shown over time in Figure 4.1b.  
 
To confirm the observations above, immunostaining was used to visualize the 
localization of p65 subunits relative to the nucleus at 30 minutes post LPS 
stimulation (Figure 4.2). NF-κB p65 subunits were stained with a FITC-
conjugated antibody (green). The p65 signal was overlayed with the DAPI 
stained nuclei (blue) to determine the localization of the subunits in the polarized 
macrophages (Figure 4.2a). Similar to the observations in Figure 4.1, a strong 
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nuclear signal was observed in IFNγ polarized macrophages while azithromycin 
treatment was associated with a strong cytoplasmic signal. The nuclear 
translocation scoring (Figure 4.2b) shows a significant decrease in p65 nuclear 
translocation with azithromycin treatment at all the concentrations tested 
compared to IFNγ polarized macrophages.  
 
The impact of azithromycin upon the expression of NF-κB associated proteins 
was then assessed. The amounts of IκB-α, IKKβ, and pIKKβ were measured 
over time after stimulation with LPS as described. For cells incubated with IFNγ, 
LPS caused the expected decrease in IκB-α within 2 minutes, with a steady 
reemergence over time (Figure 4.3). This is due to activation of this pathway, 
because when IκB-α is phosphorylated it is rapidly ubiquitinated and degraded. 
The presence of azithromycin at concentrations as low as 5 μM prevented this 
decrease in IκB-α, as graphically represented in Figure 4.3b. The amount of IKKβ 
present in cell lysates was increased at all timepoints even before the addition of 
LPS in cells polarized with azithromycin and IFNγ (Figure 4.3a). The 
phosphorylated form of IKKβ was also increased by azithromycin (Figure 4.3a).  
 
This increase in IKKβ is likely a result of the inhibition of p65 translocation to the 
nucleus, as transcription of the IKKβ gene (Ikbkb) is normally inhibited when p65 
is in the nucleus as a feedback mechanism [89, 91, 382, 392-394]. To test this, 
we compared messenger RNA expression for Ikbkb via RT-PCR and found that 
azithromycin treatment caused an increase as compared to the control condition 
(Figure 4.3c). Significant differences were observed only at higher azithromycin 
concentrations at 0 and 5 minutes post LPS stimulation while all azithromycin 
concentrations were associated with significantly higher levels of Ikbkb 
expression at 30 minutes after LPS stimulation. 
 
Inhibition of IKKβ activation prevents azithromycin from polarizing macrophages 
to the M2 phenotype. Because azithromycin increased the amount of IKKβ 
present, we sought to determine whether azithromycin exerts its effect on 
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macrophage polarization via this mechanism. Previous reports have shown that 
excessive IKKβ activation prevents the activation of pro-inflammatory 
characteristics of macrophages [391]. We treated macrophages with cytokines 
and azithromycin to polarize them into either M1 or M2 cells, and in addition 
added IKK-16, an inhibitor of IKKβ (Figure 4.4). This inhibitor displays a high 
affinity for IKKβ, with an IC50 of 40 nM. At higher concentrations, it can also 
inhibit the activation of the entire IKK complex [395]. Arginase-1 (Arg1) is an 
important effector of M2 macrophages and it is a marker of M2 macrophage 
polarization induced in response to Th2 cytokines [396]. Azithromycin increased 
Arg1 gene expression in cells incubated with IFNγ and exposed to LPS (Figure 
4.4a). The addition of the IKKβ inhibitor significantly negated the effect of 
azithromycin on Arg1 gene expression. Interestingly, the decrease in Arg1 gene 
expression was not statistically significant when IKK-16 was added to wells 
treated with IL4 and IL13 (the M2 control condition) (p=0.115). These data 
suggest that azithromycin’s ability to induce expression of Arg1, an important M2 
effector, is dependent on its ability to activate IKKβ. 
 
We next assessed the effect of IKK-16 on arginase protein activity (Figure 4.4b). 
In this series of experiments cells were treated with 100 nM of IKK-16, a 
concentration chosen due to its maximal inhibition. Once again azithromycin 
increased the amount of arginase activity as previously published, but not to the 
extent of the M2 control condition of IL4 and IL13 treatment. The inhibitor had no 
effect on arginase activity in cells treated with IL4 and IL13 plus LPS, but for the 
cells incubated with azithromycin, treatment with IKK-16 decreased arginase 
activity to similar levels as cells that were not exposed to the drug. When cells 
were treated with increasing concentrations of IKK-16, the inhibition of 
azithromycin-induced arginase activity was consistent over a wide range of 
concentrations, with statistically significant decreases from 12.5 to 200 nM 
(Figure 4.4c). The inhibition of IKKβ had a little effect however on IL4 and IL13-
dependent arginase production over the broad range of concentrations. 
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Inhibition of STAT-1 phosphorylation by azithromycin is dependent upon IKKβ. 
We then assessed the effect of azithromycin on the phosphorylation of STAT-1. 
Phosphorylated STAT-1 represents the activated form. It dimerizes and 
translocates to the nucleus of the cell where it initiates the transcription of several 
cytokines and inflammatory genes, most of which are associated with M1 
macrophage activation [383, 384]. J774 macrophages were polarized under 
conditions to drive them to an M1 (IFNγ) or an M2 (IL4/13) phenotype. Cells were 
also polarized using different azithromycin concentrations (5, 30, 60, and 100 
µM) in the presence of IFNγ. After stimulation with LPS we assessed the levels of 
phospho-STAT-1 and STAT-1 (Figure 4.5a). As shown in Figure 4.5b, IFNγ 
activated STAT-1 leading to an increase in the phosphorylated form whereas IL4 
and IL13 blunted this increase in phosphorylation and resulted in suppressed 
levels of pSTAT-1 as expected. Azithromycin treatment also blunted IFNγ-
dependent STAT-1 phosphorylation decreasing pSTAT-1 levels in a 
concentration-dependent manner. These results support our previous 
observation that azithromycin blunts NF-κB activation and subsequently shifts 
macrophage polarization away from the M1 phenotype. Importantly, inhibiting 
IKKβ via IKK-16 was associated with a reversal of azithromycin's effect on 
pSTAT-1 levels. The addition of IKK-16 to the azithromycin polarized 
macrophages prevented the suppression of pSTAT-1 levels and resulted in a 
restoration of STAT-1 phosphorylation. 
 
III. Discussion 
 
Macrophages constitute the first line of defense for pathogen infiltration into the 
lungs through their ability to initiate inflammation. This is accomplished in the 
case of Gram-negative pathogens primarily through the binding of TLR4 to 
bacterial LPS [397]. Together with IFNγ, this initiates NF-κB signal activation that 
leads to the transcription of inflammatory genes including cytokines and 
chemokines. The NF-κB signaling cascade works along with STAT-1 activation to 
polarize macrophages to a classically activated phenotype to govern this process 
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[383, 384]. Here we demonstrate that the immunomodulatory mechanism of 
azithromycin involves elements of both of these pathways, stemming from the 
inhibition of the translocation of p65 to the nucleus. This leads to an increase in 
IKKβ which then in turn blocks the phosphorylation of STAT-1, increasing the 
expression of M2 effectors. 
 
In the case of PA, influx of neutrophils into infected tissues is the primary 
mechanism to prevent the pathogen’s replication and spread. In chronic 
inflammatory lung conditions, responses to bacteria like PA induce exaggerated 
or prolonged neutrophilia leading to pulmonary damage and fibrosis caused by 
excessive neutrophil elastase concentrations, an imbalance in the protease-
antiprotease ratio, and a vicious cycle of excessive inflammation that leads to 
scarring [186, 312, 398-400]. While many groups have demonstrated that 
azithromycin reduces NF-κB activation [390, 401-404], we showed that 
azithromycin also polarizes macrophages to an M2-like phenotype, both in vitro 
and in vivo during PA infection [310, 311]. Subsequently, we demonstrated in a 
mouse model of PA infection that polarizing the macrophage response to one in 
which the M2 phenotype predominates early in the inflammatory process reduces 
neutrophil influx, decreases inflammation, and reduces fibrotic changes that 
correlate to improved morbidity and survival [311]. This includes decreased 
production of iNOS and an increased production of the M2 effectors, mannose 
receptor and arginase-1. Utilizing the anti-inflammatory effects of azithromycin, it 
appears that by polarizing the macrophage response early in the infection, lung 
damage is controlled, and importantly the clearance kinetics of the pathogen are 
not altered [311]. The efficacy of azithromycin in this setting is also reflected in 
clinical practice, as this agent is used as a chronic therapy for patients with cystic 
fibrosis. Quality of life is improved according to multiple clinical trials that utilized 
azithromycin chronically. Additionally, extended treatment with azithromycin 
slowed the pulmonary function decline in patients with CF who are colonized with 
PA [299-301]. We have observed in our mouse model that the clearance of PA is 
not altered, and likewise no changes in the incidence of bacterial infection have 
 181 
been observed in these studies that place subjects on azithromycin long-term 
[299-301]. 
 
Future studies will investigate whether the modulation of macrophage phenotype 
with azithromycin via cross-inhibition of the NF-κB and STAT-1 signaling 
pathways is beneficial in patients with cystic fibrosis. Several groups have 
studied the impact of macrolides including azithromycin, clarithromycin, and 
erythromycin on ERK1/2 and p35 MAPK signaling cascades which result in 
decreased downstream NF-κB and AP-1 signaling. Azithromycin was shown in 
vivo and in vitro, both in human and murine cell culture models, to decrease NF-
κB activation, decrease its nuclear translocation, and decrease NF-κB and Sp1 
transcription factor binding to DNA [390, 402-405]. These effects are associated 
with a significant reduction in inflammatory cell infiltration into infected lungs, and 
a profound decrease in pro-inflammatory cytokine concentrations in the alveolar 
space. Groups studying the anti-inflammatory mechanisms of azithromycin show 
decreases in NF-κB binding to DNA along with suppressed induction of pro-
inflammatory genes and cytokine production in different murine and in vitro 
models of various inflammatory and infectious diseases [389, 390, 401-406]. We 
expanded these studies to address the specific effects on the upstream 
mediators of the NF-κB signaling cascade and their cross-talk with the other 
inflammatory signaling pathways. 
 
Previous studies demonstrate that the nuclear translocation of phospho-p65 is 
inhibited by azithromycin [403, 404]. Additionally, Vrancic et al. showed no 
overall impact of azithromycin on the phosphorylation of p65—this is also 
consistent with our findings when factoring in the increase in phospho-p65 in the 
cytoplasmic fraction, as this group did not fractionate the nuclear compartment 
[402]. They also demonstrated that azithromycin inhibits the phosphorylation of 
STAT-1. We extend these studies here in our model to prove a direct relationship 
between increased IKKβ protein concentrations and this effect on STAT-1 
through experimentally blocking IKKβ through competitive inhibition. 
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Evidence from the work by Fong and colleagues alludes to a potential link 
between the NF-κB and STAT-1 signaling pathways. This group demonstrated 
that the NF-κB signaling molecule IKKβ can inhibit STAT-1 signaling in 
macrophages in a model of group B streptococcus (GBS) infection [391]. While 
deletion of IKKβ in airway epithelial cells led to a decrease in inflammation, 
macrophage-specific deletion of IKKβ caused a resistance to GBS infection that 
was associated with increased expression of M1-associated inflammatory 
molecules including IL-12, iNOS, and MHCII [391]. Additionally, in macrophages 
infected with GBS and in macrophages incubated with IFNγ, the absence of IKKβ 
led to an increase in phosphorylation of STAT-1 [391]. These findings, along with 
our data, suggest that the increase in IKKβ expression in macrophages by 
azithromycin may be the mechanism through which polarization to the M2 
phenotype occurs. 
 
There are other examples of small molecules that inhibit the translocation of NF-
κB including aspirin, non-steroidal anti-inflammatory drugs, and 1,8-Cineol [407-
410]. The nuclear binding of p65 normally provides a feedback signal to shut 
down the production of IKKβ [91, 411-417]. Therefore, it is likely that the 
inhibition of p65 translocation is causing the increase in IKKβ production. 
Additionally, IKKβ degradation occurs through a mechanism of 
autophosphorylation. Because p65 concentrations are high in the cytoplasm, this 
autophosphorylation process is likely decreased, which turns the degradation 
pathway off [411, 416-423]. We have shown by PCR that message expression 
for Ikbkb is increased, therefore a reversal of the feedback loop is at least partly 
responsible. However, message expression is not increased until 30 minutes 
after LPS stimulation at lower azithromycin concentrations, whereas the IKKβ 
protein expression is increased earlier, even at time zero, suggesting other 
potential mechanisms. 
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Despite the evidence concerning macrophage polarization, the primary 
immunomodulatory mechanism of azithromycin remains to be discovered. 
Because increases in IKKβ expression and phosphorylation should lead to 
increased NF-κB activation, it is highly likely that the effect of azithromycin is 
below this step in the pathway, involving either IκB itself or other mechanisms 
that regulate nuclear translocation. Clearly this process is highly dependent upon 
the degradation of IκB [411, 413, 416, 424]. Our data shows that with 
azithromycin treatment, degradation of IκB-α is inhibited, leading to decreases in 
p65 nuclear translocation. IκB-α concentration is decreased upon stimulation with 
LPS for 30 minutes, and then rebounds to baseline concentrations (Figure 4.3), 
with p65 translocation peaking at the corresponding 30-minute timepoint (Figure 
4.1)—all of which is blocked by azithromycin. However, nuclear translocation of 
p65 also depends upon a number of other factors. Alteration of the nuclear 
location sequence of p65 can occur through a number of mechanisms, including 
changes in the dimerization or improper folding, which are both required. The 
function of importins and other nuclear shuttling machinery [425-427], and 
permeability characteristics of the nuclear membrane can be disrupted [428-433]. 
Additionally, acetylation of the activated subunit in the nucleus at multiple lysine 
residues is required for translocation and is governed by histone regulation and 
coactivators such as CREP-binding protein [434, 435, 436 1994, 437]. We are 
continuing to evaluate the impact of azithromycin on these mechanisms. 
 
In conclusion, the immunomodulation of macrophage function by azithromycin is 
a complex effect associated with the alteration of STAT1 signaling through the 
inhibition of NF-κB mediators, linked through cross-talk via IKKβ. Macrolides 
have been demonstrated to have an effect through the polarization of 
macrophages to a regulatory phenotype in several models of inflammation. 
Studies have been extended to investigations of spinal cord injury, stroke, and 
other cerebrovascular events. An improved understanding of the mechanisms 
associated with these agents could lead to promising therapeutic target discovery 
in these and other devastating disease processes. And, defining interactions 
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between signaling pathways will lead to a better understanding of cellular biology 
and provide the impetus for future drug discovery. 
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Figure 4.1a 
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Figure 4.1b 
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Figure 4.1. Azithromycin decreases NF-κB activation and prevents p65 nuclear 
translocation.  
J774 cells were plated at 2.5 x 10^5 cells per 1 ml of DMEM in 24 well plates. 
Cells were allowed to attach for 8 hours and then polarized overnight with INFγ 
(50U/ml) alone or with azithromycin (5, 10, 15, 30, 60, and 100 µM). Cells were 
then stimulated with LPS (10 nM) for 0, 2, 5, 10, 15, 30, and 60 minutes. (a) Cells 
were harvested by scrapping and NF-κB Assay Kit (FivePhoton Biochemicals, 
San Diego, CA) was used to collect nuclear and cytoplasmic fractions according 
to the manufacturer protocol. Western blots for p65 in nuclear and cytoplasmic 
fractions were performed. (b) Bar graph represents the ratio of nuclear to 
cytoplasmic fractions of p65 from (a). Data represents mean ± SD.  Data is 
representative of 3 independent experiments.  Statistical significance determined 
by two-way ANOVA with Sidak's multiple comparisons test (p-value < 0.05 (*); p-
value < 0.005 (**); p-value < 0.0005 (***)). Bar graphs plotted using GraphPad 
Prism 7. Western Blots quantified using ImageJ. 
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Figure 4.2b 
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Figure 4.2. NF-κB p65 subunit accumulates in the cytoplasm around the nuclear 
membrane in azithromycin treated macrophages.  
J774 murine macrophages were plated at 2.5 x 10^5 cells on round glass 
coverslips. Cells were allowed to attach to the glass and then polarized overnight 
with INFγ (50 U/mL) alone or with azithromycin (5, 10, 15, 30, 60, and 100 µM). 
Additionally, some azithromycin polarized macrophages were treated with IKK-
16. Cells were then stimulated with LPS (10 nM) for 0, 2, 5, 10, 15, 30, and 60 
minutes. (a) Immunostaining for p65 subunit was performed on the glass 
coverslips in a wet chamber. Images were taken using Zeiss fluorescent 
microscope at 100X oil objective. Images show NF-κB p65 subunits stained in 
green (FITC) overlayed with DAPI nuclear staining. (b) Bar graphs represent the 
nuclear vs cytoplasmic fractions of p65 quantified using the scoring system in 
Table 2.5. Data represents mean ± SD.  Data is representative of 3 independent 
experiments. Statistical significance determined by two-way ANOVA (p-value < 
0.05 (*); p-value < 0.0005 (***); p-value < 0.0001 (****)). Bar graphs plotted using 
GraphPad Prism 7. 
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Figure 4.3a  
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Figure 4.3b 
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Figure 4.3c  
 194 
Figure 4.3d 
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Figure 4.3e 
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Figure 4.3. Azithromycin prevents IκB-α degradation while accumulating IKKβ.  
J774 cells were plated at 2.5 x 10^5 cells per 1 ml of DMEM in 24 well plates. 
Cells were allowed to attach for 8 hours and then polarized overnight with INFγ 
(50 U/mL) alone or with azithromycin (5, 10, 15, 30, 60, and 100 µM). Cells were 
then stimulated with LPS (10 nM) for 0, 2, 5, 10, 15, 30, and 60 minutes. Proteins 
and RNA were then collected and probed for mediators in the NF-κB signaling 
cascade using western blot and RT-PCR. (a) Western blots for IκB-α, IKKβ, and 
p-IKKβ. (b) Bar graphs represent the relative fold change in protein concentration 
over time in INFγ treated macrophages versus azithromycin and INFγ treated 
macrophages. (c) Bar graphs represent fold change in IKKβ gene expression 
calculated from the ΔΔCt values and normalized to GAPDH and compared to 
INFγ treated macrophages over time. Data represents mean ± SD.  Data is 
representative of 3 independent experiments. Statistical significance determined 
by two-way ANOVA with Sidak's multiple comparisons test (p-value < 0.05 (*); p-
value < 0.0005 (***); p-value < 0.0001 (****)). Bar graphs plotted using GraphPad 
Prism 7. Western Blots quantified using ImageJ.  
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Figure 4.4a 
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Figure 4.4b  
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Figure 4.4c 
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Figure 4.4. Azithromycin induced arginase gene expression and activity are 
reversed with IKKβ inhibition.   
J774 cells were stimulated overnight with IFNγ, IL4 and IL13, or with 
azithromycin (concentration 10 μM shown here) and IFNγ in the presence or 
absence of the IKKβ inhibitor, IKK-16.  Cells were then stimulated with LPS for 
24 hours. (a) Arginase-1 gene expression was analyzed by qRT-PCR. Bar 
graphs represent fold change in arginase-1 gene expression calculated from the 
ΔΔCt values normalized to GAPDH and compared to INFγ treated macrophages. 
(b) Arginase activity was determined using an enzymatic assay in lysates from 
polarized macrophages. Bar graph represents fold change in arginase activity 
calculated from the standard curve under different polarization conditions 
compared to INFγ treated macrophages. (c) Bar graph represents percentage 
change in arginase activity with increasing IKK-16 concentrations compared to 
no inhibitor treatment. Data represents mean ± SD.  Data is representative of 3 
independent experiments.  Statistical significance determined by two-way 
ANOVA (p-value of < 0.05 (*); p-value of < 0.0001 (****)). Bar graphs plotted 
using GraphPad Prism 7.  
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Figure 4.5a 
   
+ + + + + + + + + + + 
  +         
+   + + + + + + + + 
   5 30 60 100 5 30 60 100 
       + + + + 
P-STAT1 
STAT-1 
Actin 
LPS 
IL4/13 
IFNγ 
AZM 
IKK16 
 
 202 
 Figure 4.5b 
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Figure 4.5. Azithromycin prevents STAT-1 activation in an IKKβ dependent 
mechanism.  
J774 cells were plated at 2.5 x 10^5 cells per 1 ml of DMEM in 24 well plates. 
Cells were then polarized with IL4 and IL13 (10 nM each), or with INFγ (50 U/mL) 
alone, or with INFγ and azithromycin (5, 30, 60, and 100 µM) with/without IKK-16 
(100 nM). After overnight polarization cells were stimulated with LPS (10 nM) for 
15 minutes and proteins were harvested by cell lysis. (a) Western blots for the 
active form pSTAT-1 and the inactive STAT-1 subunits were performed. (b) Bar 
graph represents fold change in STAT-1 phosphorylation under different 
polarization conditions compared to IFNγ and LPS stimulated macrophages 
(normalized to actin and STAT-1 levels). Data represents mean ± SD.  Data is 
representative of 3 independent experiments.  Statistical significance determined 
by two-way ANOVA with Sidak's multiple comparisons test ((*) denotes 
significant difference compared to IFNγ+LPS; (#) denotes significant difference 
compared to the corresponding AZM concentration with no IKK16 treatment; p-
value < 0.05). Bar graphs plotted using GraphPad Prism 7. Western Blots 
quantified using ImageJ. 
  
 204 
Figure 4.6 
Figure 4.6. The proposed interaction induced by azithromycin (AZM) is depicted. 
Azithromycin inhibits IFNγ-induced STAT-1 activation though cross-inhibition of 
the LPS induced NF-κB signaling mechanism. The nuclear translocation of p65 
otherwise required for induction of pro-inflammatory gene transcription is 
inhibited by azithromycin. This prevents the negative feedback which otherwise 
shuts down the inflammatory signal by decreasing IKKβ production through 
decreased Ikbkb gene expression. Simultaneously, the lack of p65 nuclear 
translocation results in sustained IκB-α levels. Accumulated IKKβ protein cross-
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inhibits the STAT-1 signaling pathway by decreasing STAT-1 phosphorylation 
thereby decreasing the associated pro-inflammatory gene transcription and 
increasing the expression of the M2-associated protein arginase-1. 
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Chapter 5: Dependence of azithromycin-induced M2-like macrophage phenotype 
on arginase-1 to alter inflammation 
 
I. Introduction 
 
Cystic fibrosis (CF) is a chronic inflammatory lung disease caused by genetic 
mutations which make the lung a favorable environment for chronic bacterial 
colonization. The dysfunctional mucociliary clearance, persistent lung injury, and 
accumulation of mucoid and endobronchial secretions promote repeated 
infections [312]. In fact, 90% of these patients die due to chronic lung infections 
with the most predominant pathogen being Pseudomonas aeruginosa (PA) [2, 6, 
18, 19]. Additionally, the immune system in these patients responds in an 
exaggerated manner to infections with a characteristic chronic dysregulated 
inflammatory response along with aberrant T cell immunity and a predominant 
recruitment of neutrophils and pro-inflammatory macrophages [312]. While it is 
known that a Th1 response is important for the clearance of PA and other 
extracellular Gram-negative pathogens, patients with CF have a dysregulated T 
cell response that emphasizes pro-inflammatory T cell phenotypes [438].  It is 
possible that this dysregulation could lead to the increased susceptibility to 
Gram-negative colonization and infection observed in this patient population. 
Thus, the continual exaggerated immune response contributes to the shortening 
of patient life expectancy by 30 years as a result of lung injury and damage, 
deteriorates lung function, and decreases the quality of life [2, 6, 18].  
 
Recently, there has been much interest in the use of azithromycin in patients with 
CF who are chronically infected with PA.  Three randomized, placebo-controlled 
trials have shown an improvement in lung function with 6-12 months of treatment 
[299-301].  To date, the mechanisms of action of azithromycin in patients with CF 
remain unknown and long-term studies to demonstrate clinical benefit are on-
going.  
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In vitro studies have demonstrated that macrolides reduce several virulence 
factors of PA infection including the disruption of biofilm formation and altering 
expression of structural proteins such as flagellin [2, 6, 17, 18, 312, 439-441]. 
From other in vitro data, the anti-inflammatory effects of azithromycin have been 
postulated to occur by inhibiting pro-inflammatory cytokine production; 
decreasing chemotaxis, oxidative burst and adhesion of neutrophils; and 
accelerating pro-apoptotic state of monocytes. Our group studied azithromycin 
immunomodulatory mechanism in vitro where azithromycin polarized 
macrophages into an alternative phenotype via a mechanism that is dependent 
on cross-inhibition of the NF-κB and STAT1 signaling pathways. This modulation 
was dependent on IKKβ, a signaling molecule in the NF-κB pathway, and 
resulted in subsequent suppression of inflammatory gene activation while 
promoting an anti-inflammatory phenotype (Chapter 4). 
 
Moreover, we have demonstrated that azithromycin-driven polarization of 
macrophages into an alternative phenotype controls several aspects of the 
immune response in mice infected with PA. Results demonstrate that 
alternatively activated macrophages shift the immune response into a monocyte 
predominant influx, decreasing the number of neutrophils that enter the lungs 
post-infection, and shifting the T cell response away from the Th1 phenotype 
[166, 310, 311]. Thus, our results are consistent with previous literature 
supporting the immunoregulatory role of azithromycin and support a macrophage 
reprogramming that could be responsible for a large portion of the beneficial 
effects observed when using the drug. 
 
Our published in vitro and in vivo data show that azithromycin significantly 
upregulates arginase expression and activity [166, 310, 311]. Arginase is an 
important effector of M2 macrophages normally induced in response to Th2 
cytokines (IL4, 10, and 13) [128-132, 135-138, 198, 331]. Its competing enzyme, 
iNOS, is induced in M1 macrophages in response to Th1 cytokines (e.g. IFNγ). 
Arginase metabolizes arginine into ornithine and urea while iNOS metabolizes 
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arginine into nitric oxide (NO) and citrulline [151, 152, 315, 316]. In addition to 
competing with iNOS for the same substrate and controlling its generation of NO, 
arginase is believed to be an immunomodulatory effector with important effects 
on T cell function and proliferation [151, 152, 154, 157, 315-318, 442]. Our group 
has shown a 10-fold increase in arginase activity in J774 murine macrophages 
polarized with IFNγ and azithromycin [166, 310, 311]. Azithromycin-induced 
arginase expression in vitro was associated with reduced M1 pro-inflammatory 
macrophage effectors (e.g. IL-6, IL-12, TNF-α, iNOS, and CCR7) along with 
increased M2 anti-inflammatory macrophage effectors (e.g. IL10, MR, and CD23) 
[166, 310, 311]. Additionally, we have shown that azithromycin treatment in mice 
infected with PA increases arginase expression which is associated with reduced 
morbidity and decreased airway damage. Therefore, we consistently observe 
increased arginase expression with azithromycin along with reduced 
inflammatory parameters and a shift in macrophage polarization into an 
alternative phenotype. 
 
Moreover, results show that arginase deletion from macrophages and neutrophils 
results in exaggerated inflammation (Chapter 3). Experiments using Arg1Δm mice 
verified that arginase deficiency is associated with greater morbidity in terms of 
more significant weight loss. Arg1Δm mice had greater neutrophil, macrophage, 
and lymphocyte infiltration with higher numbers of IL-10 and TNF-α producing 
macrophages compared to their littermate control mice. Moreover, Arg1Δm mice 
had higher numbers of CD4+ T-cells, activated T-cells, IFNγ and IL-17 producing 
CD4+ T-cells. These results validate that the production of arginase-1 by M2 
macrophages is essential to regulate the inflammatory response against PA 
pneumonia. However, whether the production of arginase by macrophages is 
essential for the immunomodulatory mechanism of azithromycin has not been 
investigated.  
 
Our group has previously studied the transcriptional profiles of inflammatory 
genes in patients with cystic fibrosis treated with azithromycin. Although 
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azithromycin treatment was not associated with an increase in M2 anti-
inflammatory genes, the group of patients treated with azithromycin did have 
significantly reduced pro-inflammatory macrophage gene expression [442]. Yet, 
these observations could not be correlated to clinical outcomes or to definitive 
mechanisms by which azithromycin is thought to exert its beneficial immune-
modulatory role. This was because of the small sample size and the fact that 
most of the subjects colonized with PA were on chronic azithromycin therapy 
making it difficult to distinguish the specific effects of azithromycin therapy on 
macrophages and inflammatory gene expression [442]. 
 
The study described herein evaluates the dependence of azithromycin anti-
inflammatory mechanisms on arginase production by alternative macrophages to 
alter inflammation. We investigated whether the beneficial response to 
azithromycin is dependent upon arginase-1.  Arg1Δm and control mice were 
dosed with azithromycin and infected with PA-laden agarose beads. Moreover, 
we developed a clinical study which improves upon the limitations and design of 
the previous studies by generating matched data from subjects while on and off 
of azithromycin. We tested the hypothesis that azithromycin balances the 
immune response by controlling the inflammatory gene expression and the 
dependence of these mechanisms on arginase-1 production. While the human 
study is still in its early phases, murine experiments suggest that azithromycin is 
protective regardless of arginase production. 
 
II. Results 
 
Azithromycin treatment in mice infected with PA protects against excessive 
morbidity and inflammation regardless of arginase production. Three groups of 
mice were infected with PA-laden agarose beads as described. Four days prior 
to infection, one group of Arg1Δm mice and one group of littermate control mice 
received a dose of azithromycin via oral gavage. Azithromycin dosing continued 
daily thereafter. As a control, a group of Arg1Δm mice received daily doses of the 
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vehicle only (2% methylcellulose). Each group of mice consisted of at least four 
mice per timepoint. Infected mice were humanely killed, and tissues were 
harvested and processed for flow cytometry analysis. Additionally, we monitored 
morbidity post-infection by comparing the daily weight to the baseline murine 
body weight prior to infection (Figure 5.1a). The control Arg1Δm mice lost weight 
faster and to a greater degree compared to the other two groups treated with 
azithromycin. While the control Arg1Δm mice lost the maximum amount of weight 
by day 2 post-infection with an average of 82.52% of their initial weight; 
maximum weight loss in the azithromycin treatment group was attained at day 3 
post-infection with an average of 85.95% of their baseline body weight (Figure 
5.1a, day 3 (x) p-value = 0.0059; day 3 (x) p-value < 0.0001, (#) p-value = 
0.0008).  
 
We also evaluated the effects of azithromycin on bacterial clearance and 
mortality in Arg1Δm mice (Figure 5.1 b and c). Lung bacterial clearance was 
evaluated at different timepoints post-infection by counting the number of viable 
PA colonies in homogenized lung tissues. Azithromycin treated groups cleared 
PA at a rate comparable to the control Arg1Δm mice. Additionally, the three 
groups failed to completely clear the infection and PA was still present in the 
lungs by day 10 post-infection (Figure 5.1b). Importantly, azithromycin treatment 
protected against mortality in both Arg1Δm and Arg1flox/flox groups (Figure 5.1c). 
Importantly, the infective inoculum used in these experiments was selected to 
cause murine pneumonia without causing severe morbidity or mortality in each 
mouse strain. Mice were euthanized and excluded from the analysis if they lose 
20% or more of their body weight prior to infection along with one sign of 
morbidity (e.g. immobility, hunched posture, or lack of response to handling).  
 
Azithromycin has been previously shown to shift the cellular influx towards a 
monocytic response and to reduce neutrophil infiltration in response to the 
infection. To examine the dependence of these mechanisms on arginase-1 
expression, we used flow cytometry to characterize populations of neutrophils 
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and macrophages (Figure 5.2). Azithromycin treatment protected against 
excessive inflammation in both Arg1Δm and Arg1flox/flox groups. There was a 
significant attenuation of neutrophil recruitment into the alveolar spaces of 
azithromycin treated groups compared to the control Arg1Δm group at day 3 post-
infection (Figure 5.2a, day 3, alveolar spaces (x) p-value = 0.0038, (#) p-value = 
0.0017). While neutrophil numbers in the lung interstitium were lower in the 
azithromycin group, the differences were not statistically significant. However, 
azithromycin treatment, regardless of arginase deletion in macrophages, 
decreased the total number of tissue and infiltrating macrophages in the lungs of 
infected mice at day 3 post-infection (Figure 5.2, day 3, alveolar macrophages (x) 
p-value = 0.0469, (#) p-value = 0.0068; infiltrating macrophages (x) p-value = 
0.0055, (#) p-value = 0.0457). Similarly, azithromycin treatment in both knock-out 
and control groups significantly reduced recruitment of M1 pro-inflammatory 
macrophages (tissue and infiltrating) into the alveolar spaces at day 3 post-
infection (Figure 5.2c, day 3, (x) p-value = 0.0107, (#) p-value = 0.0026 and 
Figure 5.2d, day 3, (x) p-value = 0.046, (#) p-value = 0.0419). However, in the 
lung interstitium, both Arg1Δm groups had significantly lower numbers of M1 
macrophages (tissue and infiltrating) compared to the azithromycin-treated 
Arg1flox/flox mice (Figure 5.2c, day 3, (+) p-value = 0.0091, (#) p-value = 0.0189 
and Figure 5.2d, day 3, (x) p-value = 0.0118, (+) p-value < 0.0001, (#) p-value = 
0.0288). 
 
Additionally, we used flow cytometry analysis to define the expression of specific 
M1 and M2 macrophage effectors. Consistently we observed lower levels of 
resident and infiltrating TNF-α producing macrophages in the azithromycin-
treated groups compared to the control Arg1Δm mice (Figure 5.2e, day 3, (x) p-
values = 0.0408 and 0.0166, (#) p-values = 0.0243 and 0.0466, respectively). 
While azithromycin reduced the number of alveolar macrophages expressing 
iNOS in both Arg1Δm and Arg1flox/flox groups (Figure 5.2f, (x) p-value = 0.0439, (#) 
p-value = 0.0416), only the Arg1Δm mice treated with azithromycin had lower 
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number of infiltrating macrophages expressing iNOS (Figure 5.2f, (x) p-value = 
0.0003, (+) p-value = 0.0003).  
 
To determine the effects of azithromycin treatment on M2 macrophage 
polarization, we used two M2 macrophage markers, mannose receptor (MR) and 
IL-10. There were no statistically significant differences in MR expressing 
macrophages among the three groups of mice (Figure 5.2g). However, both 
azithromycin treated groups had significantly lower numbers of IL-10 producing 
alveolar and infiltrating macrophages compared to the control Arg1Δm mice 
(Figure 5.2h, day 5, (x) p-values = 0.0461 and 0.0399, (#) p-values = 0.0325 and 
< 0.0001 respectively). Interestingly, the ratio of pro- and anti-inflammatory 
monocytes were comparable among the three groups with similar trends 
including the ratio of CCR7/MR expressing macrophages (Figure 5.4d, A), IL-
17/IL-10 expressing monocytes (Figure 5.4d, B), and TNF-α/IL-10 producing 
monocytes (Figure 5.4d, C). 
 
We then evaluated the role that arginase expression plays in the ability of 
azithromycin to protect against inflammatory lung injury. Lung sections from mice 
treated with azithromycin and infected with PA-laden agarose beads were 
stained with H&E. An independent pathologist evaluated the lung sections blindly 
using a scoring system adapted from the American Thoracic Society guidelines 
[326]. The scoring system takes into consideration (1) the number of neutrophils 
in the alveolar spaces; (2) the number of neutrophils in the interstitial spaces; (3) 
the formation of hyaline membranes; (4) accumulation of proteinaceous debris in 
the airspaces; and (5) septal wall thickening. The inflammatory lung injury at day 
2 post-infection was comparable among the 3 groups of mice. However, both 
azithromycin treated groups had significantly lower mean lung injury score 
compared to the control Arg1Δm mice. The lung injury score decreased in the 
azithromycin-treated Arg1Δm mice to an average of 0.1065 ± 0.031 at day 5 post-
infection and in the azithromycin-treated Arg1flox/flox mice to an average of 0.2016 
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± 0.146 versus a persistent lung injury score of 0.446 ± 0.113 in the control 
Arg1Δm mice (Figure 5.2i, day 5, (x) p-value = 0.0012, (#) p-value = 0.0078).  
 
Azithromycin treatment in arginase conditional knock-out mice reduces T cell 
recruitment and activation in response to PA pneumonia. Our results in chapter 3 
show that arginase is required for modulation of T cell responses to PA 
pneumonia and that deletion of arginase in Arg1Δm mice skews the T cell 
responses towards Th1/Th17 predominance. However, because azithromycin is 
protective in part by increasing arginase in normal infected mice, we next 
evaluated whether azithromycin required arginase expression for its effects on T 
cells. Arg1Δm mice were dosed with azithromycin and infected with PA-laden 
agarose beads intratracheally. Tracheobronchial lymph nodes draining the site of 
infection, in addition to the lung lavage and lung tissue samples were stained for 
surface and intracellular markers to evaluate T cell responses and activation 
profiles at different timepoints post-infection (Figures 5.3 and 5.4). Azithromycin 
treated Arg1Δm mice responded to PA pneumonia with lower numbers of CD4+ 
and activated CD4+ T cells in their tracheobronchial lymph nodes (Figure 5.3a, 
day 14, Total CD4+ T cells (+) p-value = 0.0059; activated T cells (x) p-value = 
0.0079, (+) p-value = 0.0017). Similarly, both azithromycin treated groups had 
significantly lower numbers of CD4+ lymphocytes and activated CD4+ 
lymphocytes in their interstitial spaces (Figure 5.3b, day 10 Total CD4+ T cells (x) 
p-value = 0.0228, (#) p-value = 0.0426; activated T cells day 14 (x) p-value < 
0.0001, (#) p-value < 0.0001). However, there were no statistically significant 
differences in the numbers of CD4+ T cells and activated CD4+ T cells in the 
alveolar spaces in the 3 groups (Figure 5.3c). 
 
Next, we used flow cytometry to analyze the different T helper cell lineages 
modulated with azithromycin treatment in Arg1Δm mice (Figure 5.4). We observed 
a consistent decrease in Th17 recruitment with azithromycin treatment in both 
Arg1Δm and Arg1flox/flox groups compared to untreated control Arg1Δm mice (Figure 
5.4a). In the lymph nodes, only the azithromycin-treated Arg1flox/flox mice had 
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significantly lower numbers compared to the control Arg1Δm mice (Figure 5.4a, 
day 3, (#) p-value = 0.0489). While in the lung tissues, both azithromycin treated 
groups had significantly reduced numbers of Th17 lymphocytes at day 3 post-
infection (Figure 5.4a, day 3, (x) p-value = 0.0047, (#) p-value = 0.0079; day 10 
(#) p-value = 0.0463). Similarly, both azithromycin treated groups had 
significantly lower numbers of Th17 lymphocytes recruited into their alveolar 
spaces at day 3 post-infection (Figure 5.4a, day 3, (x) p-value = 0.0047, (#) p-
value = 0.0079; day 10 (#) p-value = 0.0463).  
 
Additionally, azithromycin treatment was associated with attenuation of the type 1 
T helper lymphocyte counts in both Arg1Δm and Arg1flox/flox groups. In the lymph 
nodes, azithromycin treatment significantly lowered the number of Th1 
lymphocytes activated (Figure 5.4b, day 3, (x) p-value = 0.0002, (#) p-value = 
0.0004). Similarly, both azithromycin treated groups had significantly lower 
numbers of Th1 lymphocytes recruited into their interstitial spaces at day 10 post-
infection (Figure 5.4b, day 10, (x) p-value = 0.0314, (#) p-value = 0.0121). While 
in the alveolar spaces, both azithromycin treated groups had significantly 
reduced numbers of Th1 lymphocytes at day 3 post-infection (Figure 5.4b, day 3, 
(x) p-value < 0.0001, (+) p-value 0.007, (#) p-value < 0.0001; day 10 (#) p-value 
= 0.0208).  
 
Finally, azithromycin treatment was associated with increased regulatory T cell 
numbers in both Arg1Δm and Arg1flox/flox groups. In the lymph nodes, untreated 
control Arg1Δm mice had significantly higher numbers of Treg lymphocytes 
compared to both azithromycin treated groups at day 5 post-infection (Figure 
5.4c, day 5, (x) p-value = 0.0139, (#) p-value = 0.034). However, in the interstitial 
and alveolar spaces of both azithromycin treated groups, we observed increased 
numbers of Treg lymphocytes at days 3 through 10 compared to the untreated 
control Arg1Δm mice (Figure 5.4c, lung interstitium and alveolar spaces, p-values 
> 0.05). 
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Additionally, we estimated the ratios of pro- and anti-inflammatory cytokines 
expressed by all lymphoid cells. The lymphocyte population contains CD4+ T 
cells as well as other lymphoid cells including the innate lymphoid cells, CD8+ T 
cells, and NK cells. Figure 5.4d shows the ratios of total IL-17, IFNγ, TGFβ, and 
IL-10 expressing lymphoid cells in the alveolar spaces. The ratio of IL-17 to IL-10 
producing lymphocytes was significantly higher in the control Arg1Δm mice at day 
3 post-infection compared to the azithromycin groups (Figure 5.4d, D, (x) and (#) 
p-values < 0.0001). Similarly, azithromycin treated mice had decreased IFNγ to 
TGFβ ratios at days 0 and 3 post-infection compared to the control Arg1Δm group 
(Figure 5.4d, E, day 0, (x) p-value = 0.0151; day 3 (x) p-value = 0.004 and (#) p-
value = 0.0024). Additionally, azithromycin treated mice had decreased Th17 to 
Treg lymphocyte ratios at days 10 post-infection compared to the control Arg1Δm 
group (Figure 5.4d, F, day 10, (x) p-value = 0.0002, (#) p-value = 0.001). 
 
III. Discussion 
 
Azithromycin is a well-known and widely used macrolide antibiotic with 
significantly important anti-inflammatory properties. The use of azithromycin as 
an immunomodulatory drug in cystic fibrosis patients is a common practice today 
in patients chronically infected with PA. The clinical benefits of this drug are well 
established and the clinical trials showing its anti-inflammatory efficacy has led to 
a recommendation for its use in the European NICE guidelines and the American 
Cystic Fibrosis Pulmonary guidelines [306, 307]. Yet, very little is known about 
azithromycin anti-inflammatory mechanisms. Despite the extended use of this 
drug in CF patients, it is still unclear how azithromycin exerts its 
immunomodulatory functions. Therefore, there are no clear-cut guidelines on 
when to use this drug and if there is a specific population that would benefit from 
this drug more than another. Our limited understanding of azithromycin anti-
inflammatory mechanisms and the specific targets involved limits our judgment 
on the duration of use and whether we can adjust the dosing or modify the 
structure for increased benefit. 
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Our group has shown that azithromycin shifts the macrophage polarization away 
from the M1 pro-inflammatory phenotype towards an M2 anti-inflammatory 
phenotype. We consistently observe suppression of pro-inflammatory effectors 
and cytokines with azithromycin (including iNOS, TNF-α, IL-6, and IFNγ), and an 
increase in anti-inflammatory effectors (including IL-10 and arginase-1) in both in-
vitro and in-vivo PA infection models [166, 310, 311]. We have demonstrated that 
arginase-1 production by alternative macrophages is essential for regulating 
excessive inflammation in PA pneumonia and by limiting Th1 and Th17 cell 
responses (chapter 3). Here, we have focused on the question of whether 
azithromycin’s anti-inflammatory mechanisms require arginase-1 for regulation of 
inflammation.  
 
Results from experiments with arginase conditional knock-out mice treated with 
azithromycin negate this hypothesis. Our results show that azithromycin protects 
against excessive morbidity and inflammation in mice infected with PA 
pneumonia regardless of arginase production. We have previously shown that 
arginase conditional knock-out mice do worse compared to their littermate 
controls with excessive neutrophil and pro-inflammatory macrophage influx in 
response to infections with PA pneumonia. The current study shows that 
azithromycin is equally protective in both arginase conditional knock-out mice 
and in their littermate controls. Azithromycin equally blunted neutrophil influx in 
infected mice regardless of arginase production. Moreover, azithromycin reduced 
macrophage infiltration and polarization towards an M1 phenotype regardless of 
arginase deletion from myeloid cells. Therefore, azithromycin suppresses 
excessive neutrophil influx and pro-inflammatory macrophage polarization 
through mechanisms that are independent of arginase. Although we see 
increased arginase expression and activation with azithromycin treatment, it is 
most likely a consequence rather than a mechanism by which azithromycin 
exerts its clinical benefits.  
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Our in vitro data suggest that azithromycin cross-inhibits NF-κB and STAT-1 pro-
inflammatory transcription factors rather than promoting M2 anti-inflammatory 
signaling mediators. Consistently, we see suppression of pro-inflammatory 
macrophage effectors with azithromycin treatment rather than an increase in anti-
inflammatory effectors. There were no significant differences in MR expressing 
M2 macrophages, and azithromycin equally downregulated IL-10 expressing 
macrophages in both arginase conditional knock-out mice and their littermate 
controls. It is very likely that azithromycin suppresses pro-inflammatory mediators 
and cytokines rather than increasing anti-inflammatory mediators; thus, it adjusts 
the balance of the pro- and anti-inflammatory effectors and protects against 
excessive inflammation.  
 
Similar to arginase-mediated modulation of the T cell phenotype, azithromycin 
modulates the T cell responses, but independently of arginase. Our previous 
data suggest that arginase production by neutrophils and macrophages is 
essential for limiting Th1 and Th17 pro-inflammatory responses. However, the 
current study shows that azithromycin can suppress excessive Th1 and Th17 
responses regardless of arginase deletion from myeloid cells. Additionally, we 
saw reduced T cell numbers in the interstitial spaces with azithromycin treatment 
while the effects were variable in the lymph nodes and alveolar spaces. Results 
indicate that azithromycin affects T cell polarization and disposition independent 
of arginase production. It is likely that azithromycin affects compartmentalization 
of T cell responses and that effects of azithromycin on T cell polarization are 
cytokine mediated. Future studies evaluating effects of azithromycin in the 
presence of neutralizing cytokine antibodies are essential to determine the major 
cytokines driving the effects of the drug on T cells and other immune responses 
to PA pneumonia.  
 
Lastly, azithromycin treatment promoted a regulatory T cell phenotype in the 
lungs of mice infected with PA regardless of arginase. While azithromycin 
reduced the numbers of Treg lymphocytes in the lymph nodes of infected mice, 
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there were more Treg lymphocytes in the lungs and alveolar spaces. It is 
possible that the attenuation of the Th17/Th1 responses tilts the balance towards 
a Treg predominant phenotype. The specific mechanisms by which azithromycin 
affects the Th17/Treg balance is independent of arginase-mediated modulation 
of T cell phenotype. It is possible that azithromycin might have direct effects on T 
cell proliferation and expression of activation markers. Yet, the specific 
mechanisms involved are yet to be elucidated.  
 
Collectively, our results show that azithromycin protects against excessive 
inflammation in PA pneumonia by attenuating the release of pro-inflammatory 
cytokines and thus shifting the T cell responses away from the Th1/Th17-
mediated inflammation. This modulation is associated with reduced neutrophil 
influx and is independent of arginase production. Additionally, we have extended 
our studies to show protective effects of azithromycin in myocardial infarction, 
spinal cord injury, stroke, and other diseases with potential inflammatory 
pathology [443-446]. It is clear that arginase production in these models can 
modulate the immune response; however, we show here that azithromycin exerts 
its anti-inflammatory mechanism independent of its ability to increase arginase. It 
is possible that the increased arginase expression and activity with azithromycin 
assists in better modulation of the immune response and in speeding the 
recovery and inducing wound healing and repair. However, azithromycin 
mediates faster recovery via non-arginase pathways. We hypothesize that 
azithromycin regulates inflammation via increased TGFβ secretion thereby 
modulating the T cell subset distribution and function in response to PA infection. 
In support of this notion, we observed increased TGF-β expression in 
azithromycin-treated mice. TGFβ is an important type II cytokine which inhibits T 
cell activation and alters the differentiation of naïve T cells into effector 
phenotypes [447]. According to Cottrez et al., TGF-β expression suppresses T 
cell proliferation and cytokine secretion. These effects are potentiated with 
increased IL-10 concentrations which increase the surface expression of TGF-β 
receptors [448]. According to Cottrez and colleagues, IL-10 restores TGF-β 
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inhibitory effects on activated and memory T cells [448]. Therefore, it is very 
likely that the increased IL-10 concentrations with azithromycin treatment along 
with the induced TGF-β levels, act synergistically to modulate T cell responses 
and to induce a regulatory phenotype. In a murine model of helminth infection, 
mice colonized with the nematode, Heligmosomoides polygyrus, have increased 
IL-10 and TGF-β concentrations which inhibits the release of Th1 cytokines [449]. 
Ince and colleagues show that increase TGF-β mediates a Treg predominant 
immune response via an IL-10 dependent mechanism and suppresses Th1 and 
Th2 responses thereby protecting against chronic colitis in mice infected with H. 
polygyrus [449]. Similarly, IL-10/TGF-β synergism promotes an increase in Treg 
numbers in active Mycobacterium tuberculosis infections [450]. Feruglio and 
colleagues suggest that early inhibition of IL-10/TGF-β pathway facilitates M. 
tuberculosis clearance by rescuing the Th1 responses [450]. Additionally, 
deletion of TGF-β drastically affects Treg development and promotes Th1 
responses. This effect is dependent on the TGF-β mediated regulation of T-bet, 
the Th1 transcription factor, expression [447, 451]. Therefore, it is possible the 
azithromycin induces a Treg phenotype through TGF-β dependent mechanisms 
thereby limiting the Th1 and Th17 responses. Moreover, it is likely that TGF-β is 
driving fibrogenesis and wound healing which we otherwise see with arginase. In 
fact, TGF-β is a master regulator of fibrosis through signaling pathways 
independent of arginase. It is possible that azithromycin-mediated modulation of 
TGF-β affects the latter signaling through Smad and non-Smad pathways which 
regulates myofibroblast activation and extracellular matrix deposition [452]. 
Future studies utilizing TGF-β neutralizing antibodies in azithromycin-treated 
Arg1Δm mice will help validate this hypothesis. Additionally, future studies will 
examine the effects of azithromycin on non-arginase mediated signaling 
pathways involved with wound healing including the Smad pathway [452]. This 
will be achieved by utilizing Lck-creSmad4 mice. These mice lack the Smad4 
intracellular signaling molecule in lymphoid cells.  This protein is responsible for 
the signaling cascade through the receptor that binds to members of the TGFβ 
superfamily [453].  
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Some of the limitations of our study include the “leakiness” of the LysMcre 
system and the deletion of arginase from both neutrophils and macrophages as 
discussed in Chapter 3. Briefly, the deletion of arginase in our murine model is 
controlled by lysozyme expression. Lysozyme M is expressed in neutrophils and 
macrophages. So, it is difficult to delineate the difference between neutrophil 
versus macrophage arginase functions as both are deleted. Additionally, new 
reports show different levels of lysozyme expression between tissue and 
infiltrating macrophages thus accounting for different levels of arginase deletion 
from these two populations [368]. 
 
Importantly, it is possible that azithromycin induces arginase expression in non-
myeloid cells. Hence, non-myeloid sources of arginase may be rescuing the 
effects of its deletion from neutrophils and macrophages in Arg1Δm mice. 
Therefore, it is essential to study the effects of azithromycin in other models of 
conditional arginase deletion or global inhibition. For instance, ILC2s are an 
important source of arginase which may be induced with azithromycin thereby 
counteracting the effects of deleted arginase from myeloid cells. In fact, Amantea 
et al. show that pharmacologic arginase inhibition in peritoneal macrophages 
reversed the neuroprotective effects of azithromycin in ischemic stroke [445]. The 
authors suggest that polarization of migratory macrophages towards an M2 
phenotype with azithromycin is essential for the reduced ischemic injury which 
requires arginase production by these macrophages. This group shows that 
azithromycin does not alter microglia or tissue macrophages but affects 
infiltrating macrophages. These results are similar to our observation that 
differential effects of azithromycin on alveolar versus interstitial macrophages in 
the lungs. However, this group shows a 10-fold increase in M2 anti-inflammatory 
macrophage numbers rather than a suppression of the pro-inflammatory M1 
macrophage numbers which we see in our model. Therefore, it might be possible 
that azithromycin acts differently in different disease models. While a shift in 
macrophage polarization towards the M2 phenotype underlies the beneficial 
effects of the drug in ischemic stroke thus requiring arginase function for 
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neuroprotection, a shift in macrophage polarization away from the M1 phenotype 
underlies the beneficial effects of the drug in PA pneumonia thus functioning 
independent of arginase.  
  
Finally, we designed a clinical study to evaluate the applicability of our 
observations in patients with cystic fibrosis. As discussed in chapter 1, the 
immunomodulatory role of arginase-1 in humans is controversial. It is well 
established that increased arginase expression promotes suppressed immunity 
and increased inhibitory Treg responses in cancer, type I diabetes, rheumatoid 
arthritis, and many other auto-immune diseases [454-456]. However, increased 
arginase expression is also associated with exaggerated inflammation and 
exacerbations in patients with cystic fibrosis as well as in patients with systemic 
lupus erythematosus, myasthenia gravis, autoimmune encephalomyelitis, and 
obesity [109, 135, 164, 165, 248, 370-375, 457]. Additionally, several studies 
suggest that the two arginase isoforms function differently in humans [248, 371]. 
However, a direct link between arginase expression and pathogenesis of the 
above-listed diseases have not been elucidated yet. It is likely that arginase 
upregulation follows the activation of exaggerated inflammation and that arginase 
induction is a regulatory mechanism. Therefore, future studies are needed to 
validate the immunomodulatory mechanisms of arginase in humans. Additionally, 
the specific mechanisms by which azithromycin exerts its clinically beneficial 
effects and whether arginase is required for azithromycin anti-inflammatory 
mechanisms are yet to be elucidated. Our proposed clinical study will help 
answer these questions and will improve our understanding of azithromycin’s 
clinical benefits. This will provide the opportunity to individualize therapy for 
maximal benefits in different patient populations. Additionally, knowing the 
effectors involved in modulating inflammation identifies future drug targets for 
new and improved immunomodulatory agents for cystic fibrosis and many other 
inflammatory and autoimmune diseases.  
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The clinical study was approved by the Institutional Review Board at the 
University of Kentucky. We are currently pre-screening cystic fibrosis patients 
between 12 and 50 years of age, who are clinically stable and have been on 
azithromycin for at least a year. We hope to recruit about 20 subjects within the 
next 1 year. Patients who meet our inclusion/exclusion criteria will take a drug 
holiday discontinuing azithromycin treatment for 2-3 months. We will utilize the 
methods proposed in Chapter 2 including flow cytometry, gene expression 
assays, and cytometric bead arrays to compare immune signatures and 
inflammatory responses in patients when on and off azithromycin. Additionally, 
we will use principal component analysis and paired sample T-tests to compare 
the matched samples over time after re-initiating azithromycin therapy in these 
patients. We will also utilize statistical analysis to correlate our results with 
clinical outcomes (including demographic information, pulmonary function tests, 
requirement for hospitalization, and requirement for antibiotics).  
 
Along with the in vitro and in vivo data, our research leads the way towards fully 
describing the role and mechanism of azithromycin in modulating the immune 
response to PA infections. Completion of this study will have a positive impact by 
defining the immune-regulatory mechanisms of azithromycin in the context of 
chronic inflammatory lung disease. Additionally, it will provide evidence on the 
mechanisms of arginase-mediated regulation of the immune response. Results 
from this pilot clinical study will broaden our knowledge of the specific role of 
arginase in the anti-inflammatory mechanisms of azithromycin. With this, we 
hope to identify essential regulatory pathways and specific downstream signaling 
cascades which modulation can be of therapeutic value for future drug targets in 
patients with non-resolving pulmonary infections and in other chronic and acute 
inflammatory pathologies. 
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Figure 5.1a 
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Figure 5.1b 
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Figure 5.1c 
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Figure 5.1. Azithromycin treatment protects against excessive morbidity and 
weight loss in arginase-1 conditional knock-out mice. 
Arg1Δm and their littermate Arg1flox/flox mice were treated with azithromycin 
starting 4 days prior to infection and daily thereafter. A third control group of 
Arg1Δm mice was dosed with the vehicle (2% methylcellulose). The 3 groups of 
mice were infected with PA-laden agarose beads through intratracheal instillation 
of 2 × 10^6 CFU/ mL as described. Murine morbidity post infection was evaluated 
in terms of weight loss measured at least once daily before and after infection. 
(a) The graph represents the percentage weight loss normalized to the baseline 
body weight prior to infection. (b) The graph represents bacterial clearance from 
the lungs post-infection. (c) Kaplan-Meier graph represents murine survival post-
infection. Data represent mean ± SD and is representative of 3 independent 
experiments. Statistical significance was determined by two-way ANOVA ((x) 
azithromycin treated arginase conditional knock-out mice significantly different 
than control arginase conditional knock-out mice; (#) azithromycin treated 
littermate control mice group significantly different than control arginase 
conditional knock-out mice; (+) azithromycin treated arginase conditional knock-
out mice significantly different than the azithromycin-treated littermate control 
mice; p-value < 0.05). Graphs plotted using GraphPad Prism 7 (Note: for some 
points, the error bars are shorter than the height of the symbol. In these cases, 
Prism simply does not draw the error bars).  
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Figure 5.2a 
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Figure 5.2b 
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 Figure 5.2c 
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Figure 5.2d 
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Figure 5.2e 
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Figure 5.2f  
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Figure 5.2g 
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Figure 5.2h 
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Figure 5.2i 
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Figure 5.2i (continued) 
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Figure 5.2. Azithromycin treatment attenuates acute inflammatory infiltration of 
innate immune cells in arginase conditional knock-out mice.  
Lungs from infected mice were lavaged with PBS to collect cells from the alveolar 
spaces and lung tissues were then harvested to collect cells from the lung 
interstitium. Lavage and lung tissue samples were collected from at least four 
mice per timepoint per group. Harvested samples were processed into single cell 
suspensions and stained for flow cytometry analysis as described. At least 
50,000 events per sample were analyzed using the FlowJo software to quantify 
different immune cell populations. Data represent total count of each cell 
population as a fraction of the total number of live cells analyzed. (a) Neutrophil 
recruitment into the alveolar and lung interstitial spaces (b) Total number of 
tissue and infiltrating macrophages. (c, d) The total number of tissue and 
infiltrating M1 macrophages expressing CCR7 receptor and positive for iNOS 
and TNF-α. (e, f, g, h) Total counts of alveolar and infiltrating macrophages 
producing TNF-α, iNOS, IL-10, or expressing Mannose receptor (MR). (i) Lungs 
were insufflated and fixed in paraformaldehyde for sectioning. Lung sections 
were stained with H&E and lung injury was assessed by an independent blinded 
investigator. Lung injury was scored as described in methods. The score ranges 
from 0-1 (inclusive). Data represent mean ± SD and is representative of 3 
independent experiments. Statistical significance determined by two-way ANOVA 
((x) azithromycin treated arginase conditional knock-out mice significantly 
different than control arginase conditional knock-out mice; (#) azithromycin 
treated littermate control mice group significantly different than control arginase 
conditional knock-out mice; (+) azithromycin treated arginase conditional knock-
out mice significantly different than the azithromycin-treated littermate control 
mice; p-value < 0.05). Graphs plotted using GraphPad Prism 7 (Note: for some 
points, the error bars are shorter than the height of the symbol. In these cases, 
Prism simply does not draw the error bars). 
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Figure 5.3a 
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Figure 5.3b 
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Figure 5.3c 
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Figure 5.3. Azithromycin treatment in arginase conditional knock-out mice is 
associated with decreased CD4+ lymphocyte recruitment and activation. 
Tracheobronchial lymph nodes draining the site of infection were harvested and 
processed into single cell suspensions by passing through mesh strainers. Lung 
lavage and lung tissue samples were collected and processed as described. 
Single cell suspensions were stained for flow cytometry analysis as described. At 
least 50,000 events per sample were analyzed using the FlowJo software to 
quantify different immune cell populations. Data represent total count of each cell 
population as a fraction of the total number of live cells analyzed. (a, b, c) Total 
number of CD4+ T cells recruited and activated in the lymph nodes, alveolar 
spaces, and lung interstitium of infected mice. Data represent mean ± SD.  Data 
are representative of 3 independent experiments. Statistical significance 
determined by two-way ANOVA ((x) azithromycin treated arginase conditional 
knock-out mice significantly different than control arginase conditional knock-out 
mice; (#) azithromycin treated littermate control mice group significantly different 
than control arginase conditional knock-out mice; (+) azithromycin treated 
arginase conditional knock-out mice significantly different than the azithromycin-
treated littermate control mice; p-value < 0.05). Graphs plotted using GraphPad 
Prism 7 (Note: for some points, the error bars are shorter than the height of the 
symbol. In these cases, Prism simply does not draw the error bars). 
  
 242 
Figure 5.4a 
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Figure 5.4b 
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Figure 5.4c 
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Figure 5.4d 
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Figure 5.4. Azithromycin treatment in the arginase conditional knock-out mice 
suppresses the exaggerated recruitment of inflammatory lymphocytes. 
Tracheobronchial lymph nodes draining the site of infection and lung tissue 
samples were collected and processed as described. Single cell suspensions 
were stained for flow cytometry analysis as described. At least 50,000 events per 
sample were analyzed using the FlowJo software to quantify different immune 
cell populations. Data represent total count of each cell population as a fraction 
of the total number of live cells analyzed. (a, b, c) Total number of Th17, Th1, 
and regulatory T lymphocytes in the lymph nodes, alveolar spaces, and lung 
interstitium of infected mice. (d) Bar graphs represent ratios of CCR7 to MR 
expressing cells in A; ratio of IL-17 to IL-10 expressing monocytes in B; ratio of 
TNF-α to IL-10 expressing macrophages in C; ratio IL-17 to IL-10 expressing 
lymphocytes in D; ratio of IFNγ to TGFβ expressing lymphocytes in E, and ratio 
of Th17 to Treg cells in F. Data represent mean ± SD.  Data are representative of 
3 independent experiments. Statistical significance determined by two-way 
ANOVA ((x) azithromycin treated arginase conditional knock-out mice 
significantly different than control arginase conditional knock-out mice; (#) 
azithromycin treated littermate control mice group significantly different than 
control arginase conditional knock-out mice; (+) azithromycin treated arginase 
conditional knock-out mice significantly different than the azithromycin-treated 
littermate control mice; p-value < 0.05). Graphs plotted using GraphPad Prism 7 
(Note: for some points, the error bars are shorter than the height of the symbol. 
In these cases, Prism simply does not draw the error bars).  
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Chapter 6: Summary and conclusions 
 
I. Project Overview 
  
Research work presented in this dissertation aimed at defining the 
immunomodulatory functions of the alternative macrophage effector, arginase-1, 
as well as defining the immunomodulatory mechanisms of azithromycin. We 
utilized genetically modified mouse models, pharmacological inhibitors, in-vitro 
assays, and clinical approaches to better understand the immune response to 
infections with PA pneumonia.  
 
Infections with PA pneumonia are the leading cause of morbidity and mortality in 
patients with cystic fibrosis [1-6]. As discussed in the introduction, cystic fibrosis 
is an autosomal recessive disorder caused by mutations of the CFTR gene. This 
mutation is associated with disrupted ion flux across the epithelium resulting in 
the production of abnormally thick and dense mucus which obstructs the airways, 
pancreatic ducts, intestines, and other organs [1-7]. Additionally, patients 
suffering from this mutation develop structural airway abnormalities including 
increased smooth muscle content and smooth muscle cell hyperplasia [12].  
These changes predispose the patients to chronic and repetitive lung infections 
against which the immune system responds in an exaggerated manner. The 
increased risk for infections is attributed to the failure of the epithelium to perform 
its role as the first line of defense against inhaled microbes. This happens due to 
the abnormally viscous mucus which causes ciliary dyskinesis thereby hindering 
the mucociliary clearance essential for expelling trapped pathogens [63, 133]. 
Additionally, the altered airway surface liquid and the increased pH inactivate the 
epithelial microbicidal substances essential for killing the invading bacteria, 
viruses, and yeasts [63-91, 102-105, 133, 458]. Additionally, CFTR mutations 
potentiate the signaling through the NF-κB pathway in epithelial cells which 
results in a robust and vigorous release of pro-inflammatory mediators upon 
activation by non-self antigens [63-75, 77-95, 102-105, 133, 458, 459]. These 
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pro-inflammatory cytokines function to recruit innate and adaptive immune cells 
which are essential for containing the infection and resolving the immune 
response. However, several alterations of the innate and adaptive immune 
responses occur in cystic fibrosis rendering the inflammatory response 
disproportionate to the severity of the infection.  
 
First, neutrophils are recruited in excessive numbers due to the persistent 
infections and continuous stimulation. These neutrophils are affected by the 
CFTR mutations which impair the degranulation of important neutrophil 
microbicidal products from the secondary and tertiary granules [102]. 
Additionally, neutrophils release excessive amounts of neutrophil elastases and 
proteases in the cystic fibrosis lungs which overwhelm the antiproteases that 
protect the lungs. The excessive amounts of neutrophil elastases break down the 
connective tissues and matrix proteins leading to a structural loss in the small 
airways [106-110]. Additionally, neutrophils in cystic fibrosis patients fail to 
undergo programmed cell death and the resultant necrosis releases the massive 
intracellular contents like inflammatory mediators and cytokines, oxidants and 
proteases, in addition to large DNA fragments and actin [117]. Thus, the death of 
neutrophils releases tremendous amounts of intracellular contents that are 
extremely harmful to the lungs. 
 
Second, macrophages are recruited into the lungs of cystic fibrosis patients in 
response to the infection. However, changes in lung microenvironment and the 
altered inflammatory signals result in altered macrophage polarization, 
phagocytic function, and antigen presentation. Several reports observed intrinsic 
macrophage alterations which result in an exaggerated release of pro-
inflammatory mediators from cystic fibrosis macrophages compared to normal 
human macrophages [27, 166-170]. This is attributed to the potentiated NF-κB 
and STAT-1 signaling pathways in these cells. Additionally, the lung environment 
in cystic fibrosis skews macrophage polarization depending on the stability of the 
disease and the nature of infections at specific timepoints. This results in a 
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disproportional balance of M1/M2 macrophages in patients with cystic fibrosis. 
Moreover, malfunctional CFTR on the surface of macrophages impairs their 
microbicidal functions by dysregulating the formation of phagosomes with 
appropriate pH and by impairing the late endosome/lysosome maturation 
essential for trafficking of surface pattern recognition receptors [25, 134, 170-
176]. Hence, mutated CFTR on the surface of macrophages drastically affects 
their ability to present antigens for incoming immune cells. 
 
Third, altered adaptive immune responses in patients with cystic fibrosis are 
attributed to the impaired communication between innate and adaptive immune 
cells and to the skewing of the T cell responses towards a Th2 and Th17 
predominant response. Innate immune cells fail to present antigens and provide 
necessary costimulation for B and T cell selection. This results from non-CFTR 
genetic mutations of the MHC complex which affects efficient antigen 
presentation. Moreover, suppressed PD-L1/PD-1 interaction between airway 
epithelial cells and T cells results in uncontrolled activation of the adaptive 
immune response [63, 133, 182, 183, 188-192]. Additionally, naïve T cells 
isolated from cystic fibrosis patients are inherently predisposed to be polarized 
towards Th2 and Th17 phenotypes [203, 204]. Moreover, there is a significant 
imbalance of signals and cytokines which drive T cell differentiation towards a 
Th17 predominant phenotype versus signals essential for limiting this response. 
In fact, T cells with mutated CFTR can equally differentiate under the influence of 
appropriate cytokines into Th1 and Treg phenotypes. However, when T cells with 
CFTR mutations are polarized with Th17 stimulants, there is a higher and faster 
shift into the Th17 phenotype compared to wild-type lymphocytes. Importantly, 
Th17 lymphocytes and IL-17 production are associated with poor prognosis as 
they play an early role in disease pathology. They are associated with sustained 
neutrophil recruitment and a decline in lung function [67, 210-219, 221]. 
 
Collectively, intrinsic and environmental alterations result in an exaggerated 
immune response. These alterations impair the function of immune cells thereby 
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failing to contain and clear the infections. This results in a vicious cycle of 
exaggerated inflammation, inflammatory lung injury, and persistent infections  
[185, 233, 235-247, 460]. Our long-term goal is to define key regulators of this 
exaggerated immune response that can be of therapeutic value for 
immunotherapy in cystic fibrosis. Our group has previously demonstrated that 
azithromycin, a macrolide antibiotic, drives macrophages into an alternative M2 
phenotype in-vitro [166, 310, 311]. Additionally, murine experiments with early 
polarization of macrophages into an alternative phenotype show decreased 
neutrophil influx and pulmonary injury in mice infected with PA. Alternatively, 
abolishing alternative macrophage polarization was associated with a profound 
acute immune response along with exaggerated neutrophil influx and an altered 
T cell response. The absence of alternative macrophages was also associated 
with increased morbidity and mortality in our murine model of PA pneumonia 
[166, 310, 311]. Closely examining the different effectors of alternative 
macrophages revealed an important role of arginase-1. Arginase-1 expression 
and activity are increased in alternative macrophages polarized with 
azithromycin. Moreover, preliminary experiments using arginase-1 conditional 
knock-out mice verified that arginase deficiency is associated with greater 
morbidity in terms of more significant weight loss. Additionally, arginase-1 has 
unique immunomodulatory properties where it is shown in other disease models 
to control of NO-mediated injury, to suppress T cell function and proliferation, and 
to promote a Treg phenotype [17, 151, 152, 154, 157, 312, 314-318].  
 
Hence, the objective of this project was to investigate the regulatory role of 
arginase in the immune response to PA pneumonia and its modulation of T cell 
immunity. Additionally, our second objective was to evaluate the anti-
inflammatory mechanisms of azithromycin and the dependence of these 
mechanisms on arginase. Our central hypothesis was that regulation of 
exaggerated inflammation achieved by polarizing macrophages into an 
alternative anti-inflammatory phenotype is dependent on arginase production. 
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Our second hypothesis was that azithromycin controls immunity in PA 
pneumonia via cross-inhibition of the NF-κB and STAT-1 signaling pathways.  
 
II. Results overview 
 
i. Myeloid arginase production is essential for regulation of excessive 
inflammation in PA pneumonia 
 
Our results show that arginase production by myeloid cells is essential to 
regulate immunity against PA pneumonia. We utilized Arg1Δm mice with 
conditional arginase deletion from macrophages and neutrophils along with two 
global pharmacological arginase inhibitors to examine the effects of arginase on 
the immune response. Mice were infected with PA-laden agarose beads to cause 
a prolonged infection similar to the chronic PA pneumonia in patients with cystic 
fibrosis. We used flow cytometry analysis to identify the immune cell populations 
activated and recruited in response to the infection. Our results show that 
arginase deletion from myeloid cells resulted in increased morbidity and weight 
loss post infection, while global arginase inhibition resulted in exaggerated weight 
loss (Chapter 3). Additionally, Arg1Δm mice responded to the infection with an 
amplified influx of neutrophils and pro-inflammatory macrophages into their lungs 
and alveolar spaces. BALBc/J mice dosed with arginase inhibitors responded 
with significantly higher numbers of neutrophils and macrophages compared to 
the Arg1Δm mice. Additionally, Arg1Δm mice responded with significantly 
increased numbers of CD4+ T cells and activated T cells along with a 
predominant polarization towards a Th1 and Th17 response. Conversely, global 
arginase inhibition was associated with increased numbers of CD4+ T cells and 
activated T cells in the lymph nodes and in the lung interstitial spaces of infected 
mice while these effects were reversed in the alveolar spaces. This trend also 
applied to the Th1, Th17, and Treg polarized lymphocytes in the lymph nodes 
with potentially reduced transmigration of these lymphocytes to the lung 
interstitial and alveolar spaces of mice treated with BEC or L-norvaline.   
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Therefore, our results show that myeloid arginase is essential to limit T cell 
proliferation and activation and to protect against disproportionate polarization 
towards a Th1 and Th17 predominant response which contributes to excessive 
neutrophil and pro-inflammatory macrophage recruitment. However, global 
arginase inhibition results in exaggerated morbidity and inflammation along with 
blunted lymphocyte recruitment and chemotaxis to the lungs. 
  
ii. Azithromycin balances the M1/M2 macrophage polarization by 
cross-inhibiting the M1-associated transcription factors, NF-κB and 
STAT-1 
 
Our results show that azithromycin acts directly on macrophages by cross-
inhibiting the NF-κB and STAT-1 signaling pathways. We utilized an in vitro 
model of J774 murine macrophages which were polarized with azithromycin and 
cytokines to drive macrophage polarization towards an M1 or an M2 phenotype. 
Using a p65 translocation assay coupled with western blot analysis of p65 protein 
in the nuclear versus the cytoplasmic compartments and using 
immunofluorescence assay to visualize p65 localization in the cell upon 
stimulation, we demonstrated that azithromycin significantly suppresses p65 
translocation to the nucleus of stimulated macrophages. We also showed that 
azithromycin results in increased IKKβ protein concentrations along with blunted 
IκB-α degradation. Our results also show increased IKKβ gene expression with 
azithromycin treatment suggesting that increased IKKβ protein concentration 
results from the inhibited p65 nuclear translocation which blunts the negative 
feedback response essential to downregulate IKKβ and to turn off the NF-κB 
pathway. Additionally, we showed that accumulated IKKβ was associated with 
cross-inhibition of the STAT-1 pathway with azithromycin. Moreover, our results 
show that IKKβ played a critical role in azithromycin anti-inflammatory 
mechanisms. Results from experiments with IKK-16, an IKKβ inhibitor, showed a 
reversal of azithromycin effects on arginase expression and activity as well as on 
the suppressed STAT-1 activation. Therefore, azithromycin polarizes 
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macrophages towards an alternative M2 phenotype by cross-inhibiting the NF-κB 
and STAT-1 signaling pathways through a mechanism dependent on IKKβ. 
 
iii. Azithromycin protects against excessive morbidity and inflammation 
through mechanisms independent of arginase-1 production 
 
Our results show that azithromycin regulates neutrophil influx and T cell 
responses in mice infected with PA independent of myeloid arginase production. 
Arg1Δm mice were pre-treated with azithromycin starting four days prior to the 
infection and daily thereafter. Azithromycin protected against excessive morbidity 
and weight loss in Arg1Δm and Arg1flox/flox mice. Additionally, azithromycin 
suppressed the excessive recruitment of neutrophils and pro-inflammatory 
macrophages independent of myeloid arginase production. Importantly, 
azithromycin suppressed Th1 and Th17 responses and skewed towards a Treg 
phenotype equally in Arg1Δm and Arg1flox/flox mice. Additionally, azithromycin 
treatment in Arg1Δm and Arg1flox/flox mice was associated with faster recovery in 
terms of earlier resolution of inflammatory lung injury compared to untreated 
mice. Therefore, azithromycin protects against excessive morbidity and 
inflammation in chronic PA pneumonia through mechanisms independent of 
arginase production by macrophages and neutrophils. 
 
III. Significance 
 
i. Myeloid arginase, a therapeutic target to control inflammation 
 
Arginase production by myeloid cells was essential to limit inflammation and to 
regulate the influx of pro-inflammatory neutrophils and lymphocytes into the lungs 
in response to PA infections. We provided evidence that exaggerated 
inflammation can be regulated by directly modulating the production of arginase 
by myeloid cells while other cellular sources of arginase exert potentially different 
functions. The significance of this evidence lies in the potential of myeloid 
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arginase production to regulate the influx of neutrophils and Th17 lymphocytes, 
both of which are highly pathogenic in patients with cystic fibrosis. The increased 
IL17 release by Th17 lymphocytes is associated with increased disease severity, 
decline in lung function, and end-stage bronchiectasis [461]. According to 
Mulcahy et al., cystic fibrosis is a Th17-mediated disease [221]. They evaluated 
T cell responses in 42 cystic fibrosis patients ranging from 6 months to 53 years 
of age. They observed a very strong association between Th17 numbers and 
poor lung function. Malcahy et al. suggest that peripheral blood Th17 levels may 
be a surrogate marker of lung function in cystic fibrosis [221]. Additionally, Th17 
lymphocytes contribute to pathology by recruiting neutrophils in cystic fibrosis as 
well as in other disease models like Leishmaniasis, rheumatoid arthritis, 
inflammatory bowel disease, and crescentic glomerulonephritis [348, 349, 462]. 
Neutrophils are immunopathogenic in these disease models where they 
contribute to inflammatory tissue injury as a result of the extensive release of 
proteinases, neutrophil elastases, DNA, and oxidative free radicals [348, 349, 
462]. In the case of PA infections in cystic fibrosis, Dubin and colleagues 
conclude from an extensive literature review that the inability to clear PA results 
in chronic IL-17 production and the development of a Th17 phenotype [163, 215-
218, 222, 463]. The persisting neutrophilia fails to clear the pathogen [222, 464, 
465], which triggers the recruitment of more neutrophils that result in 
inflammatory lung injury and a decline in lung function [466, 467]. Therefore, 
identifying a pathway that can limit Th17 lymphocyte activation thereby 
controlling the influx of neutrophils represents a very promising target to 
manipulate excessive inflammation in cystic fibrosis, cancer, autoimmunity, and 
other inflammatory diseases. Our data suggest that arginase can serve as a 
novel target to control immunity and to prevent inflammatory lung injury in cystic 
fibrosis.  
 
In fact, there are recombinant human arginase formulations in clinical trials being 
evaluated in multiple disease models. A pegylated recombinant human arginase 
(BCT-100) is currently in phase I/II trial where its safety and efficacy in children 
 255 
and young adults with relapsed/refractory leukemia, neuroblastoma, sarcoma 
and high-grade gliomas are being evaluated [468]. Moreover, there are several 
small molecules that are being evaluated for inducing endogenous expression of 
arginase by signaling through pathways involved with arginase expression [208, 
469-472]. However, whether those approaches can control immunity in cystic 
fibrosis without dampening the essential functions of the immune system is yet to 
be elucidated. It is important to develop new approaches that would balance the 
immune response rather than suppressing it and preventing bacterial clearance. 
Therefore, it is pertinent to closely evaluate the effects of arginase administration 
in humans on the immune system and to consider targeted approaches to deliver 
arginase to the sites of infection or to stimulate arginase expression in particular 
cells without globally promoting suppressed immunity. 
 
ii. NF-κB signaling pathway, a targeted approach to limit pro-
inflammatory macrophage polarization 
 
We show that azithromycin controls pro-inflammatory macrophage activation by 
cross-inhibiting the NF-κB and STAT-1 signaling pathways. The beneficial clinical 
effects of azithromycin are well established in patients with cystic fibrosis [296-
304]. Azithromycin is known to regulate pro-inflammatory cytokines and to 
improve lung function in these patients [296, 297, 299-304, 306, 307]. Our results 
are significant in that they identify the specific molecular mechanisms that can be 
targeted to modulate the M1/M2 macrophage balance thereby regulating 
inflammation. Targeting macrophage-specific NF-κB and STAT-1 signaling 
pathways provide a novel approach that would protect against the unwanted side 
effects of azithromycin and against the potential antimicrobial resistance and 
other issues of collateral damage. Additionally, it protects against global NF-κB 
inhibition that would result in suppressed immunity. According to Hoesel et al., 
inhibition of the NF-κB pathway is a very effective approach to limit chronic 
inflammation and to promote anti-tumorigenic effects of many chemotherapeutic 
agents [394]. However, NF-κB is activated in several cell lineages and is 
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essential to induce sufficient inflammation needed to clear infections and to 
promote regulated cell death and other physiological functions activated through 
the NF-κB signaling pathway [394]. For example, dexamethasone, prednisone, 
methylprednisolone, aspirin, cyclosporin A, indomethacin, and ibuprofen are all 
reported to inhibit NF-κB [416, 417]. However, their effects are generalized and 
non-macrophage specific thereby resulting in suppressed immunity and inability 
of the immune system to clear the invading pathogen. Additionally, azithromycin 
inhibits the NF-κB pathway through a unique mechanism which cross-inhibits the 
pro-inflammatory STAT-1 transcription factor. According to Breuer a STAT1 gain 
of function mutation promotes severe bronchiectasis even in non-cystic fibrosis 
patients [473]. Additionally, Kretzmer and colleagues report that increased STAT-
1 phosphorylation was associated with recurrent pneumonia, exaggerated 
inflammation, and severe bronchiectasis in a 5-year-old child [474]. Whereas 
Kreiselmeier et al., report that cystic fibrosis pathology is associated with altered 
STAT-1 activation which mediates pathogenesis by altered iNOS induction while 
statin-mediated correction of STAT-1 signaling may represent a potential avenue 
for therapeutic intervention in cystic fibrosis [475]. Therefore, the ability of 
azithromycin to target two transcription factors involved in immunopathogenesis 
and exaggerated inflammation in cystic fibrosis constitutes a favorable approach 
to limit pathology using a single agent. Identifying the cross-inhibitory mechanism 
of azithromycin mediated via IKKβ presents a promising approach to be 
considered for the development of immunomodulatory agents that target several 
pathological mediators. 
 
Additionally, identifying the molecular mechanisms of azithromycin is essential to 
improve the efficacy and functionality of the drug in other disease models. Our 
group has shown promising cardioprotective effects with azithromycin pre-
treatment in myocardial infarction (MI). Unpublished preliminary data show a 
significant reduction in mortality in a murine model of MI. Additionally, 
azithromycin pretreatment resulted in attenuated inflammation and enhanced 
recovery post-MI in mice. Our collaborators have shown in a murine model of 
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spinal cord injury that azithromycin promotes an anti-inflammatory phenotype 
and improves tissue sparing and recovery of gross and coordinated locomotor 
functions [443]. However, myocardial infarctions and traumas resulting in spinal 
cord injury in humans happen suddenly; therefore, it is essential to identify 
azithromycin analogs that exert comparable beneficial anti-inflammatory effects 
post-injury or to develop formulations that are associated with fast attainment of 
steady-state concentrations essential for azithromycin’s immunomodulatory 
effects. Moreover, our group is working with medicinal chemists to develop 
azithromycin analogs that lack the antimicrobial activity and improve upon the 
anti-inflammatory properties. Thus, identifying azithromycin molecular targets 
and developing new analogs or small molecules that would exert immediate 
beneficial effects are crucial to extend the usefulness of this drug. 
 
iii. Arginase production by myeloid cells is not required for azithromycin 
anti-inflammatory effects 
 
Azithromycin blunts the Th1 and Th17 immune responses thereby protecting 
against excessive neutrophil recruitment and inflammatory lung injury in 
response to PA infections. Importantly, azithromycin does not require myeloid 
arginase production to exert its anti-inflammatory effects. These effects were 
associated with increased secretion of TGF-β and IL-10 which are most likely 
responsible for the induction of the regulatory T cell phenotype thereby 
suppressing Th1 and Th17 responses [447-453]. Therefore, the significance of 
these results includes the identification of alternative pathways for targeted 
immunotherapy against aberrant T cell responses and exaggerated inflammation 
in cystic fibrosis. According to Kramer and colleagues, TGF-β targeted 
therapeutics can be complicated in cystic fibrosis due to differential effects on 
this cytokine on different cellular mechanisms [476]. For instance, Sun et al., 
show that TGF-β disrupts the function and the numbers of CFTR channels along 
the cystic fibrosis epithelium [477]. Similarly, Arkwright suggests that increased 
TGF-β concentrations are associated with a decline in lung function in patients 
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with cystic fibrosis [478]. These effects were mediated via direct effects of TGF-β 
on the lung parenchyma and ion flux across the CFTR channels. Therefore, 
developing targeted TGFβ-dependent therapeutics is required to prevent the 
unwanted detrimental effects [477, 478]. Accordingly, we have identified 
azithromycin as a potentially novel and targeted TGFβ-modulator which regulates 
T cell responses without broadly impacting other necessary TGFβ signaling 
effects.  
 
Additionally, the ability of azithromycin to exert protective effects independent of 
arginase suggests possible synergistic mechanisms between these two powerful 
immunomodulatory effectors. New therapeutic approaches focus on combination 
therapies to target the different elements of the altered immune response. 
According to Randhawa et al., combination immunotherapy including 
azathioprine and cyclosporine which act through independent mechanisms 
resulted in significantly improved lung function and reduced hospitalization along 
with reduced need for IV antibiotics [479]. Similarly, Obaid and colleagues report 
that combination immunotherapy including IL-21 and anti-IL10 antibodies act 
synergistically by correcting the different aspects of the altered immune response 
in patients with Hepatitis C Virus (HCV) infections [480]. Additionally, the NICE 
clinical guidelines recommended a combination of nivolumab and ipilimumab 
both of which boost the activity of the immune system against cancer cells [481]. 
Therefore, combination immunomodulatory therapies are widely considered in 
several disease models where different aspects of the immune response are 
altered. Here we identify two distinct immunomodulators which act through 
independent mechanisms to be considered for new potential combinations. 
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IV. Future directions 
 
i. Evaluating the contribution of L-arginine synthesis in modulating T 
cell responses to PA infections 
 
Our results show that arginase controls T cell proliferation and polarization 
towards Th1 and Th17 phenotypes. As discussed in Chapter 3, these effects are 
very likely to be mediated with L-arginine depletion. Future studies will evaluate 
the hypothesis that eliminating T cell L-arginine synthesis will impair Th17 
proliferation, recruitment, and cytokine production in response to PA infection. 
The studies will focus on whether L-citrulline metabolism regulates the 
accumulation and effector profile of T cells during PA infection, and whether PA-
associated pathophysiology or burden is regulated by T cell L-citrulline 
metabolism. L-citrulline is an essential precursor for L-arginine synthesis. Recent 
evidence supports the contribution of L-citrulline during immune cell activity, 
especially during host defense to infectious disease [482]. We will test whether T 
cells require L-citrulline to L-arginine synthesis to regulate neutrophil recruitment 
and defense to PA. This will be achieved using AslΔTcell mice, a novel mouse 
model in which T cells cannot synthesize L-arginine from L-citrulline. We 
anticipate decreased CD4+ T cell accumulation and Th17 responses in AslΔTcell 
mice as compared to littermate controls. We also expect decreased neutrophil 
accumulation and increased PA burden in the lungs of AslΔTcell mice as compared 
to littermate controls. If our hypothesis is correct, this will validate the effects of 
arginase on T cell activation and neutrophil recruitment via arginine depletion.  
 
ii. Evaluating the requirements of non-myeloid arginase in the anti-
inflammatory mechanisms of azithromycin   
 
It is important to note that we evaluated the effects of azithromycin in a murine 
model with conditional arginase deletion from macrophages and neutrophils. It is 
possible that other cellular sources of arginase can rescue the depleted myeloid 
 260 
arginase. It is also possible that azithromycin promotes arginase expression in 
other immune cells. Therefore, it is essential to evaluate the effects of 
azithromycin with global arginase inhibition and in other models of conditional 
deletion from non-myeloid cells. We will evaluate the effects of azithromycin on 
the immune response in BALB/cJ mice and C57BL/6 mice dosed with BEC and 
L-norvaline. Also, will evaluate the immunomodulatory effects of azithromycin in 
AslΔTcell mice. Therefore, we will test if azithromycin can control inflammation and 
modulate T cell disposition in these models.  
 
Additionally, we will evaluate the requirement for TGF-β for azithromycin 
protective effects. This will be achieved by utilizing TGF-β neutralizing antibodies 
in azithromycin-treated Arg1Δm mice. Additionally, future studies will examine the 
effects of azithromycin on non-arginase mediated signaling pathways involved 
with wound healing including the Smad pathway [452]. This will be achieved by 
utilizing Lck-creSmad4 mice. These mice lack the Smad4 intracellular signaling 
molecule in lymphoid cells.  This protein is responsible for the signaling cascade 
through the receptor that binds to members of the TGFβ superfamily [453].  
 
iii. Evaluating the effects of arginase deletion in cystic fibrosis mouse 
models 
 
Work presented in this dissertation evaluated the immune response against 
chronic PA pneumonia in non-cystic fibrosis murine models. We used a mucoid 
PA strain isolated from a cystic fibrosis patient and we incorporated the bacteria 
in agarose beads to imitate the infection in humans. Heeckeren and colleagues 
show that this method causes a chronic infection in mice that mimics the 
colonization in humans. Intra-tracheal instillation of PA immobilized in agarose 
beads has proven to be very successful in revealing cystic fibrosis defects in 
bacterial clearance and it ensues an exaggerated inflammatory response [483]. 
However, it is important to take into consideration the various alterations of the 
immune response caused by CFTR mutations in humans (discussed in chapter 
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1). Therefore, future studies will utilize CFTR knock-out mice to validate that 
arginase controls inflammation and that azithromycin is effective in mice with 
mutated CFTR. At least 11 models of CFTR knock-out mice are available 
targeting the most common mutations ΔF508 and G551D [484]. Earlier models of 
CFTR knock-out mice were limited by the very low survival rate, lack of cystic 
fibrosis pulmonary manifestations, resistance to certain pathogens, and 
development of severe intestinal obstruction [484-489]. We will use CFTRtm1G551D 
and CFTRtm1EU to examine the effects of arginase and azithromycin in mice with 
the most common mutations, G551D and ΔF508. If our clinical studies reveal any 
preferential effects with specific mutations in humans, we will consider mouse 
models representative of these mutations. 
 
iv. Evaluating the clinical applicability of azithromycin anti-inflammatory 
mechanisms 
 
Investigating the clinical applicability of our results is still ongoing. In order to 
study the immune changes induced with azithromycin in patients with cystic 
fibrosis we proposed a prospective, unblinded, non-randomized study in which 
each patient will serve as his or her own control. Patients with cystic fibrosis 
currently taking azithromycin who meet the inclusion/exclusion criteria will be 
consented/assented.  Enrolled subjects will be taken off of azithromycin for 60-90 
days. Three sputum samples induced via inhalation of hypertonic saline will be 
collected from each patient at 3 different timepoints. The first sputum sample will 
be collected after the patient had been on azithromycin for at least a year and 
prior to the initiation of the 60-90 day azithromycin holiday. The second sputum 
sample will be collected by the end of the 60-90 day drug holiday period and 
patients will re-initiate azithromycin therapy. Finally, the third sample will be 
collected again 2-3 months after azithromycin re-initiation. This pilot clinical study 
is unique in that it generates matched data from subjects while on and off of 
azithromycin. Data generated from this study will be very useful in identifying 
pathways affected by azithromycin in humans. Additionally, this study will allow 
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us to identify specific genes and immune cells induced with azithromycin and the 
possible correlation with clinical effectiveness by measuring the patient’s 
performance when on and off of azithromycin. The study protocol has been fully 
established and the study was approved by the Institutional Review Board at the 
University of Kentucky. Three leading pulmonologists at the KY clinic are 
involved in the study and are pre-screening potential study patients. Our 
inclusion/exclusion criteria have been very carefully selected to minimize 
variability in immune function due to parameters including age, medication 
exposure, and other disease states.  Therefore, recruiting patients into our study 
has been challenging due to the strict inclusion/exclusion criteria. Future work 
aims to screen more potential subjects and to reassess the inclusion/exclusion 
criteria if no subjects were eligible. 
 
v. Additional future studies 
 
Future work includes extending our human studies and closely evaluating the 
effects of arginase on T cell responses and transmigration. We hope to broaden 
our human experiments to evaluate changes in arginase expression and its 
effects on T cell immunity in cystic fibrosis as well as other disease models. 
Additionally, future studies aim to delineate the NOS/arginase paradigm and how 
disruptions in arginine/NO balance can affect the beneficial effects of arginase 
expression in non-resolving inflammatory conditions. Moreover, future studies will 
evaluate the mechanisms involved in skewing T cell responses with azithromycin 
and with arginase and whether it is cytokine-mediated versus a specific direct 
effect on T cell activation. It is also essential to define the mechanisms by which 
arginase and azithromycin affect T cell disposition and compartmentalization in 
the alveolar versus the interstitial spaces. Further studies are also needed to 
define the effects on T cell chemotaxis and transmigration from the lymph nodes 
to the sites of infection. Last but not least, it is crucial to define the specific effects 
of arginase-1 versus arginase-2 isoforms and whether one and not the other 
modulates T-cell immunity in humans. 
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V. Conclusions 
 
I- Arginase-1 immunomodulatory role in PA pneumonia 
 
We conclude that decreases in inflammation in response to PA pneumonia 
achieved by polarizing macrophages to an alternatively-activated phenotype is 
dependent upon the production of arginase-1. Arginase-1 is an important 
immunomodulatory enzyme which suppresses exaggerated inflammation in PA 
pneumonia by controlling the Th1 and Th17 responses and therefore protecting 
against the excessive influx of neutrophils and pro-inflammatory macrophages. 
 
II- Azithromycin anti-inflammatory mechanism of action 
 
We conclude that azithromycin polarizes macrophages to an M2 phenotype via 
inhibition of STAT1 through cross-talk from the NF-κB signaling mediators. 
Azithromycin inhibits p65 nuclear translocation which results in IKKβ 
accumulation due to suppressed negative feedback. Thus, inhibiting the NF-κB 
signaling pathway cross-inhibits the STAT-1 pathway. This modulation is 
dependent on IKKβ and results in subsequent suppression of inflammatory gene 
activation while promoting an anti-inflammatory phenotype. 
   
III- Dependence of azithromycin-induced M2 macrophage phenotype on 
Arginase-1 to alter inflammation 
 
Azithromycin balances the immune responses in PA pneumonia via mechanisms 
independent of arginase.  Azithromycin protects against excessive morbidity and 
exaggerated inflammation by regulating the Th17/Treg balance and thus 
controlling the influx of neutrophils and inflammatory macrophages to the lungs 
regardless of arginase production. 
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Collectively, the work presented in this dissertation significantly improves our 
knowledge of the immune system in cystic fibrosis. Defining the 
immunomodulatory mechanisms of arginase and of azithromycin identifies new 
molecular targets for immunotherapy in patients with non-resolving pulmonary 
inflammation. Therefore, our research provides hope for the development of new 
targeted therapies that control inflammation and prevent lung injury without the 
need for long-term antibiotic use. Moreover, the ability of azithromycin to balance 
macrophage polarization provides a unique approach for controlling the function 
of the immune system without blunting the immune response or promoting 
severe systemic immune suppression like with steroids and other non-specific 
immunosuppressants.  
 
Additionally, the significance of this work extends to other immune-mediated 
diseases. In fact, immune dysregulation has been shown to be involved in many 
disorders where the role of the immune system in disease pathogenesis has not 
been previously considered. Immune dysregulation has been found to contribute 
to pathology in solid and hematological tumors, Alzheimer’s disease, Parkinson’s 
disease, major depressive disorder, autism, obsessive-compulsive disorders, as 
well as epilepsy, stroke, and brain injury [490, 491]. Therefore, defining key 
regulators of the immune response and the primary regulatory mechanisms 
involved identifies new drug targets for other diseases. 
 
Research from this dissertation provides insight into specific downstream 
signaling cascades and mechanisms involved with arginase and azithromycin’s 
immunomodulatory functions. We identify specific pathways which modulation 
can be of therapeutic value for targeted immunotherapy that could be 
generalizable to multiple immune-mediated disorders. 
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APPENDIX A: DATA COLLECTION FORM 
 
 
Subject Study Code Number _______________ 
 
 
Visit 1: Patient on Azithromycin 
 
Specimen Date _______________  
 
Specimen collection: _____Induced 
 _____Spontaneous 
Inclusion/Exclusion 
Age _______ CF diagnosis age __________  CFTR 
mutation_____________ 
 
Receiving immunomodulatory agent    Yes  No 
     (steroids—date last dose received__________) 
Pregnant, lactating      Yes  No 
Immunomodulatory disease     Yes  No 
     (cancer, DM, obesity, malnutrition, SLE 
HIV-infection, transplantation) 
 
Azithromycin Treatment 
Receiving azithromycin     Yes  No 
 Dose  __________ 
 Start  __________ 
 Duration __________ 
 
Demographics 
Wt ____ Ht ____ Gender ____ 
Ethnicity ___ white ___ black ___ Asian ___ other   Hispanic ___yes ___no 
Current medications: 
 Drug  Start  Stop 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
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Subject Study Code Number _______________ 
 
Other drugs:    
     Non-
prescription_______________________________________________________ 
     Other vitamins, 
supplements_____________________________________________________ 
 
 
 
Labs:  Date _________ 
Metabolic panel:  Glucose____ BUN____ SrCr____ 
WBC____ Hgb____ Hct____   Diff:  N___ L___ E___ B___            
 
Pulmonary Function Tests: 
Date _________ FEV1 ____ FVC ____ 
Date _________ FEV1 ____ FVC ____ 
Date _________ FEV1 ____ FVC ____ 
 
Pulmonary Cultures 
Date  Result/organism   Sensitivities 
_________ _________________________  
_________ _________________________  
_________ _________________________  
_________ _________________________  
_________ _________________________  
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Subject Study Code Number _______________ 
 
Visit 2: After Azithromycin Holiday 
 
Specimen Date _______________  
 
Specimen collection: _____Induced 
 _____Spontaneous 
 
Demographics 
Wt ____ Ht ____  
 
Current medications: 
 Drug  Start  Stop 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 
Other drugs:    
     Non-
prescription_______________________________________________________
_______ 
     Other vitamins, 
supplements_____________________________________________________ 
 
 
 
Labs:  Date _________ 
Metabolic panel:  Glucose____ BUN____ SrCr____ 
WBC____ Hgb____ Hct____   Diff:  N___ L___ E___ B___            
 
Pulmonary Function Tests: 
Date _________ FEV1 ____ FVC ____ 
Date _________ FEV1 ____ FVC ____ 
Date _________ FEV1 ____ FVC ____ 
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Subject Study Code Number _______________ 
 
 
Pulmonary Cultures 
Date  Result/organism   Sensitivities 
_________ _________________________  
_________ _________________________ 
_________ _________________________  
_________ _________________________  
_________ _________________________  
 
Visit 3: After Azithromycin Restart 
 
Specimen Date _______________  
 
Specimen collection: _____Induced 
 _____Spontaneous 
 
Demographics 
Wt ____ Ht ____  
 
Current medications: 
 Drug  Start  Stop 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 ____________ ____________ _____________ 
 
Other drugs:    
     Non-
prescription_______________________________________________________
_______ 
     Other vitamins, 
supplements_____________________________________________________ 
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Subject Study Code Number _______________ 
 
 
 
Labs:  Date _________ 
Metabolic panel:  Glucose____ BUN____ SrCr____ 
WBC____ Hgb____ Hct____   Diff:  N___ L___ E___ B___            
 
Pulmonary Function Tests: 
Date _________ FEV1 ____ FVC ____ 
Date _________ FEV1 ____ FVC ____ 
Date _________ FEV1 ____ FVC ____ 
 
Pulmonary Cultures 
Date  Result/organism   Sensitivities 
_________ _________________________  
_________ _________________________  
_________ _________________________  
_________ _________________________  
_________ _________________________  
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APPENDIX B: HUMAN GENES FOR ARRAY PLATES 
 
 
384 well Micro Fluidic Card; 47 genes + 1 mandatory control; 
Format 48, Part #  4342253 
 
Wel
l Gene Fisher # 
A1 CD86 Hs01567026_m1 
A2 CD64/CD64 Hs00417598_m1 
A3 ITGAM Hs00167304_m1 
A4 CD14 Hs02621496_s1 
A5 CD68 Hs02836816_g1 
A6 CD23/FCER2 Hs00233627_m1 
A7 CD40 Hs01002915_g1 
A8 STAT1 Hs01013996_m1 
A9 SOCS3 Hs02330328_s1 
A10 SLAMF1 Hs00234149_m1 
A11 RNA18S5 manufacturing control (housekeeping gene)  
A12 TNF Hs00174128_m1 
A13 IL6 Hs00174131_m1 
A14 IL12B Hs01011518_m1 
A15 IL1B Hs01555410_m1 
A16 IL10 Hs00961622_m1 
A17 TGFB1 Hs00998133_m1 
A18 IL12A Hs01073447_m1 
A19 IL8/CXCL8 Hs00174103_m1 
A20 IL23A Hs00372324_m1 
A21 IL4RA Hs00965056_m1 
A22 IL27RA Hs00945029_m1 
A23 HLA-DRA Hs00219575_m1 
A24 MARCO Hs00198937_m1 
B1 CCL17 Hs00171074_m1 
B2 CCR2 Hs00704702_s1 
B3 TREM2 Hs00219132_m1 
B4 CCL22 Hs01574247_m1 
B5 CCL18 Hs00268113_m1 
B6 NOS2 Hs01075529_m1 
B7 RETNLB Hs00395669_m1 
B8 ARG1 Hs00163660_m1 
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B9 PPARG Hs01115513_m1 
B10 IKBKB Hs01559460_m1 
B11 ARG2 Hs00982833_m1 
B12 IDO1 Hs00984148_m1 
B13 IRF1 Hs00971965_m1 
B14 MRC1/CD206 Hs00267207_m1 
B15 NLRP1 Hs00248187_m1 
B16 CASP1 Hs00354836_m1 
B17 MAP1LC3B Hs00797944_s1 
B18 AKT1 Hs00178289_m1 
B19 PCNA Hs00427214_g1 
B20 ATG5 Hs00169468_m1 
B21 MTOR Hs00234508_m1 
B22 
GCN2/EIF2AK
4 Hs01010957_m1 
B23 GAPDH Hs02786624_g1 
B24 
CCND1/cyclin 
D1 Hs00765553_m1 
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